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ARTHRITIS: RHEuMATOID VERSuS uNDIFFERENTIATED ARTHRITIS
Rheumatoid arthritis (RA) is a prevalent (0.5-1/100 persons) auto-immune inflammatory 
disease which primarily affects the joints, but can also cause extra-articular manifestations.1-3 
Uncontrolled disease may lead to structural joint damage, disability, reduced quality of life, 
work productivity loss and premature mortality.4-6 To date, the pathogenesis of RA is largely 
unknown, although some genetic risk factors and environmental factors have been sug-
gested to contribute to the etiology.7-9 
Until recently, RA has been classified according to the 1987 revised American College of 
Rheumatology (ACR) criteria10 including: morning stiffness (for at least one hour); arthritis 
of at least three joints; arthritis of hand joints; symmetrical joint swelling; subcutaneous 
rheumatoid nodules; positive rheumatoid factor and typical radiographic changes on hand 
and wrist radiographs. Patients are classified as having RA, when at least four out of these 
seven criteria are present for at least six weeks. The 1987 ACR criteria were developed as 
classification rather than diagnostic criteria, to harmonize disease definitions used in clinical 
trials. However, the 1987 criteria lack sensitivity and specificity for early disease and reflect 
hallmarks of the chronic disease state.11 
The ‘window of opportunity’ hypothesis states that treatment in an early phase of RA (e.g. 
when still in the phase of undifferentiated arthritis (UA)) can prevent progression or even es-
tablish reversal of the inflammatory process to a pre-disease state.21 Therefore, it is preferable 
to diagnose and start treatment for RA in an early stage to maximize opportunity for steering 
the disease course towards a better outcome. This is why new criteria12;13 have recently been 
developed, classifying RA in patients with recent onset arthritis in an earlier phase than was 
previously possible with the 1987 criteria.14-16 As a consequence of classifying earlier, in some 
newly classified patients, their future disease course may not require medication or show 
persistence of symptoms and signs. As also the new criteria are developed to classify rather 
than identify RA, it remains a clinical process to diagnose RA.17 
In patients presenting with recent onset arthritis it is often difficult to distinguish early RA 
from other types of inflammatory oligo- or polyarthritis. Undifferentiated arthritis is poorly 
defined as arthritis not fulfilling any of the classification criteria for a rheumatological dis-
ease.18 Depending on baseline characteristics in various early arthritis cohorts, approximately 
one third of UA patients will eventually develop RA (according to 1987 criteria) and thus may 
be ‘RA detected in an early phase’, but the majority of UA patients has self-limiting disease.18-20 
Since the latest changes in classification criteria for RA, the characteristics of patients with 
‘UA’ appear to also have changed. Literature in actual UA patients as oppose to early RA 










































1 Despite the development of various prediction models 
21-23, outcome prediction in patients 
with UA is difficult and early treatment is associated with the risk of overtreatment for pa-
tients with self-limiting disease. 
Outcomes in arthritis and treat to target
To assess outcomes in (rheumatoid) arthritis patients numerous parameters are available. 
Properly defining outcomes and outcome thresholds ensures that results of interventions in 
clinical trials can be compared and uniformly interpreted. For UA, persistence of symptoms 
and signs can be considered an outcome, as well as a more clinically based ‘physician’s deci-
sion to start anti-rheumatic therapy’. Both in UA and RA, disease activity, structural damage as 
seen on radiographs of the most commonly affected joints, physical disability, health related 
quality of life (HRQoL) and mortality are amongst the most widely used outcomes.24-27 The 
instruments used for the assessments of these outcomes have been further adapted during 
the past decades, yet limitations in their performance remain.
Outcomes are also important in light of the recent shift in the management of RA towards 
a treat to target approach.28 It has been shown that not only regular assessments of disease 
activity in RA contribute to better disease control, but also therapy adjustments based on a 
pre-defined level result in improved outcomes.29-31 International recommendations for the 
management of RA also emphasize a targeted approach aiming for remission or at least low 
disease activity by early introduction of disease modifying anti-rheumatic drugs (DMARDs), 
the use of methotrexate as an anchor drug and early introduction of combination therapy 
(which may include a biological agent in patients with poor prognostic factors).28;32-34 Never-
theless, it is unknown which targets should be set, how and how strict should be monitored, 
and in what way this impacts on the outcome of RA. 
Imaging
Inflammation in the joints leads to joint damage, of which both may result in physical dis-
ability, decreased health related quality of life and work productivity loss.35;36 Inhibition or 
prevention of inflammation and subsequently joint damage, can prevent future disability 
and other unfavorable outcomes, and is therefore an important goal in anti-rheumatic treat-
ment.36;37 In clinical trials as well as in daily practice, different imaging modalities are used in 
arthritis patients to assess inflammation of the joints and the structural joint damage that 
is the measurable result after periods of active inflammation.38;39 These imaging modalities 
include conventional radiographs, magnetic resonance imaging (MRI) and ultrasound (US). 
Historically, radiographs of hand and feet are the most widely used and best manner of as-










































1randomized in time order, and damage progression can be measured over time.
40 Radio-
graphs could display bony damage to joints, thinning of cartilage, and ligament or soft tissue 
abnormalities seen as malalignment in patients with arthritis.40 Typical radiographic damage 
in RA includes erosions, joint space narrowing (JSN) and juxta-articular osteopenia.41 Erosions 
are seen as cortex interruptions and reflect damage to the bone, whereas JSN is thought to 
reflect damage to the cartilage. Erosions are indicative for RA, yet single erosions may not be 
disease specific as erosions can also occur in for example psoriatic arthritis or gout, although 
the shape of the erosions in the respective disorders may differ. A recent EULAR initiative 
defined erosiveness typical for RA quantitatively when an erosion is seen on radiographs of 
both hands and feet in three or more separate joints at specific locations.42
Several scoring methods have been developed for the quantitative assessment of radio-
graphic joint damage including different sets of joints, but in general hands and feet are in-
cluded. Damage in these joints has been shown to associate with large joint damage, thereby 
implying that monitoring and prevention of joint damage in hands and feet is sufficient for 
the prevention of damage in the larger joints.43 
Global scoring methods (per patient or joint) are available37;44;45, but also methods scoring 
erosions and JSN separately.46;47 Both factors were shown to carry independent information 
and thus assessment of both features is preferable.41 Sharp was the first to develop a radio-
graphic scoring system for erosions and JSN in hands and wrist, after formally testing which 
joints should be included in this system based on their involvement in RA and the reliability 
of scoring them.48 The modification of the Sharp score by van der Heijde also included the 
feet in the scoring system, which are frequently displaying joint damage in an earlier phase of 
the disease and thus provides additional information.49-51. Also (sub)luxation was introduced 
as part of the JSN scoring in this modification. 
Increased awareness of the potential treatment benefit in an early phase of the disease leads 
to earlier diagnosis and consequently more patients initiating treatment before radiographic 
damage is present.52;53 Subsequently, other imaging modalities are progressively introduced 
as potentially more sensitive methods to detect joint damage or inflammation. US is more 
sensitive to detect synovitis than clinical examination54-56 and could be used to rule out syno-
vitis in case of uncertainty or absence of clinically inflamed joints. It has been shown that in 
patients in remission, abnormalities such as gray scale synovitis and power Doppler activity 
can be present57;58, and that these abnormalities may be associated with joint damage on 
conventional radiographs.59 
Likewise, MRI detects early changes in bone and cartilage and displays abnormalities such as 
erosions, bone marrow edema and synovitis, often without signs of damage on conventional 










































1 of abnormalities may also occur, and the clinical relevance of these abnormalities on either US or MRI is not fully clarified to date. 
Ongoing research is examining the additional value of these imaging techniques next to 
clinical and serological tests. Most studies on imaging techniques have concentrated on 
early RA patients. To assess the value of imaging techniques for patients with UA we have 
performed a systematic literature review to examine the diagnostic and prognostic value of 
radiographs, MRI and US (Chapter 2 and 3). These papers were used as the scientific base for 
the 3E recommendations on the management and follow-up of undifferentiated arthritis as 
displayed in Chapter 4. 
Physical functioning in relation to structural damage
Steinbrocker was the first to develop a classification method to measure functional disability 
on a four point scale45, but the sensitivity to change of this measure was poor.64 Nowadays, 
physical disability is nowadays usually assessed with the Health Assessment Questionnaire 
(HAQ), one of the most validated patient questionnaires in RA.65 The original HAQ was devel-
oped in the 1980s and is an important outcome measure. It has shown to be associated with 
joint damage, quality of life, disease activity, work related measures and even mortality.66-70 
The initial HAQ comprised of five dimensions, which are undesirable for patients: death, 
disability, discomfort, iatrogenic effects and costs. Currently, a shorter version of the total 
HAQ, the HAQ disability index (HAQ-DI), is most frequently used and translated into more 
than over 60 languages or dialects including Dutch.71;72 The HAQ consists of 24 questions 
regarding eight distinct categories (‘dressing’, ‘arising’, ‘eating’, ‘walking’, ‘hygiene’, ‘reach’, ‘grip’ 
and ‘usual activities’). The total score (range 0-3) is calculated by summing the highest score 
per category and dividing the total by eight. If patients use any aids or devices for certain 
daily activities a minimum score of two per category is awarded. The HAQ is of immediate 
importance to patients and physicians as it reflects day-to-day physical abilities and is related 
to reversible components such joint pain and swelling due to inflammation, but also to more 
irreversible components such as damage to joints, deformations, or muscle weakness.73   
The relationship of physical functioning with radiological damage has been extensively 
reviewed in literature.35;74;75 Until now, the general paradigm states that radiological damage 
accumulates in time and causes limitations in physical functioning. A J-shaped curve has 
been described for physical functioning over time in which initially, when starting treat-
ment, a marked improvement in HAQ is seen, whereas after 3-6 years of follow-up the HAQ 
score irreversibly starts to increase again due to accumulated joint damage.36;37 Improved 
targeted treatment strategies, for example in the BeSt study, have been shown to prevent 










































1to radiological damage remain important for certain subsets of patients. Recently, it has been suggested that in particular JSN on radiographs, rather than erosive damage, is associated 
with impaired physical functioning.77 More JSN was associated with higher mean HAQ scores 
in patients in clinical remission. However, it remains unclear what the influence of damage in 
distinct joint groups on this relationship is, and also whether this relationship is still present 
in a longitudinally measured cohort. In Chapter 5 we have addressed these issues. 
Disease activity
Active disease in RA patients manifests through inflamed joints, usually in a symmetrical pat-
tern and with frequent involvement of the small joints of hands and feet. Generalized morn-
ing stiffness may be a pronounced symptom. Other signs include rheumatoid nodules and 
swelling and tenderness of joints on examination. In laboratory tests elevated acute phase 
reactants (erythrocyte sedimentation rate, (ESR) and C-reactive peptide, (CRP)) can be found 
and patients may have inflammation related anemia. Evaluation of signs and symptoms over 
time as indicators of disease activity is advised to monitor patients’ response to treatment.34 
To harmonize and compare outcomes in clinical trials several core sets of disease activity 
indicators were defined. Moreover, different composite scores were developed by several 
groups, all based on the assumption that combinations of these indicators yield a more valid 
estimate of current disease activity.78-80 EULAR/ACR recommendations on reporting disease 
activity in clinical trials advise the reporting of disease activity states and responses, both in 
composite measures and as individual measures. In addition, the course over time of these 
measurements should be reported.81;82 Nowadays, it has been recognized that the composite 
scores are also useful to follow patients in daily clinical practice and to use a pre-specified 
level of disease activity as a treatment goal for therapy adjustments in individual patients 
in order to improve long-term outcomes, such as physical ability, HRQoL and radiographic 
damage progression.29-31;83 
The Disease Activity Score (DAS)
The disease activity score (DAS) was the first score to be developed for the assessment of 
disease activity and included a swollen joint count (out of 44 joints scored), the Ritchie Ar-
ticular Index (RAI) assessing tenderness in 53 joints (some scored per group), ESR and a visual 
analogue scale for patient’s assessment of global health (VAS-GH).84 The formula for the DAS 
is as follows: 0.54 * √RAI + 0.0065 * SJC + 0.33* ln(ESR) + 0.007 * VAS-GH. The RAI includes 
a graded assessment for joint tenderness (0=no pain on examination; 1=pain on pressure, 
2=pain and winced 3= winced and withdrew).85 The DAS strongly relates to disability, joint 










































1 Later, alternative versions of the original DAS using CRP rather than the ESR, as well as 
simplifications have been described, using only 28 joint counts for tenderness and swelling 
(DAS28).87 Also, a composite score with a simplification in calculations (scoring 28 joints) 
has been described (simplified disease activity index (SDAI))88;89 and further simplifications 
excluding the lab result of the acute phase reactants (clinical disease activity index (CDAI); 
modified DAS28)90 are also available.90 These composite scores could be used in case ESR 
or CRP are absent at time of the clinical consultation. All these adjusted measures excluded 
the feet for the assessment, mainly with the argumentation that examination of the feet is 
difficult and time consuming, although arthritis in the feet is a common problem in RA.85
A limitations of the DAS is the inclusion of the RAI which assesses joint tenderness on a grade 
scale (range 0-3), which can introduce additional interobserver error and complicates clinical 
assessments.91 Whether this grading of joint tenderness is necessary for the assessment of 
disease activity or whether a simpler approach can be followed including pain as a yes/no 
variable in different amounts of assessed joints is discussed in Chapter 6. 
The Visual Analogue Scale (VAS)
For the assessment of disease activity both patient and physician can use a visual analogue 
scale (VAS), usually scored from 0-100 mm. Different VAS scores exist: a VAS score for pain, 
a VAS score for morning stiffness, a VAS score for assessment of general health (VAS-GH), 
but also a VAS for the assessment of disease activity. Within the DAS, the patient’s VAS for 
general health is used, but sometimes this VAS-GH is replaced by the VAS for disease activity, 
although the latter is not formally validated as part of the DAS. In Chapter 6 we validated the 
DAS including the VAS for disease activity. 
In alternative versions of the DAS, such as the CDAI and SDAI, both a patient and a physician 
derived VAS for disease activity are used.88;90 It is of interest to know how patients score their 
disease activity compared to physicians and which factors are influencing differences if pres-
ent. This issue is of importance when considering patients satisfaction with our healthcare, as 
patients and health care providers have been shown to differ in their perspectives on health 
status. 92;93 Therefore, we investigated the difference between the patient and physician 
derived VAS for disease activity and its influencing factors in Chapter 7. 
Disease remission
Remission is the ultimate goal of RA treatment an can be defined as absence of disease (activ-
ity). It has been demonstrated that DAS remission is an attainable goal for many patients with 
the current treatment possibilities94, and some patients even achieve drug free remission.95;96 
Many definitions of remission are available, often using cut-off points from composite scores 










































1with different levels of disease activity as being in remission.
94;97;98 Recently, new remission 
criteria have been developed by the ACR/EULAR99;100, defining remission at certain absolute 
levels of a patient derived visual analogue scale for global health, swollen and tender joints 
counts and the CRP.
It has been argued that remission definitions should include a reference to time and a 
specification of the used medication to differentiate between long or short-term remission 
and drug free remission or remission while on anti-rheumatic drugs. Although not included 
in the current remission definition, other important factors to incorporate in a definition 
could include the absence of joint damage progression (by whichever method determined), 
absence of deterioration of disability, and absence of impaired quality of life. Furthermore, it 
is questionable whether the more strict remission definitions denote clinically significantly 
different states and whether they are relevant for the patient’s outcome. 
As treating to target is becoming the advocated strategy, it is necessary to investigate the 
impact of different definitions of remission on outcomes. In Chapter 8 we compared nine 
composite scores and new ACR/EULAR remission criteria and determined the proportion of 
patients classified as in remission and other disease activity levels for each composite score, 
as well as the association with functional ability and structural joint damage.
Health Related Quality of Life
Health Related Quality of Life (HRQoL) can be assessed with generic or disease specific 
instruments. Although disease specific instruments could comprise more factors relevant 
to RA patients, generic instruments allow benchmarking against other conditions and can 
therefore be valuable for the development of health care management strategies. 
HRQoL can be defined as the impact of (lack of ) health on an individual’s functional ability 
and perceived well-being in life, but also reflects patient’s satisfaction and response to the 
disease.25 
The Short-Form-36 is frequently used for the assessment of generic HRQoL and is based on 
three domains of health (functional status, well-being and overall evaluation of health) com-
prising eight scales: physical functioning, role-physical, bodily pain, general health, vitality, 
social functioning, role-emotional, and mental health.101 The total score of the SF-36 ranges 
between 0 and 100 with a higher score representing better HRQoL. Two summary measures, 
in which the relative contribution of the eight scales varies, can be calculated with the SF-
36: a physical component scale (PCS) and mental component scale (MCS), and both can be 










































1 HRQoL is an outcome measure reflecting a broad patient perspective on health, and it is therefore of interest to know how HRQoL relates to active disease. High disease activity has 
been related to impaired quality of life before86;102;103 and disease activity steered treatment 
may thus lead to improved HRQoL outcomes. The magnitude into which achieving a certain 
disease activity level, and specifically remission in comparison to low disease activity, relates 
to better quality of life is less well known. This is especially interesting in the light of the treat 
to target paradigm.28;34 In addition, the longitudinal relationship between HRQoL and disease 
activity levels has not been studied before. These relationships are investigated in Chapter 9.
Implementation of regular monitoring in daily practice
Optimization of treatment resulting in improved outcomes in RA is a combined effort of 
physician and patient. To stimulate this collaboration, inclusion of the patient’s perspective 
is becoming increasingly important and already frequently introduced in rheumatologic re-
search, for example when determining a definition of a disease flare104, treatment goals105;106, 
or when defining benefits from treatment.107 Patients are also more and more involved in 
the development of guidelines and recommendations, although in some more prominent 
than in others.34;108;109 Core sets of health domains specifically for RA patients have been 
established and adjusted.110-112 
Furthermore, patient reported outcomes (PROs), such as the patient VAS for disease activity 
or questionnaires assessing functional ability, are being recognized as important outcome 
measures113;114, and these types of outcome measures have shown to be as sensitive to change 
as physician derived outcomes.115-117 PROs can be derived from patients or actually measured 
by patients themselves for example by self-assessment of pain and swelling in their joints 
and subsequent calculating a patient derived composite score for disease activity. However, 
the assessment of swollen joints by patients is unreliable to date118 as patients and physicians 
have shown a large disconcordance in their perceptions of swollen joints.105;106;119;120 
Nonetheless, patients can be of great value recording other indicators of active disease, such 
as the VAS, their functional ability or HRQoL, for example by completing questionnaires. 
These questionnaires can then be incorporated into electronic medical records (EMRs), which 
have been proven to be reliable for quality assessment and allow for benchmarking between 
health care providers or hospitals.121-123 Self-monitoring, through direct access to (parts of ) 
such databases incorporated in electronic patients files can improve sense of ownership 
of disease monitoring. Since resources in health care are becoming scarce, electronic self-
monitoring can be a tool to acquire useful clinical data without the requirement of face to 
face contact with health care providers. Patients and physicians attitude towards the use of 
EMRs in general is positive.124;125 Even so, there may be practical problems that need to be ad-










































1of systematic monitoring including patient perspective is acceptability and feasibility in daily practice by patients. We used the METEOR program126 to assess feasibility and acceptability of 
regular monitoring of physical functioning in daily clinical practice, either home based or at 
the outpatient department before the visit to the rheumatologist. (Chapter 10) 
Thesis outline
The first part of this thesis describes the work of the 3E initiative, an initiative in the field of 
rheumatology aiming at the promotion of evidence-based medicine by formulating practi-
cal recommendations addressing clinical problems. We performed two systematic literature 
reviews to determine the value of imaging modalities in UA patients. These papers served as 
a basis for developing recommendations on how to investigate and follow-up UA patients. 
(Chapters 2-4) In RA patients, we examined the relationship of radiological joint damage 
with physical functioning and more specifically if joint space narrowing is more importantly 
associated with impaired functioning than erosive joint damage. We also evaluated if joint 
damage in certain joints groups (either joint space narrowing or erosions) can explain higher 
HAQ scores. (Chapter 5)
The second part of this thesis focussed on research questions regarding disease activity. We 
investigated whether different versions of the DAS, with a reduced number of scored joints, 
without exclusion of the feet, would still be valid to use. We also wanted to ascertain that the 
DAS, using a patient VAS for disease activity would be as accurate as the DAS using patients 
VAS for general health. (Chapter 6) Furthermore, we studied if patients and physicians rated 
disease activity with a VAS differently and identified which factors explained these possible 
differences. (Chapter 7) 
Remission seems to be the optimal treatment goal. However, different definitions of remission 
exist, based on the different composite scores of disease activity. It remains to be determined 
if these different remission criteria have different associations with physical disability and 
joint damage. We have investigated this issue in
 Chapter 8. Additionally, we assessed the relationship between active disease and HRQoL: 
1) Are patients displaying or achieving lower disease activity demonstrating a better HRQoL 
compared to patients in higher disease activity? and 2) Is there extra benefit in patients 
displaying or achieving remission versus patients in low disease activity? (Chapter 9)
The final part of this thesis comprised of the implementation of monitoring in daily clinical 
practice and evaluated the feasibility of autonomic systematic monitoring of physical func-
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Objective: To perform a systematic literature review on the diagnostic and predictive value 
of conventional radiographs (CR) in patients with undifferentiated arthritis (UA).
Methods: We performed an extended search using Medline, Embase, the Cochrane library, 
and abstract from the 2007 and 2008 meeting of the American College of Rheumatology 
and the European League Against Rheumatism. Articles were included based on predefined 
inclusion criteria, and quality was assessed by using validated quality scales.
Results: In total, 25 articles were included from 6003 retrieved  references. Five articles de-
scribed a pure UA population, 20 articles described a mixed population (mostly rheumatoid 
arthritis (RA) and UA). In studies on UA, erosions on CR were strong predictors of RA diagnosis 
(positive likelihood ratio (LR+) 3.5-10.9; odds ratio 7.6 and 8.7). In a more heterogeneous 
mixed population, 20 studies reporting on 11 cohorts found a relationship between CR find-
ings and a subsequent diagnosis of RA. LR+ for erosions and/or bony decalcifications ranged 
from 1.8-9.7 and there was a greater prevalence of erosions and higher Sharp van der Heijde 
score (SvdH) in the RA group at follow up. With regard to prognosis in both UA and mixed 
populations, an association was found between number of abnormalities on CR and poor 
outcome.
Conclusion: Several studies, in pure UA and mixed populations, clearly demonstrate that 
CR are helpful in predicting future diagnosis of RA or worse prognosis. However, absence of 












































Undifferentiated arthritis (UA) is an ill-defined disease entity, since it is characterized by the 
absence of other diseases. Establishing an early diagnosis or prognosis in patients with UA is 
of major importance to obtain earlier and targeted treatment, leading to better outcomes for 
these patients. 1 To understand and learn more about this group of patients, “How to investi-
gate and follow up Undifferentiated Peripheral Inflammatory Arthritis (UPIA)” was chosen as 
the subject for the 2009 3E (evidence, expertise, exchange) Initiative in rheumatology. 
The 3E initiative promotes evidence-based medicine by formulating recommendations 
using both data form the literature and expert opinion. 2 Seventeen countries and almost 
700 experts participated in this project. In total, ten clinical questions selected by clinicians 
were chosen for a systematic review. The final recommendations based on the 10 different 
systematic reviews can be found elsewhere.3 
We present results of the systematic reviews of one of the ten clinical questions: “What is 
the diagnostic and predictive value of X-ray in UPIA? Should it be performed at baseline and 
repeated at what interval?” 
Conventional radiographs (CR) are commonly used for arthritis patients as additional tests in 
clinics. CR are relatively safe, inexpensive, and widely available, which makes them a conve-
nient test in current clinical care. Radiographs can help confirm or exclude a diagnosis such 
as rheumatoid arthritis (RA) or psoriatic arthritis. Abnormalities on radiographs might also be 
valuable in predicting other outcomes in UA, such as structural damage or impaired physical 
functioning.4.
At this time there are no systematic reviews that describe the importance of this test in UA 
for establishing either diagnosis or prognosis, since most data are collected in patients with 
early RA. 
We assessed the diagnostic and predictive value of CR inpatients with UA by reviewing all 
available literature using an extensive search strategy. As part of the 3E process, an evidence 
based recommendation on the use of CR was then formulated afterwards by combining the 
results of this review and the opinion of experts. 
PATIENTS & METHODS
The selected clinical question was rephrased according to the PICO method (Patients, In-











































into a question with epidemiological terms in order to make a literature search possible. The 
population was defined as the patient with UA, and conventional radiographs as intervention.
For our search there is no relevant control group. For the diagnostic search, outcome was 
defined as a specific diagnosis such as RA or psoriatic arthritis. Outcome in the search on 
prognosis was defined very broadly, in principle as every possible unfavorable outcome (e.g., 
progression of the disease, radiological damage, impaired physical function) and the final 
selection was dictated by the available literature. 
Three types of studies were considered for inclusion: 1 cohort studies in which patients from a 
given UA population had CR at baseline and in whom the outcome after a period of follow-up 
was recorded; 2 retrospective case-control studies in which patients had CR at baseline and 
who were known to have had UA when the baseline investigation was performed; and 3 ran-
domised controlled trials of UA patients that implicitly addressed the question of diagnostic 
or prognostic value, as each arm of a trial can be seen as a separate cohort study. 
Medline, Embase and the Cochrane library were searched for articles published between 
1950 and February 2009. The extensive search strategy (see web appendix: www.3eupia.com) 
was developed in close collaboration with a trained librarian and consisted of three parts: 
target population, intervention and preferred study type (diagnostic or prognostic). Ab-
stracts presented at the 2007 and 2008 meetings of the American College of Rheumatology 
(ACR) and European League Against Rheumatism (EULAR) were searched using the following 
terms: undifferentiated, undiagnosed, unclassified, early or probable arthritis. All references 
of selected articles and relevant reviews were hand searched for additional articles.  
The selection process consisted of two phases:(1) all titles and abstracts were checked for 
relevant articles; and (2) the full articles were reviewed in detail and retained or excluded 
based on predefined criteria. Criteria included: UA patients ≥18 years of age, presence of 
at least one clinically swollen joint, and use of CR to predict diagnosis or prognosis in these 
patients. Articles were split into two groups: a pure UA group and a mixed population, where 
only part of the group consisted of patients with UA.  
Articles included in the review were assessed for quality using validated scales. Quality as-
sessment of diagnostic studies was performed using a scale based on the Evidence-Based 
Medicine Working Group Quality.6 Assessment of the prognostic studies was done by the 
Newcastle-Ottawa Quality scale looking for three items: selection, comparability, and 
outcome. The maximum number of stars that can be awarded to a study is 9.7 The level of 
evidence was determined using the scale developed by the Oxford Centre for evidence based 











































Data were extracted using a predefined format and analyzed by two researchers. If necessary, 
corresponding authors were contacted for additional details. Likelihood ratios (LR) and con-
fidence intervals were extracted or calculated when possible; if these data were unavailable, 
descriptive results were used. The higher a positive LR (LR+) and the lower the negative LR 
(LR-), the higher the value of the test. LR+ > 5 and LR- < 0.2 represent strong diagnostic or 
prognostic evidence.6
RESuLTS
In total, 6003 references where found via Medline and Embase using the developed search 
strategy, of which 115 articles where reviewed in detail (see web appendix: www.3eupia.com). 
In total, 25 articles were included, five with a pure UA population and 20 with a mixed popula-
tion. The Cochrane Library did not retrieve any relevant articles, and two abstracts from the 
EULAR and ACR 2007/2008 had already been included in the review. Of the five studies with a 
pure UA population, four were diagnostic studies and one assessed prognosis. Three of these 
five studies were performed using the same cohort (the Leiden Early Arthritis Cohort) but 
with different numbers of patients included. Inclusion criteria and baseline characteristics 
are presented in Table 1. 
Two articles, van Aken 9 and Duer 10, found a high LR+ (Table 2) for developing RA according 
to ACR criteria11, the first one for erosions according to Sharp van der 
Heijde (SvdH) method 12 the other for Larsen grade 1. 13 In the study by van der Helm-van Mil 
14, erosions were found as predictor in a univariate analysis but not in multivariate analysis. 
The article by van Gaalen 15 demonstrated that in a model with and without anti-cyclic 
citrillunated peptide antibodies the odds ratios for developing RA were moderate (table 2). 
Prognosis was assessed by the study of Jansen 16. When differentiating between mild and 
progressive disease at 1 year, SvdH scores at baseline are significantly different (Table 3). 
Of 20 studies with a mixed population that could be included, heterogeneity in inclusion 
criteria or baseline characteristics was far greater than in the UA group (Table 1). In total, 
these studies are derived from 11 cohort studies from different countries.  Most studies used 
different features of the radiographs which makes them difficult to compare. 
In general, studies found high LR+ for erosions predicting diagnosis. When using both hand 
and foot radiographs, LR increased in comparison to using hands radiographs only.  
Bony decalcification, on the other hand, was not very informative for diagnosing RA. LR- were 































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Table 2: Likelihood ratios extracted from the different articles
Study Prognostic factor Outcome LR+ (CI) LR- (CI)
uA population
Van Aken 2005(9) Erosive disease (SvdH) hands or feet CRs RA (ACR) at 1 year 3.5 (2.1-6.0) 0.8 (0.7-0.9)
Duer 2008(10) Larsen grade 1 hand or foot CRs RA (ACR) at 2 years 10.9 (1.4-87.3) 0.7 (0.4-1.0)
Mixed population
Devauchelle 2001(17) Erosions hands CRs RA according to panel 4.1 (1.7-9.5) 0.9 (0.8-1.0)
Devauchelle 2004(18) Erosions feet CRs RA according to panel 8.6 (1.9-37.6) 0.8 (0.7-0.9)
  Erosions hands CRs   5.7 (1.6-19.8) 0.8 (0.7-1.0)
  Erosions hands and/or feet CRs   6.2 (2.4-15.6) 0.7 (0.6-0.9)
Devauchelle 2006(20) Erosions and/or decalcifications hands CRs RA according to panel 1.8 (1.0-3.1) 0.9 (0.8-1.0)
Saraux 2001(19) Erosions and/or decalcifications hands CRs RA according to panel 9.7 (3.4-27.2) 0.8 (0.7-0.9)
Gough 1994(21) Erosions hands or feet CRs Persistent  disease* 6.0 (1.9-18.7) 0.7 (0.7-0.9) 
LR+=positive likelihood ratio; LR-=negative likelihood ratio; CI=confidence interval; UA=undifferentiated arthritis; SvdH=according to Sharp 
van der Heijde method; CRs=conventional radiographs; RA (ACR)=RA according to ACR criteria; *clinical or laboratory evidence of active disease 
or required therapy with slow-acting drugs at 1 year
Table 3: Additional results 
Study Prognostic factor Outcome Results
uA      
 Van der Helm 2007(14) Erosive disease* RA (ACR)** at 1y
Univariate erosive disease non-
RA 29(7%) RA 29(16%)  p<0.001, 
multivariate logistic regression analysis 
not independent predictor
Van Gaalen 2004(15) Erosions RA (ACR) at 1y
OR 7.6 (2.4-24.4) p=0.001 (model 
without anti-CCP) OR 8.7 (2.4-31.2) 
p=0.001 (model with anti-CCP)
Jansen 2002(16) SvdH score Mild or progressive diseaseª
Mild UPA 2.0 Progressive UPA 8.0 
Significantly different in these 2 groups 






RA (ACR) at 1y
Both different in RA, UA and UA>RA 
group at 1y
Cunnane 2001(25) Erosions RA (ACR) at 1,5y
Number of erosions lower in UA group 
compared to RA
Nielen 2005(26) SvdH score RA according to rheumatologist at 1y 
Univariate analysis SvdH score 
associated with diagnosis, multivariate 
not
Daragon 2001(27) SvdH score RA (ACR) at 1y SvdH score not significantly different
Kuriya 2008(28) Erosive disease RA (ACR) at 6m
Erosive disease not independently 
predictive 
Visser 2002(29)
Erosions acc. SvdH 
score











































diagnostic studies suggest that numbers of erosions or SvdH scores are in general different in 
the patients developing RA, compared to UA, but not independently predictive 22-28 (Table 3). 
When predicting prognosis, such as progressive disease, onset of Disease Modifying Anti-
Rheumatic Drug treatment or functional ability, several studies with numerous scoring meth-
ods found that more severe abnormalities are related to worse prognosis. 21;26;29-36 (Tables 2 
and 3) There was no literature available on how often radiographs should be repeated or on 
other radiographic characteristics that could be helpful in diagnosing or following patients 
with UA.
DISCuSSION
Our systematic review summarized and evaluated all available evidence on the diagnostic 
and prognostic value of conventional radiographs. The evidence found in this review to-
gether with expert opinion was used to make a clinical recommendation, as part of the 3E 
initiative, which promotes evidence-based medicine in rheumatology. The description of the 
final recommendations can be found elsewhere.3 
Several studies in both UA and mixed populations clearly showed that finding erosions on 
radiographs gives a high probability for developing RA or a worse prognosis, as demon-
strated by high LR+. High LR- indicated that diagnostic or prognostic value in the absence 
of radiographic abnormalities  is low 9;10;17-21. There was no literature available on whether 
Table 3 (continued)
Study Prognostic factor Outcome Results
Jansen 2003(31) 
Jansen 2004(30)            
Nielen 2005(26)
SvdH scores
Mild vs progressive disease                     
Functional outcome†
Baseline SvdH scores different in these 




Onset of DMARD treatment                       
Larsen score
Larsen scores different in patients with 
different DMARD onset; Larsen scores a 






Poor outcome at 3y
Total outcome index
X-ray stage significantly different in 
patients with good and  poor outcome 
at 3y X-ray stage correlates with total 
outcome index
Boire 2004(36) Erosions Severity*** OR 3.47
* as defined by the Sharp van der Heijde method; ** diagnosis of RA according to ACR criteria; ªProgressive disease=delta radiographic 
progression≥4 or radiographic damage≥10 or HAQ≥1 at one year follow up; §arthritis in at least 1 joint and/or treatment with DMARDS or 
steroids in the last 3 months 
†progressive disease= ≥5 points change in SvdH score and Low functional outcome= HAQ≥1 High functional outcome=HAQ<1; *** M-HAQ ≥ 











































repeating radiographs during the diagnostic process or performing radiography to deter-
mine prognosis are of any value. 
Even with our extensive search strategy, the available evidence from the literature for a pure 
UA population was scarce, certainly when compared to (early) arthritis in general. Many 
mixed cohorts included patients that fulfilled ACR criteria at baseline and differed in the per-
centage of UA patients (Table 1). Nevertheless, all the studies retrieved, in both UA and mixed 
populations, pointed in the same direction, with high LR+ for the diagnostic and prognostic 
value of erosions on CR (Table 2), which increases the generalizability of the results. 
A problem in estimating the performance of CRs as a diagnostic test is that there is circular 
reasoning, since erosions are part of the 1987 ACR criteria for RA. This may lead to an overes-
timation of the diagnostic value of radiographs. Consequently, the ACR criteria as a measure 
of outcome are open for debate. Yet, this is the outcome that was used by the majority of the 
studies. It is nevertheless reassuring that the studies that used a different definition (RA as 
determined by a panel or by persistent disease) yielded the same results.
In conclusion, radiographs can be a valuable test in patients with UA and in  mixed popu-
lations for predicting diagnosis or prognosis. These finding formed the basis for the final 
recommendation, given in detail elsewhere 3.
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Chapter 3
The value of magnetic resonance imaging and ultrasound in 

















































Objectives: To perform a systematic literature review about the diagnostic and prognostic 
value of magnetic resonance imaging (MRI) and ultrasound (US) in patients with undiffer-
entiated peripheral inflammatory arthritis (UPIA) and to assess if these should be done at 
baseline and repeated at which interval.
Methods: Medline, Embase, Cochrane and ACR/EULAR 2007-08 abstracts were searched for 
diagnostic and prognostic studies of any duration examining the ability of MRI/US to predict 
the outcome of patients with UPIA. Sensitivity, specificity, predictive values and likelihood 
ratios were calculated. When available, odds ratios were extracted. Quality was appraised 
using validated scales.
Results: Regarding MRI, 11 out of 2595 screened references were included: 2 truly undif-
ferentiated populations and 9 mixed populations. Bone edema (LR+=4.5) and the combina-
tion of a distinct MRI synovitis and erosion pattern (LR+=4.8) increased the probability of 
developing rheumatoid arthritis (RA). The absence of MRI synovitis (LR-=0.2) and the absence 
of a distinct synovitis pattern (LR-=0) decreased the probability of developing RA. Regard-
ing US, 2 out of 2111 references were included, both mixed populations; no data could be 
extrapolated for UPIA.
Conclusions: MRI bone edema and the combined synovitis and erosion pattern seem useful 
in predicting the development of RA from UPIA. The value of US in UPIA is still to be de-
termined. The absence of MRI synovitis seems useful in excluding the development of RA. 
No data was found about the value of repeating MRI/US. Studies evaluating MRI/US in UPIA 










































MRI and US in UA
3
INTRODuCTION
Within the field of imaging in rheumatic diseases, large and exciting advances have been 
made during the last decade. Although radiographs continue to be the most widely used 
tool, magnetic resonance imaging (MRI) and ultrasound (US) offer advantages through more 
sensitive depiction of inflammatory and destructive disease manifestations.1
In the context of undifferentiated peripheral inflammatory arthritis (UPIA), patients’ questions 
will focus on the likelihood of developing a well-defined rheumatic disease and on what the 
future holds for disease progression, persistence, functional impairment and quality of life. 
These are questions about future diagnosis and prognosis. The answers to these questions 
are vital for clinical decision making, including the choice of treatment.2
This manuscript is part of the 3E Initiative (Evidence, Expertise, Exchange) in Rheumatology 
for 2008-09.3-5 The resulting 10 recommendations on “How to investigate and follow-up UPIA” 
are described in more detail elsewhere.5 The objective of this work was to systematically 
review the available literature about the following question: “What is the diagnostic and 
predictive value of MRI and US in patients with UPIA? Should they be done at baseline and 
repeated at which interval?”
METHODS
Strategy and criteria for considering studies for this review
The clinical question was structured in the PIO (Patients, Participants or Problem; Interven-
tion or Index test; Outcomes or target conditions) format6 and the eligible types of study 
were defined.
Patients were defined as “adults with UPIA”. The definition of UPIA is controversial and there is 
no widely accepted classification criterion for this condition. During the 2008-09 3E Initiative 
kick-off meeting, experts decided that only patients in whom clinically apparent joint swell-
ing (synovial proliferation or synovial effusion) was observed by the rheumatologist should 
be included. This is in contrast to some reports that have included patients with inflamma-
tory joint symptoms in the absence of clinically observable joint swelling (a state usually 
referred as “inflammatory arthralgia”). It was also emphasised that the terms “early arthritis” 
and “undifferentiated arthritis” should not be considered similar or interchangeable. For the 
current systematic review, the participants should be those patients that, after the initial 
visits and diagnostic investigations, did not fulfil diagnostic/classification criteria for any 
rheumatologic disorder. Because we anticipated that very few studies would have included 
truly undifferentiated populations at baseline, we also kept a record of results from studies 
in mixed populations (e.g. UPIA+arthralgia, UPIA+early rheumathoid arthritis [RA]), as these 











































The index test was defined as a certain MRI feature (e.g. synovial fluid, synovitis, erosion, bone 
edema and tenosynovitis) or US feature (e.g. US power-doppler [PD] and US grey-scale [GS] 
scores), as defined in the study.
The outcomes were defined as the development of well-defined rheumatic diseases (e.g. RA, 
psoriatic arthritis) or relevant disease outcomes (e.g. remission, radiographic progression). 
The use of internationally validated diagnostic/classification criteria (e.g. 1987 American 
College of Rheumatology [ACR] criteria for RA7) and validated outcome measures should be 
given more value when appraising the definition of outcome.
Three types of studies were considered for inclusion: 1) cohort studies in which patients from 
a given UPIA population had MRI or US at baseline and in whom the outcome after a period 
of follow-up was recorded; 2) retrospective case-control studies in which patients had MRI or 
US at baseline and in whom it is known that they had UPIA when the baseline investigation 
was performed; and 3) randomised controlled trials of UPIA patients that implicitly addressed 
the question of diagnostic or prognostic value, as each arm of a trial can be seen as a cohort 
study.
Search methods for identification of studies, selection of articles, data extraction 
and analysis, and quality assessment




A total of 1734 articles and 861 meeting abstracts were found. After title and abstract 
screening, 15 articles,8-22 3 meeting abstracts (already published or later published in article 
format(10, 11, 23)) and one additional paper from hand search24 were left for full paper 
review. The inclusion criteria were fulfilled by 11 articles,(8-17, 23) which were included in 
the systematic literature review. Two articles included truly undifferentiated populations(8, 
23) while the other 9 included mixed populations9-17 at baseline. A detailed flowchart can be 
found in the web appendix (www.3eupia.com).
MRI results (UPIA populations) 
Studies characteristics´ and results for UPIA populations are summarized in tables 1 and 2.
Tamai et al23 evaluated 129 patients with UPIA; all the patients expressed rheumatic mani-
festations of the wrists and finger joints at study entry. At a prospective follow-up of 1 year, 


































































































































































































































































































































































































































































Table 2: Performance of each variable at baseline (UPIA populations) for the prediction of progression to RA
Author, year; No at 
baseline; No (%) of  final 














Baseline UPIA = 41
Final RA = 11 (26.8)
NOS = 8 stars, LE = 2b
1) MRI synovitis and 
erosion pattern of RA*
64 87 64 87 4.8 (1.7-13.2) 0.4 (0.2-0.9)
2) MRI synovitis pattern 
of RA*
100 60 48 100 2.5 (1.6-3.9) 0 (NA)
3) MRI erosion pattern 
of RA*
64 77 50 85 2.7 (1.2-6.0) 0.5 (0.2-1.1)
4) MRI synovitis or erosion 
pattern of RA*
100 50 42 100 2.0 (1.4-2.9) 0 (NA)
5) MRI synovitis and 
erosion and scintigraphy 
patterns of RA*
45 100 100 83 Inf 0.5 (0.3-0.9)
6) RF+ 36 67 29 74 1.1 (0.4-2.8) 1.0 (0.6-1.6)
7) CRP >1mg/dl 64 63 39 83 1.7 (0-9-3.3) 0.6 (0.3-1.3)
8) Larsen grade 1† 36 97 80 81 10.9 (1.4-87) 0.7 (0.4-1.0)
9) Scintigrahy pattern 
of RA‡
64 74 50 83 2.5 (1.1-5.3) 0.5 (0.2-1.1)
Tamai 09 (23)
Baseline UPIA = 129
Final RA = 75 (58.1)
NOS = 8 stars, LE = 2b
1) MRI synovitis 91 44 69 77 1.6 (1.3-2.1) 0.2 (0.1-0.5)
2) MRI symmetric synovitis 75 59 72 63 1.8 (1.3-2.6) 0.4 (0.3-0.7)
3) MRI bone edema 41 91 86 53 4.5 (1.9-10.7) 0.6 (0.5-0.8)
4) MRI bone erosion 29 91 81 48 3.2 (1.3-7.8) 0.8 (0.7-0.9)
5) MRI bone edema and/
or erosion 48 83 80 54 2.9 (1.5-5.5) 0.6 (0.5-0.8)
6) IgM-RF 52 70 71 51 1.8 (1.1-2.8) 0.7 (0.5-0.9)
7) Anti-CCP 57 93 91 61 7.7 (3.0-20.3) 0.5 (0.4-0.6)
8) IgM-RF and/or anti-CCP 67 67 74 59 2.0 (1.3-3.0) 0.5 (0.4-0.6)
9) MMP-3 36 85 77 49 2.4 (1.2-4.9) 0.8 (0.6-0.9)
10) CRP positivity 68 70 76 61 2.3 (1.5-3.6) 0.5 (0.3-0.7)
11) 2 of the following 3: 
anti-CCP+ and/or IgM-RF+, 
MRI symmetric synovitis, 
and MRI bone edema and/
or bone erosion 68 76 80 63 2.8 (1.7-4.7) 0.4 (0.3-0.6)
12) Anti-CCP and MRI bone 
edema 29 100 100 50 Inf 0.7 (0.6-0.8)
UPIA: undifferentiated peripheral inflammatory arthritis. SE: sensitivity. SP: specificity. PPV/NPV: positive/negative predictive value. 
LR+/LR-: positive/negative likelihood ratio. Inf: denominator is zero. RA: rheumatoid arthritis. NOS: Newcastle-Ottawa Scale. LE: level 
of evidence. MRI: magnetic resonance imaging. RF: rheumatoid factor. CRP: C-reactive protein. Anti-CCP: anti-cyclic citrullinated 
peptide antibodies. MMP-3: matrix metalloproteinase 3. NA: not applicable. *MRI synovitis/erosion pattern of RA: several joints, not 
1st carpometacarpal (CMC1) joints. †Larsen grade 1 denotes the presence of joint space narrowing, soft tissue swelling and/or juxta-
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were evaluated for bone edema, bone erosion and synovitis in 15 sites in each finger and 
wrist. Patients who were positive for at least 2 of 3 objective measures (anti-cyclic citrulli-
nated peptide [anti-CCP] antibodies and/or IgM-rheumatoid factor, MRI-proven symmetric 
synovitis, and MRI-proven bone edema and/or bone erosion) progressed to RA at 1 year 
with a positive likelihood ratio (LR+)=2.8 and a negative likelihood ratio (LR-)=0.4 (sensitivity 
[SE]=68%, specificity [SP]=76%). Furthermore, in 22 UPIA patients positive for both anti-CCP 
and MRI-proven bone edema who were considered to have progressed to RA at 1 year, the SP 
and positive predictive value (PPV) was increased to 100% (however, SE was 29%). Anti-CCP 
alone and bone edema alone had SP of 93% and 91%, respectively (SE was 57% and 41%, 
respectively). MRI synovitis had a LR-=0.2 regarding progression to RA (SE=91%, SP=44%).
Duer et al8 investigated 41 patients with arthritis and subjective symptoms in the hand, who 
remained unclassified despite conventional clinical, biochemical and radiographic examina-
tions. Patients who fulfilled 1987 ACR criteria for RA7 or had radiographic bone erosions were 
excluded. Contrast enhanced MRI of the wrist and 2nd-5th metacarpophalangeal joints of 
the most symptomatic hand was performed and the MRI pattern was compared with the final 
diagnosis after a 2-year follow-up period (RA versus non-RA, according to 1987 ACR criteria). 
The combination of a distinct MRI synovitis and erosion pattern of RA (definitions can be 
found in table 2) had a LR+=4.8 and a LR-=0.4 (SE=64%, SP=87%) for the development of RA. 
When the synovitis and erosion pattern of RA was combined with a scintigraphy pattern of 
RA, SP and PPV increased to 100%, but at the cost of a low SE (45%). MRI bone edema was not 
assessed in this study. That same MRI synovitis pattern alone had a LR-=0 for progression to 
RA (SE=100%, SP=60%).
MRI results (mixed populations)
Studies characteristics´ and results for mixed populations are summarized in tables 3 and 
4. These are populations who included not only patients with UPIA but also patients with 
arthralgia or already with an established diagnosis at baseline.9-17 
US results
A total of 1250 articles and 861 meeting abstracts were found. After title and abstract 
screening, 3 articles(19, 20, 25) and 3 meeting abstracts (already or later published in ar-
ticle format(26, 27)) were left for full paper review. The inclusion criteria were fulfilled by 2 
articles (mixed populations only). A detailed flowchart can be found in the web appendix 
(www.3eupia.com). Studies characteristics´ and results for the 2 mixed populations(26, 27) are 
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Table 4: Performance of each variable at baseline (mixed populations) for the prediction of progression to RA
Author, year; No at 
baseline;















Baseline Mixed = 17*
Final RA = 5 (29.4)
NOS = 7 stars, LE = 2b
1) MRI criterion (MIP)† plus 
CARF+ and/or anti-CCP+
100 75 63 100 4.0 (1.5-11) 0 (NA)
2) Symmetrical hand synovitis 
with MRI (MIP)†
100 50 45 100 2.0 (1.1-3.5) 0 (NA)
3) CARF+ 100 58 50 100 2.4 (1.2-4.7) 0 (NA)
4) Anti-CCP+ 60 92 75 85 7.2 (1.0-53) 0.4 (0.1-1.3)
5) CARF+ and/or anti-CCP+ 100 58 50 100 2.4 (1.2-4.7) 0 (NA)
Narváez  08 (10)
Baseline Mixed = 40
Final RA = 31 (77.5)
NOS = 6 stars, LE = 2b
1) MRI synovitis with BME or 
erosions
100 78 94 100 4.5 (1.3-15) 0 (NA)
2) Anti-CCP+ 23 100 100 27 Inf 0.8 (0.6-0.9)
Tamai  06 (12)
Baseline Mixed = 113
Final RA = 80 (70.8)
NOS = 7 stars, LE = 2b
Respectively >=1, 2 or 3 of 
the following: anti-CCP+; MRI 
symmetric synovitis; MRI BME 




















Baseline Mixed = 30
Final RA = 16 (53.3)
NOS = 6 stars, LE = 2b
MRI OMERACT MCP erosion 
score >15 
63 71 71 63 2.2 (0.9-5.4) 0.5 (0.3-1.1)
Boutry  05 (14)
Baseline Mixed = 47‡
Final RA =28 (59.6)‡
NOS = 6 stars, LE = 2b
1) MRI MCP BME 71 95 95 69 14 (2-93) 0.3 (0.2-0.5)
2) MRI MCP Synovitis 100 0 60 Inf 1.0 (1.0-1.0) Inf
3) MRI MCP Bone erosions 61 53 65 48 1.3 (0.7-2.2) 0.7 (0.4-1.4)
4) MRI MCP Bone defects 39 79 73 47 1.9 (0.7-5.0) 0.8 (0.5-1.1)
5) MRI MCP Tenosynovitis 68 53 90 38 1.4 (0.8-2.5) 0.6 (0.3-1.2)
6) MRI Wrist BME 39 84 79 70 3.9 (1.3-11) 0.5 (0.3-0.9)
7) MRI Wrist Synovitis 100 0 60 Inf 1.0 (1.0-1.0) Inf
8) MRI Wrist Bone erosions 100 16 64 100 1.2 (1.0-1.4) 0 (NA)
9) MRI Wrist Bone defects 64 37 60 41 1.0 (0.7-1.6) 1.0 (0.4-2.1)
10) MRI Wrist Tenosynovitis 96 21 64 80 1.2 (1-1.6) 0.2 (0-1.4)
Klarlund 00 (15)
Baseline Mixed = 13 
Final RA =5 (38.5)
NOS = 7 stars, LE = 2b
1) MRI erosions 20 100 100 67 Inf 0.8 (0.5-1.2)
2) MRI Tenosynovitis 60 63 50 71 1.6 (0.5-5) 0.6 (0.2.2.1)
Sugimoto  00 (16)
Baseline Mixed = 29§ 
Final RA =8 (27.6)
NOS = 6 stars, LE = 2b
Bilateral MRI synovitis of the 
same joint area (wrist, MCP 
or PIP) 
88 90 78 95 9.2 (2.4-35) 0.1 (0-0.9)
Sugimoto  96 (17)
Baseline Mixed = 27
Final RA =16 (59.3)
NOS = 6 stars, LE = 2b
Bilateral MRI synovitis of the 
same joint area (wrist, MCP 
or PIP)












































Author, year; No at 
baseline;














Zampogna  08 (11)
Baseline Mixed = 39
Final RA = 12 (30.8)
NOS = 7 stars, LE = 2b
MRI rate of early enhancement 
ratio (REE)**, MRI relative 
enhancement (RE)**, morning 
stiffness, SJC, TJC, patient 
global, Ritchie index, DAS, 
HAQ, ESR, IgM RF, anti-CCP 
1) Need for immunosuppressive treatment at the end of follow-up: 
predicted by higher REE and lower RE (MvA)
2) RA ACR criteria during follow up: predicted by higher RE (MvA)
3) RA ACR criteria at the end of follow-up: MRI not predictive (MvA)
4) Complete remission††: predicted by lower RE (UvA)
RA: rheumatoid arthritis. SE: sensitivity. SP: specificity. PPV/NPV: positive/negative predictive value. LR+/LR-: positive/negative likelihood ratio. 
Inf: denominator is zero. NOS: Newcastle-Ottawa Scale. LE: level of evidence. MRI: magnetic resonance imaging. BME: bone marrow edema. 
Anti-CCP: anti-cyclic citrullinated peptides antibodies. CARF: anti-agalactosyl IgG antibodies. MCP: metacarpophalangeal joints. PIP: proximal 
interphalangeal joints. SJC: swollen joint count. TJC: tender joint count. DAS: disease activity score. HAQ: health assessment questionnaire. ESR: 
erythrocyte sedimentation rate. RF: rheumatoid factor. NA: not applicable. MvA: multivariate analysis. UvA: univariate analysis. *Initial cohort 
was 21 patients but 4 (19%) did not complete follow-up. †MRI criterion: MRI synovitis was diagnosed if there was significant intra-articular 
enhancement or periarticular synovial tendinitis after gadolinium-enhanced 3D transverse images were processed by means of the maximum 
intensity projection (MIP) method. ‡Data available for 47/56 patients (final diagnosis: 28 RA, 14 SLE, 5 Sjögren; not-analyzed: 2 reactive 
arthritis, 3 unclassified self-limited arthritis, 1 lost to follow-up, 3 uninterpretable MRI). §After exclusion of 2 patients who abandoned the study 
and exclusion of the data from 19 patients who fulfilled RA ACR criteria at baseline. **The MRI synovial enhancement ratio was calculated both 
as rate of early enhancement (REE) per second during the first 55’’ and as relative enhancement (RE) at t seconds; the REE shows the slope of the 
curve of contrast uptake and is steeper if inflammation is higher; the RE indicates the steady state of enhancement. ††Remission was defined as 
the absence of morning stiffness, absence of tender and swollen joint count and normal acute phase reactants.


















































































































































SJC: swollen joint count. CRP: C-reactive protein. ESR: erythrocyte sedimentation rate. RF: rheumatoid factor. Anti-CCP: anti-cyclic citrullinated 
antibodies. SD: standard deviation. UPIA: undifferentiated peripheral inflammatory arthritis. NA: not applicable. NR: not reported. *Data 
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DISCuSSION
This systematic literature review summarizes and evaluates the available evidence about the 
value of MRI and US in UPIA.
The results showed that MRI bone edema (LR+=4.5) is more likely to be seen in UPIA patients 
who will develop RA than in patients who will not develop RA and that the combination 
of MRI bone edema and anti-CCP positivity is highly specific for the development of RA 
(LR+=infinite, meaning that specificity was 100%).23 However, the absence of both these 
features does not allow excluding the development of RA.23 On the other hand, the results 
also showed that patients without MRI synovitis have a decreased probability of developing 
RA (LR-=0.2).23
In another study, the combination of a distinct MRI synovitis and erosion pattern with the 
involvement of several hand joints but not the first carpometacarpal joint was more likely to 
be seen in UPIA patients who developed RA (LR+=4.8) than in patients who did not develop 
RA.8 The combination of such MRI pattern with a scintighraphy pattern with the involvement 
Table 6: Performance of each variable at baseline (mixed population) for the prediction of progression to persistent inflammatory arthritis 
(Freeston et al) or for the prediction of relapse (Scirè et al)
Author, year; 
Population, No; 















Baseline Mixed = 49* 
(UPIA? + Arthralgia)
Final pIA = 38 (77.6)
NOS = 7 stars, LE = 2b
1) US GS≥1† 92 18 80 40 1.1 (0.8-1.5) 0.4 (0.1-2.3)
2) US GS≥2† 76 64 88 44 2.1 (0.9-4.7) 0.4 (0.2-0.8)
3) US GS=3† 47 91 95 33 5.2 (0.8-35) 0.6 (0.4-0.8)
4) US PD≥1† 71 82 93 45 3.9 (1.1-14) 0.4 (0.2-0.6)
5) US PD≥2† 50 100 100 35 Inf 0.5 (0.4-0.7)
6) US FT in any finger 47 64 82 26 1.3 (0.6-3.0) 0.8 (0.5-1.4)
7) Erosive on US‡ 53 73 87 31 1.9 (0.7-5.3) 0.7 (0.4-1.1)
8) RF+ 32 100 100 30 Inf 0.7 (0.6-0.8)
9) Anti-CCP+ 45 100 100 34 Inf 0.6 (0.4-0.7)
Scirè 09 (27)
Baseline Mixed = 106 (33 
UPIA + 73 Early RA)
Final RA = 106 (100)
NOS = 7 stars, LE = 2b
1) Ultrasound (44 joints): US JC, US 
PD, US GS
2) SJC, RAI, DAS
3) CRP, ESR
4) Steroid use
DAS relapse after achieving a DAS≤1.6 at two consecutive visits 3 
months apart, after ≥12 months follow-up: 
- US-PD was the only significant predictor of disease flare 
(OR=12.8;  95%CI 1.6-103.5; multivariate logistic regression)
UPIA: undifferentiated inflammatory peripheral arthritis. pIA: persistent inflammatory arthritis. RA: rheumatoid arthritis. SE: sensitivity. SP: 
specificity. PPV/NPV: positive/negative predictive value. LR+/LR-: positive/negative likelihood ratio. Inf: denominator is zero. NOS: Newcastle-
Ottawa Scale. LE: level of evidence. RF: rheumatoid factor. Anti-CCP: anti-cyclic citrullinated antibodies. US PD: power doppler ultrasound. US 
GS: grey scale ultrasound. US FT: ultrasound finger tenosynovitis. US JC: joint count ultrasound. SJC: swollen joint count. RAI: Ritchie’s articular 
index. DAS: disease activity score. CRP: C-reactive protein. ESR: erythrocyte sedimentation rate. OR: odds ratio. CI: confidence interval. *1/50 
patients lost to follow-up. †Bilateral MCP joints, flexor tendons and wrists were scanned and each joint was scored for GS and PD on a 0-3 semi-











































of several joints but not distal interphalangeal joints and first carpometacarpal joint was even 
more specific for the development of RA (LR+=infinite, meaning that specificity was 100%).8 
However, again, none of these features allowed to exclude the development of RA.8 On the 
other hand, the results also showed that patients without the above MRI synovitis pattern 
had a decreased probability of developing RA (LR-=0, meaning that sensitivity for RA was 
100%).8
Results based on MRI studies in mixed populations(9, 10, 12-17) must be viewed with cau-
tion due to the heterogeneity of the study populations and the different measurements and 
outcomes that were used and made the pooling of data impossible. Overall they provide 
some evidence for the usefulness of MRI (bone oedema, synovitis and erosions) in predicting 
RA, but direct extrapolation of results to UPIA cannot be performed.
Regarding US, no studies were found in UPIA. We describe one study in a cohort of patients 
with very early inflammatory hand symptoms26 and another in a population mainly with 
(very) early RA.27 Again, extrapolation of results to UPIA cannot be made, although they 
suggest that US-PD signal and US-GS synovitis can be regarded as potential candidates for 
futures studies in UPIA. Their usefulness in this population is yet to be determined though.
Definite answers about the diagnostic and prognostic value of MRI and US in UPIA can only 
be achieved through well-conducted longitudinal studies of patients with UPIA. Studies 
of this kind are scarce, particularly in truly undifferentiated populations. The value of MRI 
and US should be compared with other potentially useful variables; this should be done not 
only by assessing the performance of the single variables alone, but also using multivariate 
logistic regression analysis with the aim to develop the best possible predicting model. This 
has never been done taking into account MRI and US.28 The definition of a positive index test 
is also of great importance and ideally this should be done using validated and reproducible 
scoring systems. For the clinician, US may have some advantages due to the low-running 
costs and easy accessibility, however, extremity MRI is a promising answer for the costs of 
MRI. No data was found about the value of repeating MRI or US in UPIA and this should also 
be a matter of study in the future. The recent new ACR/EULAR criteria for RA29 should also be 
taken into account in the future, as several of the patients we now describe as having UPIA 
will likely be labelled as RA patients.
In conclusion, a distinct MRI pattern of erosion and synovitis and the presence of MRI bone 
edema increased the probability of developing RA from UPIA; however, some UPIA patients 
presenting these MRI features may still remain undifferentiated, develop other diseases or 
have a self-limited course. The absence of MRI synovitis decreased the probability of develop-
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assessment, US-PD signal and US-GS synovitis are potential candidates for futures studies 
in UPIA. Current knowledge already provides evidence for the usefulness of MRI in UPIA and 
strongly encourages further testing of both MRI and US in undifferentiated arthritis.
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Chapter 4
Multinational evidence-based recommendations on “How 
to investigate and follow-up undifferentiated peripheral 
inflammatory arthritis”: integrating systematic literature 
research and expert opinion of a broad international panel of 













































































Objective: To develop evidence-based recommendations on how to investigate and follow-
up undifferentiated peripheral inflammatory arthritis (UPIA).
Methods: 697 rheumatologists from 17 countries participated in the 3E (Evidence, Expertise, 
Exchange) Initiative of 2008-2009 consisting of three separate rounds of discussions and 
modified Delphi votes. In a first round, 10 clinical questions were selected. A bibliographic 
team systematically searched Medline, Embase, the Cochrane Library and ACR/EULAR 
2007-2008 meeting abstracts. Relevant articles were reviewed for quality assessment, data 
extraction and synthesis. In a second round, each country elaborated a set of national rec-
ommendations. Finally, multinational recommendations were formulated and agreement 
among the participants and the potential impact on their clinical practice was assessed.
Results: A total of 39.756 references were identified, of which 250 were systematically re-
viewed. Ten multinational key recommendations about the investigation and follow-up of 
UPIA were formulated. One recommendation addressed differential diagnosis and investiga-
tions prior to establishing the operational diagnosis of UPIA, seven recommendations related 
to the diagnostic and prognostic value of clinical and laboratory assessments in established 
UPIA (history and physical examination, acute phase reactants, autoantibodies, radiographs, 
magnetic resonance imaging and ultrasound, genetic markers and synovial biopsy), one 
recommendation highlighted predictors of persistence (chronicity) and the final recommen-
dation addressed monitoring of clinical disease activity in UPIA.
Conclusions: Ten recommendations on how to investigate and follow-up UPIA in the clinical 
setting were developed. They are evidence-based and supported by a large panel of rheuma-
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INTRODuCTION
In clinical practice, a large number of patients who present with recent-onset arthritis have 
undifferentiated peripheral inflammatory arthritis (UPIA). In this context patients’ initial ques-
tions will focus on their likelihood of developing a well-defined rheumatic disease and on 
what the future holds for disease progression, persistence, functional impairment and quality 
of life. These are questions about future diagnosis and prognosis. The answers to these ques-
tions are vital for clinical decision making, including the choice of treatment.
The 3E Initiative (Evidence, Expertise, Exchange) in rheumatology is a multinational effort, 
aimed at promoting evidence-based medicine by formulating practical recommendations 
addressing clinical problems.1,2 The objective of the 3E Initiative of 2008-2009 was to develop 
practical recommendations on “how to investigate and follow-up undifferentiated peripheral 
inflammatory arthritis”, by integrating systematically generated evidence and expert opinion 
of a broad panel of international rheumatologists. Although the term “inflammatory” in UPIA 
may seem redundant, the reason for its use was to clearly distinguish the target population 
from patients with degenerative joint disease, often called osteoarthritis or degenerative 
arthritis in the English medical literature.
METHODS
A total of 697 rheumatologists from 17 countries participated in the 3E Initiative of 2008-
2009. Each country was represented by a scientific committee, consisting of one principal 
investigator and 5-13 members. The bibliographic team consisted of ten international fellows 
(PM, IC, WK, RK, BK, MS, LS-F, KT, WV, EV) and five mentors (DA, LC, RL, DvdH, CB), one of the 
mentors also being the scientific organizer (CB). The 17 national principal investigators were 
selected and invited by the 3e scientific organizer (CB) and each national chair was in charge 
of composing a national steering committee. The experts were all the members of the 17 
national Steering Committees who attended the multi-national meetings for 3e Initiative.
During the first international meeting (n=113 participants), 10 clinically relevant questions 
on how to investigate and follow-up UPIA were formulated and selected via a modified 
Delphi vote. The areas addressed were fourfold: 1) the phase prior to establishing the op-
erational diagnosis of UPIA- namely which differential diagnosis should be considered in a 
patient presenting with (inflammatory) arthritis and the minimal investigations necessary to 
consider a patient as having UPIA; 2) the diagnostic and prognostic value of clinical assess-
ment and investigations in UPIA (history and physical examination, acute phase reactants, 
autoantibodies, radiographs, magnetic resonance imaging, ultrasound, genetic markers and 
synovial biopsy); 3) the predictors of persistence (chronicity) in UPIA; and 4) the measures of 











































The clinical questions were structured using the PIO format (Patients, Participants or Prob-
lem; Intervention or Index test; Outcomes or target conditions).3 The patients included “adults 
with UPIA”. Duration of symptoms was not an exclusion criterion. The definition of UPIA is 
controversial and there is no widely accepted classification criterion for this condition. Dur-
ing the 2008-2009 3E Initiative kick-off meeting, experts decided that only patients in whom 
clinically apparent joint swelling (synovial proliferation or synovial effusion) was observed by 
the rheumatologist should be included. For our review, we systematically searched for studies 
of patients who did not fulfil diagnostic/classification criteria for any specific rheumatic disor-
der after initial assessment. Studies with mixed populations (e.g. UPIA+arthralgia, UPIA+early 
rheumatoid arthritis [RA]) were also retained, as these could be useful for extrapolating 
results. The intervention or index test was defined according to each question (e.g. erosions 
on radiographs, anti-citrullinated protein/peptide antibodies [ACPA] positivity) and the index 
test should have been assessed at baseline. The outcomes were defined as the development 
of well-defined rheumatic diseases (e. g. RA, psoriatic arthritis) or relevant disease outcomes 
(e.g. remission, radiographic progression). As diagnostic/classification criteria we accepted 
either internationally validated criteria (e.g. American College of Rheumatology criteria for 
RA4) or the opinion of the treating physician/investigator.
A systematic literature search for articles published up to February 2009 was carried out in 
Medline, Embase and Cochrane Library, using comprehensive search strategies, elaborated in 
collaboration with experienced librarians. The searches were limited to diagnostic and prog-
nostic studies, using a modification of published sensitive search strategies.5-8 No language 
restrictions were used. Retrieved citations were screened for titles, abstracts and full text 
using predefined inclusion and exclusion criteria; full read papers and review articles were 
hand-searched for additional references. Retained articles were graded for their method-
ological quality according to the Levels of Evidence of the Oxford Centre for Evidence-Based 
Medicine (http://www.cebm.net/index.aspx?o=1025 [accessed April 2009]).
Each question was addressed separately by independent searches. For each question, rel-
evant data were extracted and appropriate statistics were calculated, including odds ratio, 
sensitivity, specificity, positive/negative predictive values and positive/negative likelihood 
ratios. Details and results of the literature search for each question will be published sepa-
rately, while the current article describes the merging process between the evidence found 
for each question and the interpretation of this by the experts, having the ten recommenda-
tions as the result.
In the second round, a national meeting was held in each country (total=697 participants) 
to discuss the generated evidence and propose a set of recommendations. In a third joint 
meeting, the 17 scientific committees (n=94 participants) merged all propositions into 10 
final recommendations via discussion and modified Delphi vote. The grade of recommenda-
tion according to the Oxford Levels of Evidence was attributed and the level of agreement 
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Finally, the potential effect of each recommendation in clinical practice was assessed accord-
ing to 3 impact statements voted by the rheumatologists.
RESuLTS
A total of 39756 references were identified, of which 250 were systematically reviewed (table 
1). The 10 multinational key recommendations are listed in table 2, with the corresponding 
level of evidence and grade of recommendation. The mean level of agreement among the 
rheumatologists was 8.7 (range 7.4 to 9.1). The percentage of rheumatologists who indicated 
they would change their clinical practice according to each recommendation is shown in 
table 3. Evidence for repeating investigations was not found for any of the questions, there-
fore all recommendations about this topic were based on expert opinion.
Table 1. Results of the systematic literature search for each recommendation topic
Recommendation
(number an topic)
Retrieved references by systematic 
literature search (n)
Articles included in the 
systematic reviews (n)
1. Pre-UPIA differential diagnosis and investigations 540 51
2. History and physical examination 2914 37
3. Acute phase reactants 3699 18
4. Autoantibodies 13217 64
5. Radiographs 3585 25
6.1. Magnetic resonance imaging 2595 11
6.2. Ultrasound 2111 2
7. Genetic markers 3109 26
8. Synovial biopsy 6536 4
9. Predictors of persistence (chronicity) 437 7
10. Measures of clinical disease activity 1013 5
Total 39756 250











































Table 2. Multinational recommendations on “How to investigate and follow-up undifferentiated peripheral inflammatory arthritis”
Recommendation (with level of evidence and grade of recommendation) Agreement
mean (SD)
1. All possible causes of arthritis (idiopathic, autoimmune, degenerative, infectious, 
malignancy, traumatic, metabolic) should be considered in the differential diagnosis. 
Complete history and thorough physical examination will determine the ranking order of 
possible differential diagnoses [5, D]. Investigations should be based on the differential 
diagnosis of the patient [5, D].
9.0 (1.7)
2. To establish a specific diagnosis and prognosis following presentation of UPIA, a careful 
systematic history and physical examination should be performed, with particular attention 
to age, gender [1a, A], geographic area [5, D], functional status [1a, A], duration of symptoms/
early morning stiffness, number plus pattern of tender/swollen joints [1a, A], axial/entheseal 
involvement and extra-articular/systemic features [5, D].
8.8 (1.3)
3. ESR and CRP should be performed at baseline in the work up for diagnosis [2b, B] and 
prognosis [2b, B] of UPIA and repeated when clinically relevant [5, D].
9.1 (1.4)
4. Testing of RF and/or ACPA should be performed in the evaluation of patients with UPIA, 
as these factors are predictive of RA diagnosis and prognosis; negative tests do not exclude 
progression to RA [1a, A]. If a connective tissue disease/systemic inflammatory disorder is 
suspected, additional autoantibody tests should be considered [5, D].
9.1 (1.2)
5. Radiographs of affected joints should be performed at baseline [5, D]. Radiographs of 
hands, wrists, and feet should be considered in the evaluation of UPIA, as presence of 
erosions is predictive for the development of RA and persistence of disease [1a, A]. These 
should be repeated within one year [5, D].
7.4 (2.6)
6. There is insufficient evidence to recommend the routine use of MRI and US for diagnosis 
or prognosis in UPIA [5, D]; in UPIA and suspicion of RA, MRI of hands and wrists could be 
considered for diagnosis [2b, B].
8.2 (2.0)
7. There is no genetic test that can be routinely recommended [3b, D], however HLA-B27 
testing may be helpful in specific clinical settings [5, D].
8.8 (1.5)
8. Routine synovial biopsy is not recommended but can give information for differential 
diagnosis, especially in patients with persistent monoarthritis [2b, B].
8.8 (1.8)
9. Predictors of persistent inflammatory arthritis should be documented and include disease 
duration of ≥6 weeks [1b, A], morning stiffness >30 minutes [4, C], functional impairment [4, 
C], involvement of small joints [4, C] and/or knee [4, C], involvement of ≥3 joints [1b, B], ACPA 
[4, C] and/or RF positivity [4, C] and presence of radiographic erosion [1b, B].
8.6 (1.7)
10. Disease activity should be monitored [5, D], however no specific tool can be 
recommended [3b, C].
9.0 (1.7)
Between brackets: [level of evidence, grade of recommendation], according to the Oxford Centre for Evidence-based Medicine Levels of 
Evidence. Agreement was voted on a scale from 1 to 10 (fully disagree to fully agree) by the 94 rheumatologists attending the 3E Multi-
National Closing Meeting. These attendees were members of the 17 scientific committees involved in the 3E Initiative of 2008-2009. SD: 
standard deviation. UPIA: undifferentiated peripheral inflammatory arthritis. ESR: erythrocyte sedimentation rate. CRP: C-reactive protein. 
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Table 3. Percentage of rheumatologists in the 3E Initiative who indicated for each recommendation if it would change their clinical practice
Recommendation
(number an topic)
The recommendation will 
change my practice (%)
The recommendation is 
already my practice (%)
I don´t want to change 
my practice for this 
aspect (%)
1. Pre-UPIA differential diagnosis and 
investigations
0 96.5 3.5
2. History and physical examination 0 98.3 1.8
3. Acute phase reactants 5.4 91.1 3.6
4. Autoantibodies 1.8 96.4 1.8
5. Radiographs 16.1 48.2 35.7
6. Magnetic resonance imaging and 
ultrasound
17.9 64.3 17.9
7. Genetic markers 1.8 92.9 5.4
8. Synovial biopsy 8.9 83.9 7.1
9. Predictors of persistence (chronicity) 24.6 66.7 8.8
10. Measures of clinical disease activity 12.3 84.2 3.5
UPIA: undifferentiated peripheral inflammatory arthritis.
Table 4. Diagnosis reported as exclusion criteria and baseline investigations undertaken prior to inclusion as UPIA (ordered by the frequency 
of reporting in the retrieved literature), both in studies including patients exclusively with UPIA as well as in selected mixed populations that 
included a well-defined subset of patients with UPIA
A) Reported differential diagnosis prior to establishing the operational diagnosis of UPIA
- Rheumatoid arthritis
- Osteoarthritis
- Spondyloarthritis (reactive arthritis, psoriatic arthritis, 
ankylosing spondylitis and undifferentiated spondyloarthritis)
- Crystal-related arthritis
- Trauma 
- Connective tissue diseases (systemic lupus erythematosus, 













B) Reported investigations prior to establishing the operational diagnosis of UPIA
- History
- Tender and swollen joint count 
- Rheumatoid factor
- C-reactive protein 
- Physical examination 
- Hands and feet radiographs 
- Full blood count
- Anti-nuclear antibodies 
- Erythrocyte sedimentation rate 
- Biochemistry (liver function tests, 
glucose, urate and renal function)
- HLA typing (HLA-B27 and HLA-DR)
- Microbiologic assessment
- Anti-citrullinated protein/peptide antibodies
- Radiography of the chest and/or of other affected joints
- Urinalysis
- Thyroid function tests
- C3, C4
- Immunoglobulins
- Antibodies to extractable nuclear antigens
- Antibodies to double stranded deoxyribonucleic acid
- Specific serologic assessment











































Recommendation 1. All possible causes of arthritis (idiopathic, autoimmune, degenerative, 
infectious, malignancy, traumatic, metabolic) should be considered in the differential diagnosis. 
Complete history and thorough physical examination will determine the ranking order of possible 
differential diagnoses. Investigations should be based on the differential diagnosis of the patient.
As UPIA is an operational diagnosis after excluding well-defined rheumatic diseases, the 
question about pre-UPIA differential diagnosis and investigations was analysed by looking at 
the diagnosis that were excluded in cohorts of patients with UPIA and by identifying the in-
clusion and exclusion criteria of these studies as well as the investigations performed before 
the UPIA cohort was established. RA was the most frequent diagnosis reported as exclusion 
criterion10-59 and there was no standard baseline investigation undertaken prior to inclusion 
as UPIA (table 4).41-60 
Experts agreed that when facing a new patient presenting with arthritis every diagnosis 
needed to be kept in mind as UPIA is an exclusion diagnosis. Although, the consensus was 
that it was impossible to name all possible diagnoses, it was felt useful to mention some 
major disease categories to make sure that these are considered. Experts also advised that 
UPIA should be constantly rethought, as patients may develop a disease that can be labelled 
with a specific diagnosis at anytime. Moreover, this recommendation applies only if arthritis 
persists, and not if it is self-limiting. Again, as the investigations will vary according to context 
and clinical presentation, experts felt that it would not be useful to make a list of recom-
mended minimal investigations. 
Recommendation 2. To establish a specific diagnosis and prognosis following presentation of 
UPIA, a careful systematic history and physical examination should be performed, with particular 
attention to age, gender, geographic area, functional status, duration of symptoms/early morn-
ing stiffness, number plus pattern of tender/swollen joints, axial/entheseal involvement and 
extra-articular/systemic features.
Although selected observational studies were of good quality, there was large heterogeneity 
with respect to the type of history and physical exam features that were described.39,40,42-49,61-87. 
Of the quantified features, advanced age,44,83 female gender44 and greater morning stiffness43,44 
were predictive of an eventual diagnosis of RA. A higher number of tender44 and swollen 
joints,43,44,61 involvement of small joints of hands and feet,44,83 involvement of both the upper 
and lower extremities44 and symmetrical involvement43 were also associated with progres-
sion to RA. Similar features were associated with disease persistence81-87 and development 
of erosions,48,63,78 while self-reported functional disability (Health Assessment Questionnaire 
[HAQ] score)67,76 and the presence of extra-articular features76 were uniquely predictive of fu-









































 How to investigate and follow-up UA
4
Experts recognized the importance of the above mentioned evidence-based features and 
based on their clinical experience also highlighted the contribution of the patient’s geo-
graphic area of residence, the presence of axial/entheseal involvement and the presence of 
extra-articular/systemic features. However, the greater relevance given to features included 
in the recommendation does not preclude the need to perform a careful systematic history 
and physical examination in every UPIA patient.
Recommendation 3. Erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) should 
be performed at baseline in the work-up for diagnosis and prognosis of UPIA and repeated when 
clinically relevant.
Elevated ESR showed some diagnostic value for the development of RA74,85 but no prognostic 
value for persistence (chronicity) or structural damage.40,45,88 CRP appeared a poor predictor 
of persistent arthritis, radiological progression and functional disability.80,89 However, there 
was some evidence for the usefulness of elevated CRP in predicting RA, especially when the 
CRP levels are higher.48,88 In one study, CRP did not have any diagnostic value with regard 
to spondylarthropathy.39 For other acute phase reactants, the evidence on diagnostic or 
prognostic value was scarce, negative, or controversial.32,42,48,79,80,90-95
Based on sparse evidence and on personal experience, regarding acute phase reactants, 
experts recommended that only ESR and CRP should be performed at baseline and repeated 
according to the clinical setting.
Recommendation 4. Testing of rheumatoid factor (RF) and/or ACPA should be performed in the 
evaluation of patients with UPIA, as these factors are predictive of RA diagnosis and prognosis; 
negative tests do not exclude progression to RA. If a connective tissue disease/systemic inflamma-
tory disorder is suspected, additional autoantibody tests should be considered.
The association of ACPA and RF11,42-44,48,50,73,96-110 with a diagnosis of RA at follow-up was com-
pelling in the retrieved literature. The absence of ACPA or RF was diagnostically less helpful. 
The presence of ACPA or RF75,106-109,111-115 also increased the probability of developing persis-
tent synovitis or a worse radiographic outcome.73,75,84-86,116 For anti-keratin antibodies (AKA) 
and anti-perinuclear factor (APF), evidence suggests diagnostic usefulness, AKA also appears 
to have some prognostic value.11,96-99,107,110,114,117 For all other markers, including a variety of 
other autoantibodies as well as bone and cartilage biomarkers, the evidence for diagnostic 
or prognostic value is scarce, negative, or controversial.57,102,118-126 The same applies to disease 
outcomes different from those already  mentioned.59,74,76,81,93,100,116,127,128
The value of ACPA and RF in UPIA was recognized, and based on clinical experience, experts 
also advised consideration of additional autoantibody tests if non-RA systemic inflammatory 











































describes several tests for detecting antibodies to citrullinated peptides (such as anti-CCP1 
and anti-CCP2) and newer-generation tests are also expected to be used in the future.
 
Recommendation 5. Radiographs of affected joints should be performed at baseline. Radio-
graphs of hands, wrists, and feet should be considered in the evaluation of UPIA, as presence 
of erosions is predictive for the development of RA and persistence of disease. These should be 
repeated within one year.
 
Radiographic erosions43,49 and Larsen grade 1 (in a population without erosions at baseline)20 
increased the probability of developing RA from UPIA. Moreover, when comparing mild 
versus progressive disease after 1 year follow-up, Sharp/van der Heijde scores at baseline 
were significantly higher in the progressive disease group.48 In another study,44 erosions were 
found to be a predictor of RA in univariate but not in multivariate analysis. 
Overall, studies in mixed populations also provided some evidence for the usefulness of 
radiographs in predicting RA.72,88,92,109,122,129-135 In general, prognosis was worse when radio-
graphic abnormalities at baseline were more severe.75,91,109,116,133,136-140
Experts recognized the clinical value of hand and feet radiographs in UPIA, and based on 
clinical experience also recommended that radiographs of affected joints should be per-
formed at baseline; furthermore, experts advised that radiographs should be repeated within 
one year (in case of disease persistance). Moreover, although not voted to be included in the 
recommendation, some of the experts expressed their opinion that pelvic/sacroiliac joints 
radiographs should also be considered, particularly in RF and ACPA negative patients or if 
spondyloarthritis is suspected.
There was a slightly lower agreement about this recommendation (table 2, 7.4 agreement), 
with a larger proportion of experts stating that they didn’t want to change their practice 
for this aspect (table 3, 35.7%). This lower concordance was mainly related to the inclusion 
of “radiographs of affected joints at baseline” and about the advice to repeat radiographs 
“within one year”.
Recommendation 6. There is insufficient evidence to recommend the routine use of magnetic 
resonance imaging (MRI) and ultrasound (US) for diagnosis or prognosis in UPIA; in UPIA and 
suspicion of RA, MRI of hands and wrists could be considered for diagnosis.
Bone oedema was found to be an independent predictor of the future development of 
RA from UPIA141 and the presence of a distinct MRI synovitis and erosion pattern with the 
involvement of several hand joints but not the first carpometacarpal joint also increased the 
probability of developing RA.20 The absence of the same MRI synovitis pattern decreased the 
probability of developing RA.20 Overall, MRI studies in mixed populations101,134,142-147 provided 
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RA. Regarding US, 2 mixed populations revealed US-power Doppler signal and US-gray-scale 
synovitis as potential candidates for futures studies in UPIA.148,149
Experts recognized that MRI of the hands and wrists has already shown to be useful in predict-
ing the development of RA from UPIA, while the value of US in UPIA is still to be determined. 
However data is still too scarce to recommend the routine use of any of these imaging tools. 
This recommendation does not dispute the fact that compared to physical examination and 
radiographs, both MRI and US may offer advantages through more sensitive depiction of 
inflammatory and destructive disease manifestations. The current recommendation pertains 
only to the diagnostic and prognostic value of these imaging tools in UPIA.
Recommendation 7. There is no genetic test that can be routinely recommended, however HLA-
B27 testing may be helpful in specific clinical settings.
There was a great heterogeneity among the genetic markers that were test-
ed.39,40,46,50-52,65,84,127,133,150-165 The shared epitope (SE) was the most frequently studied marker. 
Eight studies40,50,65,133,153-155,158 tested its diagnostic utility showing poor results. Only in one 
study was the positive likelihood ratio for RA relevant, but this result came from the study 
with the poorest quality and smallest sample size.40 In isolation, no other genetic marker was 
informative of a future diagnosis in patients with UPIA. With regard to prognosis, the SE was 
weakly associated with a poor prognosis of arthritis in terms of  development of erosions, 
mortality, disability and persistent synovitis.65,127,133,163,164 Other genes were not good predic-
tors of erosions or other less studied outcomes.
The experts acknowledged the current lack of evidence for the practical utility of genetics 
in UPIA. However, based on their clinical experience, experts chose to highlight that HLA-
B27 may be helpful in the appropriate clinical setting, namely when spondyloarthritis is 
suspected.
Recommendation 8. Routine synovial biopsy is not recommended but can give information for 
differential diagnosis, especially in patients with persistent monoarthritis.
Studies had significant clinical and statistical heterogeneity.22,23,166,167 Three broad synovial 
features of interest were identified in the literature: ACPA staining, immunohistochemistry 
and vascular patterns. In contrast to serologic ACPA testing, ACPA staining was shown not to 
be highly specific for a diagnosis of RA.167 In one study, synovial histopathology seemed to 
differentiate between RA and non-RA.166 The vascular pattern in undifferentiated arthritis was 
not specific enough to differentiate between spondyloarthritis and RA.22,23
The exact role of synovial biopsy in UPIA is yet to be determined and experts felt that it 
could not be recommended as a routine procedure. However, experts also highlighted that 











































persistent/chronic refractory monoarthritis, suspicion of malignancy or suspicion of chronic 
infection, such as tuberculosis).
Recommendation 9. Predictors of persistent inflammatory arthritis should be documented and 
include disease duration of ≥6 weeks, morning stiffness >30 minutes, functional impairment, 
involvement of small joints and/or knee, involvement of ≥3 joints, ACPA and/or RF positivity and 
presence of radiographic erosion.
The question about chronicity was investigated by looking at prognostic studies that used 
multivariate analysis to identify independent predictors of persistence (chronicity). At 
baseline, the following variables were found to be independent predictors of persistent 
(inflammatory) arthritis: disease duration,75,82,116 duration of morning stiffness,75,85,86 change of 
functional status (measured by HAQ) at the first 3 months,82 failure to respond 2 weeks after 
local treatment with intraarticular corticosteroids,82 small joint involvement,168 knee involve-
ment,85 presence of RF,75,85 presence and level of ACPA,75,86,168 functional status (HAQ),169 arthri-
tis of at least 3 joints,75 proximal interphalageal joint involvement,169 metatarsophalangeal 
joint involvement75 and radiographic erosion at the hands and feet.75 The magnitude of the 
association in the same predictor was diverse among the studies depending on the patient 
characteristics (namely if the population was purely UPIA or not), the study design, and the 
variables used to adjust for in the models.
Recommendation 10. Disease activity should be monitored, however no specific tool can be 
recommended.
Five studies evaluated the validation of different clinical measures in patients with UPIA. 
Validation aspects of 4 questionnaires - WHO Disability Assessment Schedule (WHODAS),170 
London Handicap Scale (LHS), Disease Repercussion Profile (DRP) and the HAQ,171 and 
3 physical measures - RA Disease Activity Index (RADAI),172 McGill Range of Motion Index 
(McROMI)173 and NOAR Damage Joint Count (NOAR-DJC),174 were partially assessed in these 
studies, but none of the instruments of disease activity was fully validated for its use in UPIA.
Although no instrument of disease activity has been fully validated for its use in UPIA, experts 
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DISCuSSION
Ten multinational recommendations on how to investigate and follow-up UPIA in the clinical 
setting were developed, which are practical, evidence-based and supported by a large panel 
of international rheumatologists in the 3E Initiative.
We followed an established group decision method. A representative expert panel of 697 
academic and community rheumatologists from 17 countries selected relevant questions 
that reflect the challenges of approaching a patient with UPIA. They openly discussed the 
evidence from the literature followed by a silent voting process. We used the touch pad 
methodology with pre-specified cut-off levels of agreement to generate the final recom-
mendations. Several rounds of rewording and re-voting were sometimes required to reach 
the specified cut-off for agreement. This process highlights the International dimension of 
this collaboration and strengthens the current recommendations.1,2 It ensured that the final 
recommendations were evidence-driven as well as clinically relevant.
Furthermore, the broad participation increases external validity and enhances future dissemi-
nation and implementation into rheumatological practice worldwide. Another main feature 
of the 3E Initiative was the promotion of epidemiology and systematic literature research, all 
participants having been updated on how to appraise published evidence. 
There is widespread interest in predictive medicine. Following a strict methodology, we 
aimed to find all available evidence regarding each question, which resulted in a large num-
ber of reviewed articles. However, the evidence in truly UPIA populations is scarce, exposing 
the need to create a research agenda addressing this topic. In particular, future studies 
should clearly distinguish between individuals with early well-defined rheumatic diseases, 
individuals with UPIA and individuals with inflammatory joint symptoms but no obvious joint 
swelling. All these populations can be studied for predictive algorithms and results may be 
different depending on the study population.
The definition of UPIA is controversial and much of the literature is skewed towards early RA. 
The difficulty in defining UPIA is underlined by the continuous changing face of different 
categories of patients, which can be well illustrated by the recent new ACR/EULAR criteria for 
RA,175 as several of the patients we now describe as having UPIA will likely be labelled as RA 
patients. Nevertheless, despite the influence that this changing may have on research and 
daily practice, the recommendations presented in this article are based on currently available 
evidence. They may help the clinician in the effective management of patients with UPIA and 
can be adjusted if future studies or clinical experience reveal new insights. 
In summary, multinational recommendations for the investigation and follow-up of patients 











































literature review and expert opinion, with the aim of promoting evidence-based medicine 
and ultimately improving patient care.
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Chapter 5
Insights in the relationship of joint space narrowing versus 
























































To evaluate the contribution of joint space narrowing (JSN) and erosions in general and in 
four different joint groups in relation to physical disability in rheumatoid arthritis (RA).
Methods
Five-year follow-up data from the Behandel Strategieën (BeSt) trial were used, where 508 
patients with recent onset RA were treated aiming at a disease activity score ≤2.4. Joint 
damage was assessed annually and scored according to the Sharp-van der Heijde method. 
Physical disability was measured three-monthly with the Health Assessment Questionnaire 
(HAQ). Generalized Estimating Equations analyses were performed to assess the relationship 
between the HAQ and JSN scores and erosions scores, separately and in joint groups.
Results 
Overall, damage scores were low, and neither total JSN nor erosions showed significant effect 
on the HAQ (β=0.001 95%CI -0.003 to 0.004 and β=0.002 95%CI -0.001 to 0.006 respectively). 
Of the total damage scores per joint group, damage in the wrist shows a trend for association 
with physical disability displaying the largest effect size  (β=0.005 95%CI 0.000 to 0.011). Also 
in the analysis with erosions per joint group, the wrist was most strongly related with physical 
functioning (β=0.016 95%CI 0.003 to 0.029); in the analysis with JSN per joint group no joint 
group was significantly related to the HAQ. Analysis of all erosion and narrowing scores per 
joint group in one model reveals only erosions in the wrist to be independently associated 
with impaired physical functioning (β=0.017 95%CI 0.003-0.030). 
Conclusion
Joint damage in the wrist, erosions more than JSN, is associated with impaired physical func-
tioning even in patients with early RA patients with limited overall damage after five years of 
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INTRODuCTION
Joint damage is an early and potentially progressive feature of Rheumatoid Arthritis (RA) 
and is related to functional disability together with other factors such as disease activity 
and co-morbidity.1-5 Previous research has shown that in early disease physical functioning 
is mostly determined by the disease activity score (DAS), whereas in late disease, it is mostly 
determined by the extend of joint damage.6 
RA related joint damage on radiographs involves damage to the bone (bone mineral density 
loss and erosions), damage to cartilage (scored as joint space narrowing (JSN)) and dam-
age to ligaments causing malalignment, which is sometimes also scored as part of the JSN 
scoring, depending on the scoring method used. 7-9 Recently it has been suggested in a 
cross-sectional study that JSN rather than erosiveness is associated with physical disability.10 
It is not clear whether the relation between JSN or erosions and physical functioning is in-
fluenced by the location of damage in particular joints or joint groups. Further insight in this 
could lead to specific site evaluations to assess treatment efficacy, and possibly to specific 
therapy targets. Therefore, we evaluated the contribution of JSN and erosions in general, and 
in four different joint groups, in relation to physical disability over time, in a cohort of patients 
with recent onset of RA, dynamically treated during five years in a tight control setting aimed 
at low disease activity.  
METHODS
Patients
Data from the Behandel Strategieën (BeSt) trial were used, where 508 patients with recent 
onset active RA were dynamically treated according to a protocol directed by 3-monthly 
assessments of disease activity, aiming at a DAS ≤2.4. Patients were randomized into four 
different treatment strategies: 1. sequential monotherapy (n=126); 2. step-up combination 
therapy (n=121); 3. initial combination therapy with prednisone (n=133) and 4. initial combi-
nation therapy with infliximab (n=128). Clinical assessment of disease activity was performed 
3-monthly, and included a 68/66 graded joint count for tenderness and swelling, erythrocyte 
sedimentation rate measurements and patient’s assessment of global disease activity. This 
study was approved by the ethical committees of participating centers and all patients pro-
vided informed consent. More details about the BeSt study have been described elsewhere.11 












































Annual radiographs of hands, wrist and feet from baseline until year 5 were scored in random 
order by two observers blinded for patient identity and treatment allocation. The modifica-
tion of the Sharp method by van der Heijde (SHS)8 was used for the scoring of joint space nar-
rowing and erosiveness on the radiographs. JSNis scored on a scale of 0-4 with a maximum 
total of 120 in the hands and 48 in the feet. Erosions are scored on a scale of 0 (no erosion) - 3 
(large erosion) and are scored cumulatively with a maximum of 5 points per joint in the hands 
and with a maximum of 10 points in the feet. The maximum total erosion score in the hands is 
160 and in the feet 120 points. Average scores of the two readers were used for the analysis. 
Outcome assessment
Physical functioning was assessed using the Dutch version of the Health Assessment Ques-
tionnaire (HAQ).12 The HAQ consists of 24 questions in eight different categories which are 
answered on a 0-3 severity scale. To calculate the total HAQ score, which ranges between 0 
(no disability) and 3 (severe disability), all highest scores per category are summed up and 
divided by eight. 
Statistical methods
Statistical analyses were performed with the software program SPSS V.17.0 (SPSS, Chicago, 
Illinois, USA). Generalized Estimating Equations (GEE) regression models were used to inves-
tigate the relationship between joint damage (in general and per joint group) and physical 
functioning during five years follow-up, while correcting for within patient correlation. The 
total HAQ score at the yearly visits was used as outcome for all analyses. GEE modeling was 
chosen as it is relatively robust against violations of normality, which is frequently the case 
with SHS, erosion and JSN scores. 
Separate models were specified to be able to assess the effect size of the independent vari-
able in relation to the dependent variable. Combined models were specified to evaluate the 
independent contribution of one dependent variable in the presence of other dependent 
variables. Adjustments were made for possible confounding variables time, DAS, gender, 
treatment group and BMI that were associated with physical functioning in the univariate 
analysis. P-values of ≤0.05 were considered statistically significant. For all analyses the 
unstructured covariance matrix was used, which does not assume a specific covariance struc-
ture and estimates every covariance individually for consecutive measurements. Since high 
disease activity was a requirement for inclusion, baseline measurements were excluded from 
the analysis to avoid a large contribution of high disease activity on disability. 
The analyses were performed by entering variables in the model in the following three steps: 
1. total score of JSN and total erosions score (in all joints) 2. total damage score (erosions and 
JSNtogether) per joint group and 3. JSN and erosion scores separately per joint group. For the 









































 Joint damage and physical functioning
5
PIPs, wrists and feet. For step 1 and 3, first erosions and JSN were analyzed separately and 
then in one model together. Finally, separate variables for JSN and erosions in all different 
joint groups were entered in one model to evaluate the independent contribution of all fac-
tors. As the maximum attributable points per joint group or per feature can differ, all analyses 
were repeated using the percentage of the maximum total damage.
RESuLTS
At baseline, patients reported severe disability with a mean (SD) HAQ score of 1.4 (0.7), which 
decreased to 0.6 (0.6) at t=1 year and remained stable over the years (HAQ 0.6 (0.6) at t=5 
years). Joint damage at baseline, although present in the majority of this population with 
severe RA, was limited, with a median SHS score (IQR) of 3.0 (0.5-9.5), and 62% of patients 
showing joint damage <5 points SHS. At baseline, 37% of patients had no JSN and 28% had 
no erosions. After 5 years, these percentages had decreased to 30% and 18%, respectively. 
The median SHS score (IQR) at t=5 years was 7.0 (1.5-20.3). 
JSN was mostly seen in the wrists with a mean (SD) JSN score of 2.9 (6.7), and to a lesser extent 
in the feet with a mean (SD) JSN score of 2.3 (5.2) at year 5. Erosions were most frequently 
seen in the feet with a mean (SD) score 4.4 (7.4) and thereafter in the wrists with a score of 
1.2 (3.6). Mean percentage JSN ranged from 2.0% of the maximum score (in the PIPs) to 6.1% 
(in the wrists) and mean percentage erosions ranged from 1.8% (in the PIPs) to 3.7% (in the 
feet). More details are described in supplementary table S1 of the online published version 
of this paper.
The relationship of joint space narrowing and of erosions with functional 
disability
In the univariate analysis (table 1) the effect on disability of erosion score and JSN score is 
similar. JSN and physical functioning show a statistically significant relationship with a beta 
estimate (β) (increase in HAQ per point increase in JSN score) of 0.004 (95%CI 0.001-0.008). 
Erosions are related to physical functioning in the same order of magnitude, however this 
relationship is not statistically significant (β=0.003 95%CI -0.001-0.006). The main clinically 
relevant predictor for disability, showing the largest effect size, is the DAS (β=0.250; 95%CI 
0.220 – 0.280). Other univariate predictors are (female) gender, time, BMI, baseline DAS and 
treatment group. When applying a multivariable model with correction for disease activity 
(concurrent and baseline), BMI, time, gender and treatment group, effect sizes for the ero-
sions and JSN scores are smaller (β=0.001 and β=0.002, respectively), and the relationship is 
no longer statistically significant, neither separately nor combined in a model together. (see 











































Joint damage in joint groups in relation to disability
The relationship between the total damage scores per group and the HAQ is shown in table 
2. Total damage in the wrist shows a trend for association with the HAQ and is demonstrating 
the largest effect size in both the separate analysis and in the analysis combining with the 
other joint groups (β=0.005 95% CI 0.000-0.010 and β=0.005 95% CI 0.000-0.011, respectively). 
In analyses including erosions and narrowing separately per joint group, only erosions in 
the wrist (β=0.014 95% CI 0.003-0.026) show a statistically significant relation with physical 
functioning (table 3).  
When applying a model including joint space narrowing in all groups there is no statistically 
significant relationship of any joint group with physical functioning, but in the model for 
erosions in all joint groups, erosions in the wrist are found as an independent explanatory 
variable with a large effect size (β=0.016 95%CI 0.003-0.029). (see supplementary table S3; 
published online only) 
Table 1 Univariate predictors of physical functioning as measured by the Health Assessment Questionnaire (HAQ). 
Predictor Beta SE 95% CI
Erosions 0.003 0.002 -0.001– 0.006
Narrowing 0.004 0.002 0.001 – 0.008†
Age 0.002 0.002 -0.002 – 0.005
Female gender 0.142 0.048 0.048 – 0.236†
BMI 0.017 0.006 0.006 – 0.029†
Disease duration 0.016 0.019 -0.021 – 0.053
DAS 0.250 0.015 0.220 – 0.280†
DAS baseline 0.130 0.027 0.077 – 0.183†
ACPA positive -0.029 0.049 -0.125 – 0.067
RF positive -0.027 0.053 -0.130 – 0.076
Treatment group
group 1 0.176 0.040 0.047 – 0.578†
group 2 0.148 0.070 0.017 – 0.279†
group 3 0.076 0.057 -0.035 – 0.188
group 4 reference reference reference
Time
year1 reference reference reference
year 2 -0.041 0.021 -0.082 – -0.0002†
year 3 -0.025 0.024 -0.072 – 0.022
year 4 -0.001 0.025 -0.049 – 0.048
year 5 0.004 0.025 -0.044 – 0.052
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Finally, in the extended model including all joint groups, both, as JSN score and as erosion 
score while correcting for BMI, DAS (baseline and concurrent), time, gender and treatment 
group, we find erosions in the wrist as the only independent predictor in the presence of all 
other associated factors (β=0.017 95%CI 0.003-0.030) (table 4). 
We repeated the analyses using the percentage of the maximum score in stead of absolute 
scores (as the maximum attributable point can differ per feature or group), and found com-
parable results (data not shown). 
Table 2 The total joint damage score per group in relation to physical functioning measured by the Health Assessment Questionnaire (HAQ). 
Predictor Beta SE 95% CI
Separate models*
Total damage score feet -0.001 0.002 -0.005 to 0.003
Total damage score wrists 0.005 0.003 0.000 to 0.010†
Total damage score MCPs 0.003 0.004 -0.006 to 0.012
Total damage score PIPs 0.001 0.007 -0.014 to 0.015
One model*
Total damage score feet -0.003 0.002 -0.008 to 0.001
Total damage score wrists 0.005 0.003 0.000 to 0.011†
Total damage score MCPs 0.004 0.006 -0.007 to 0.014
Total damage score PIPs -0.002 0.008 -0.018 to 0.014
Separate models: effect of the total damage score per joint group on physical functioning. One model: effect of the total damage score per joint 
group in the presence of the other joint groups.  SE: standard error; CI: confidence interval; MCPs: metacarpophalangeal joints; PIPs: proximal 
interphalangeal joints. *Adjusted for BMI, DAS, DAS baseline, time, gender and treatment group; †trend; p<0.10
Table 3 Narrowing and erosion scores per joint group in relation to physical functioning measured by the Health Assessment Questionnaire 
(HAQ) in eight different models.
Predictor* Beta SE 95% CI
Narrowing feet -0.002 0.004 -0.010 to 0.007
Narrowing wrists 0.005 0.004 -0.002 to 0.012
Narrowing MCPs 0.007 0.007 -0.007 to 0.020
Narrowing PIPs 0.013 0.013 -0.012 to 0.038
Erosions feet -0.002 0.003 -0.008 to 0.004
Erosions wrists 0.014 0.006 0.003 to 0.026†
Erosions MCPs -0.001 0.009 -0.018 to 0.017
Erosions PIPs -0.007 0.011 -0.030 to 0.016
SE: standard error; CI: confidence interval; MCPs: metacarpophalangeal joints; PIPs: proximal interphalangeal joints. *Adjusted for BMI, DAS, 












































In a cohort of patients with recent onset of RA, over 5 years of tight controlled treatment both 
JSN and erosions showed only a small non significant effect on physical functioning defined 
by the HAQ. Of all sites evaluated with the SHS score, the wrist was the most important 
determinant, and erosions in the wrist were the only independent predictor of functional 
disability. 
Previous research in patients from various early or advanced RA trials has shown that JSN, 
rather than erosiveness, was associated with physical functioning.10 It has been suggested 
that this is due to different pathophysiological mechanisms of both types of damage.13-15 In 
our cohort, we found the effect size on outcome HAQ of JSN or erosion scores was roughly 
the same and very small. This is probably because in this cohort of patients with early RA, 
treated with DAS steered tight control strategies, there was very limited radiological damage 
progression in general. The high agreement between the analyses using the absolute scores 
and those using the percentages of the maximum scores also indicates that severe joint 
damage, (at the highest end of the scale) was rare. In these patients disability was largely 
determined by disease activity even when the disease activity at baseline was discarded. 
When analyzing damage per joint or joint group, we found that damage in the wrist was the 
main determinant of disability. As JSN frequently occurs in the wrist this finding would seem 
to corroborate the previously reported dominance of joint space narrowing in relation to 
functional disability.16However, our analyses showed that erosive damage, not narrowing, in 
the wrist was an independent predictor for functional disability. A possible explanation for 
the effect of wrist joint damage on functional ability may be that activities requiring wrist 
movement constitute a large proportion of the daily activities asked after in the questions 
 Table 4 Independent contribution of narrowing and erosion scores within each joint group in relation to physical functioning measured by the 
Health Assessment Questionnaire (HAQ). 
Predictor* Beta SE 95% CI
Narrowing feet -0.003 0.005 -0.013 to 0.008
Narrowing wrists -0.001 0.004 -0.009 to 0.007
Narrowing MCPs 0.008 0.010 -0.013 to 0.028
Narrowing PIPs 0.016 0.017 -0.017 to 0.050
Erosions feet -0.003 0.005 -0.012 to 0.006
Erosions wrists 0.017 0.007 0.003 to 0.030†
Erosions MCPs -0.002 0.014 -0.030 to 0.027
Erosions PIPs -0.016 0.015 -0.044 to 0.013
SE: standard error; CI: confidence interval; MCPs: metacarpophalangeal joints; PIPs: proximal interphalangeal joints. *Adjusted for BMI, DAS, 
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of the HAQ. Only questions on walking and climbing stairs, and possibly (but not likely) the 
questions on rising from an armless chair and getting out of bed, address activities where 
one would not need to use one’s wrists. This predominance of wrist related activities in the 
HAQ of course reflects the daily activities of a species that evolved to walk on his hind legs to 
free up the use of hands and wrists. 
This study has several limitations. Within the SHS method not only JSN as cartilage damage 
but also (sub)luxation from soft tissue damage is scored.8 Based on our scores we do not 
know the separate influence of soft tissue damage on physical functioning. This is of course 
also a limitation in other studies that use the SHS score. However, for our conclusions on wrist 
damage this appears less important, as in the wrist, the JSN is almost exclusively determined 
by loss of joint space and not (sub)luxation. Also in the PIPs, (sub)luxation is rarely scored, but 
subluxation does influence the JSN score in MTPs and MCPs. 
It has been suggested that plain radiographs are less sensitive for detecting erosive dam-
age than alternative imaging techniques such as MRI, CT or ultrasound. We have not used 
these techniques, but if this has led to an underdetection of erosions in the wrist, this would 
mean that we have underestimated and not overestimated the effect of wrist erosions on 
functional ability. 
JSN is also frequently seen on hand radiographs of patients with osteoarthritis, although it 
occurs mostly in the DIPs (not in the SHS score) and PIPs, and less frequently in the wrists.17;18 
We have not scored osteoarthritic damage separately, but as osteoarthritis frequently af-
fects the middle aged and elderly, it is bound to be present in our population with a mean 
age of 54 at the onset of the study. Still, since the SHS method does not make a distinction 
between JSN due to osteoarthritis or RA, the combined occurrence may have enlarged the 
effect of JSN and thus masked the effect of rheumatoid erosions. Again, this would mean 
we could have underestimated the effect of erosive damage on functional disability and it 
could explain why in the total scores of all joints erosions are not significantly associated with 
functional ability. On the other hand, JSN in osteoarthritis is mostly seen in the PIPs (within 
the SHS score) and not that frequently in the joints assessed in the wrist19, which may thus 
have influenced the relationship with the total JSN, but does not play a major role in the 
dominant effect of the wrist on HAQ. 
We did not take large joint damage into account, which is an important determinant of 
physical disability.20 However, since large and small joint damage are closely related to each 
other20;21, the effect of that exclusion may be limited. It is also likely that in this cohort with 












































The correlation between narrowing and erosions scores (per joint) also influences their 
independent relationship with physical functioning. Separate erosion scores and narrowing 
scores show a substantial correlation within this data set (ρ=0.70), but the joint groups per 
feature correlate significantly as well (range ρ=0.21 to ρ=0.57). Especially, narrowing in the 
feet was strongly related with erosions in the feet, and narrowing in the wrist with erosions in 
the wrist. This may explain why in combined models including both features, the effect of one 
factor seems to dominate over the other, although both could provide relevant information. 
Strong points include that we have not only assessed the damage features separately, but 
also included several joints groups, to see whether these may explain the relationships that 
were found. Also, we were able to include data of patients followed longitudinally over a 
period of 5 years. We believe that our patient population with recent RA, treated in a tight 
control setting, with limited joint damage, represents the RA patients of this and future de-
cades. A final strong point, since joint damage does not follow a Gaussian distribution, is that 
we used a GEE model, which is relatively robust against violations of normality. 
Because the wrist is an important determinant for disability, we may need to focus on the 
prevention of structural damage especially there. There is evidence that local synovitis is 
associated with damage progression in the same joint.22 It has also been suggested that intra-
articular corticosteroid injections suppress joint inflammation and damage progression.23 
Further research is needed to determine if local treatment in combination with effective 
systemic treatment has additional benefits to halt local damage progression and prevent 
disability. 
In conclusion, in a large cohort with recent onset RA patients, treated with a tight control 
treatment strategy over 5 years and limited joint damage progression, the relation of such 
joint damage progression with functional ability as measured with the HAQ concentrates 
around erosions in the wrist. This may have consequences for evaluation of treatment suc-
cess as well as for localized treatment strategies.
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Objective To evaluate three disease activity score (DAS) alternatives without the Ritchie ar-
ticular index (RAI). To compare the use of patient global assessment (PGA) of disease activity 
versus global assessment of health (GH) in DAS, DAS alternatives and DAS28.
Methods Data from the BeSt study were used, a treatment strategy trial in early rheuma-
toid arthritis patients aiming at a DAS≤2.4. DAS alternatives were DAS0-1, with the RAI(0-3) 
reduced to a no-yes (0-1) score, DAS tender joint count (DAS-TJC53), with a 0-1 TJC in 53 sepa-
rate joints, and DAS-TJC44 in 44 joints. Correlation patterns, mean difference from original, 
classification differences in disease activity level and patient percentages with radiological 
damage progression per level were determined for all scores. 
Results In the majority of patients the scores were equal and correlation was high. Mean 
difference with the DAS at year 1 was -0.03 for DAS 0-1, 0.18 for DAS-TJC53 and 0.11 for 
DAS-TJC44. Classification agreement between scores was high (κ year 1 0.76-0.98). Patient 
percentages with joint damage progression were similar for all scores. DAS, DAS alternative 
and DAS28 perform similarly using either PGA or GH. 
Conclusion Disease activity scores without the RAI perform comparably to the original DAS 
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INTRODuCTION
Measuring disease outcome in rheumatoid arthritis (RA) is important to evaluate response 
to treatment. Recent recommendations for management of RA propose measurement by 
validated composite scores including joint counts.1;2
The disease activity score (DAS) was the first composite measure developed to assess and 
compare disease activity in patients and patient groups. The DAS includes a swollen joint 
count in 44 joints, the Ritchie articular index (RAI)3 for evaluation of joint tenderness in 53 
joints, erythrocyte sedimentation rate (ESR) and a visual analogue scale (VAS) for patient 
global assessment of disease activity (PGA) or of general health (GH).4 However, the DAS with 
VAS-PGA is not yet validated. DAS28 was introduced as a simplification with a no-yes swollen 
and tender joint count (TJC) in 28 individual joints.5 
Although in general the usefulness and importance of the DAS and DAS28 are well accepted6, 
implementation in daily practice remains challenging. Some find that DAS28 unjustly ne-
glects the feet, but other scores might be too time consuming.7;8 The RAI may be subjective 
and complicated, as it is a 0-3 graded evaluation of severity of tenderness and uses joint 
groups of which only the highest score per group counts. 
Alternatives to the DAS, including more than 28 joints without the RAI, might be more attrac-
tive to use in daily routine or clinical trails. This study aims to evaluate three variations of the 
DAS compared to the original DAS. In addition, we compared DAS, DAS variations and DAS28 
using VAS-GH or VAS-PGA.
PATIENTS AND METHODS
Data from the BeSt trial were used, a randomized clinical trail with three-monthly assess-
ments aiming at a DAS≤2.4 by subsequent treatment adjustments.9 All follow-up visits in-
cluded a full 68/66 graded joint count for tenderness and swelling, as well as measurements 
of VAS-GH, VAS-PGA and ESR. The current analysis was performed based on 467 patients with 
complete data at one year follow-up.
DAS and DAS28 were calculated using the following formulae: DAS=0.5398√(RAI)+0.06465(S
JC44)+0.330ln(ESR)+0.00722(VAS) and DAS28=0.56√(TJC28)+0.28√(SJC28)+0.70ln(ESR)+0.0
14(VAS). DAS alternatives were derived as follows: the DAS0-1 was calculated by the substitu-
tion of a RAI greater than0 with ‘1’, while RAI ‘0’ score remained ‘0’, resulting in a maximum TJC 
of 26. The DAS-TJC53 was calculated with a 0=no, 1=yes TJC in the 53 joints originally assessed 











































calculated with a TJC 0=no, 1=yes in the same 44 joints that are assessed for swelling in the 
DAS. All DAS variations, as well as the original DAS and DAS28, were calculated with VAS-PGA 
and VAS-GH. 
Pearson’s correlation coefficients were calculated between the original DAS and DAS alterna-
tives. The mean of these two measurements and the mean difference was calculated at year 
1 and is displayed in Bland-Altman plots with limits of agreement of 1.96*SDmean differ-
ence.  Patients were categorized according to previously published cutoffs into remission, 
low disease activity (LDA), moderate disease activity (MDA) or high disease activity (HDA).10-14 
Percentage agreement and κ statistics were calculated to assess agreement between catego-
rization. 
An area under the curve (AUC) DAS was calculated between 3 and 12 months for all scores 
separately using the formula: (½* DAS3 months + DAS6 months + DAS9 months + ½ * DAS12 
months)/3. Baseline scores were excluded from the analysis to avoid skewness due to re-
quired HDA at inclusion. 
The AUC DAS results, indicating disease activity over time, were categorized into remission, 
LDA, MDA and HDA. Next, the percentage of patients with a greater than 5 points Sharp 
van der Heijde score (SHS) progression between baseline and year 1 (consistent with the 
smallest detectable change and indicating rapid radiological progression) was compared in 
all categories for all disease activity scores. Finally, the ability of DAS alternatives to detect 
treatment differences at three months follow-up was assessed using the difference in scores 
between baseline and 3 months.
RESuLTS
All patients had early (<2 years) RA and active disease at baseline with a mean (SD) DAS of 4.4 
(0.9). At year 1 (n=467) median (range) RAI was 3.0 (0-52), RAI 0-1 3.0 (0-23), TJC53 4.0 (0-50), 
TJC44 3.0 (0-44) and TJC28 2.0 (0-28). 
Correlation was high for all DAS alternatives compared to the original DAS and ranged be-
tween 0.96-0.99 (p≤0.01) at baseline and between 0.97-1.00 (p≤0.01) at year 1. 
Correlation between VAS-PGA and VAS-GH at five time points was limited (ρ=0.5-0.8 p≤0.01). 
Nevertheless, for the original DAS, DAS alternatives and DAS28, all versions with VAS-GH cor-
related excellently to corresponding versions with VAS-PGA (range r=0.96-1.00 p≤0.01), both 















































Figure 1 Mean of the 2 measurements (x-axis) versus the mean difference between the two values (y-axis) at year 1 (n=467).











































Table 1 Classification of the number of patients per disease activity category at year 1 according to the different indices, as compared with the 
original DAS (n=467). 
DAS
Remission LDA MDA HDA
DAS PGA
Remission 143 7 0 0
LDA 5 152 3 0
MDA 0 2 123 0
HDA 0 0 3 29
Remission LDA MDA HDA
DAS0-1 GH
Remission 148 2 0 0
LDA 0 159 3 0
MDA 0 0 126 2
HDA 0 0 0 27
Remission LDA MDA HDA
DAS0-1 PGA
Remission 143 8 0 0
LDA 5 151 6 0
MDA 0 2 122 2
HDA 0 0 1 27
Remission LDA MDA HDA
DAS-TJC53 GH
Remission 142 0 0 0
LDA 6 126 1 0
MDA 0 35 105 0
HDA 0 0 23 29
Remission LDA MDA HDA
DAS-TJC53 PGA
Remission 138 6 0 0
LDA 10 118 0 0
MDA 0 37 102 0
HDA 0 0 27 29
Remission LDA MDA HDA
DAS-TJC44 GH
Remission 142 5 0 0
LDA 6 125 3 0
MDA 0 31 105 0
HDA 0 0 21 29
Remission LDA MDA HDA
DAS-TJC44 PGA
Remission 139 11 0 0
LDA 9 118 4 0
MDA 0 32 101 0
HDA 0 0 24 29
DAS 28 
Remission LDA MDA HDA
DAS 28 PGA
Remission 172 12 1 0
LDA 6 76 11 0
MDA 1 5 137 3
HDA 0 0 9 36
DAS, disease activity score; GH, visual analogue scale for patient’s assessment of general health; HDA, high disease activity; LDA: low disease 
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Figure 1 illustrates high agreement between DAS alternatives and the original DAS. DAS-0-1 
shows a high accordance with the original DAS whereas DAS-TJC53 and DAS-TJC44 are oc-
casionally higher as demonstrated by the higher mean difference and broader agreement 
limits. However, most scores remain unchanged compared with the original DAS. DAS, DAS 
alternatives and DAS28 perform similarly using either VAS-PGA or VAS-GH. 
Categorization of all patients by different DAS is presented in Table 1. The percentage of 
overall agreement for all separate DAS at year 1 was high (range 82.9%-98.5%), chance 
corrected agreement as calculated by Cohen’s κ ranged from 0.76-0.98.  Significant disagree-
ment between categorization, for example LDA versus HDA or remission versus HDA was very 
rare (table 1). Chance corrected agreement for all scores with VAS-GH versus VAS-PGA ranged 
from 0.85-0.94.  Both correlation and (chance corrected) agreement between the original 
DAS and alternatives using either VAS score did not change over time (see supplementary 
table; published online only). 
The percentages of patients with rapid radiological progression (RRP; >5 points SHS in year 
1) are represented in table 2. All DAS alternatives show comparable percentages of patients 
with RRP within categories of disease activity level using either VAS. Overall, there are few 
patients with RRP in patients categorized as in remission or LDA by all composite scores. 
Differences in disease activity between treatment arms (eg, treatment group 1 and 2 vs. 3 and 
4) could be confirmed with all indices.
Table 2 Percentage (numbers) of patients with rapid radiological damage progression (SHS >5 points) in the first year of the study categorized 
according to the ‘mean’ disease activity level between three months and 1 year for all indices (n=386). 
Remission LDA MDA HDA
DAS 9.9 (8/81) 11.0 (13/118) 19.2 (28/146) 39.0 (16/41)
DAS-PGA 10.3 (8/78) 11.9 (14/118) 18.4 (27/147) 37.2 (16/43)
DAS-0-1 GH 9.9 (8/81) 10.9 (13/119) 20.5 (31/151) 37.1 (13/35)
DAS0-1 PGA 10.3 (8/78) 11.6 (14/121) 20.0 (30/150) 35.1 (13/37)
DAS-TJC53 GH 9.1 (6/66) 12.3 (13/106) 16.6 (25/151) 33.3 (21/63)
DAS-TJC53 PGA 10.3 (7/68) 11.4 (12/105) 17.3 (26/150) 31.7 (20/63)
DAS-TJC44 GH 11.0 (8/73) 11.1 (12/108) 19.0 (28/147) 29.3 (17/58)
DAS-TJC44 PGA 10.7 (8/75) 11.5 (12/104) 17.7 (26/147) 31.7 (19/60)
DAS28 12.1 (13/107) 8.3 (5/60) 17.2 (29/169) 36.0 (18/50)
DAS28 PGA 11.2 (12/107) 8.2 (5/61) 18.0 (30/167) 35.3 (18/51)
DAS: disease activity score GH: visual analogue scale for patient’s assessment of general health HDA: high disease activity LDA; low disease 
activity; MDA: moderate disease activity; PGA: visual analogue scale of patient’s global assessment of disease activity; SHS; Sharp-van der Heijde 












































The original DAS is sometimes criticized for being complicated because it includes the RAI. 
We compared three alternatives with the original DAS with various tender joint scores and 
patient’s assessment (by VAS) of either disease activity or GH. We found very small differ-
ences in performance of all scores. Correlation between all alternatives and the original DAS 
is high. All scores classify similarly patients in remission, LDA, MDA and HDA. Differences in 
disease activity between treatment arms could be confirmed with all indices. The percentage 
of patients with RRP is comparable for original and alternative scores in different disease 
activity levels.  
Our results on the use of VAS-PGA and VAS-GH demonstrate that either can be used as sug-
gested by the EULAR handbook15, and affirm the single study on this subject by Khan et al.16 
Although individual VAS scores itself correlate only moderately, which indicates that they 
cover a different concept, when used as part of the DAS, DAS alternatives or DAS28 the total 
effect is negligible, mostly because of limited weight that is given to this component. 
When categorizing patients in disease activity levels we see that DAS-TJC53 and DAS-TJC44 
are classifying more MDA and HDA, less LDA and similar remission percentages. This can be 
explained because both DAS-TJC53 and DAS-TJC44 assess more joints separately, causing 
a small shift to a higher disease activity category. However, the vast majority of remission 
patients have none to one painful joints in which disease activity by any score, and thus 
remission percentages, remain the same. DAS28 shows a different pattern, with many more 
patients assessed as being in remission and consequently a smaller LDA group, in line with 
discussions about the remission definition of DAS28.17 The percentage of patients with RRP in 
DAS28 remission was higher compared to the (alternative) DAS.
The slightly higher disease activity measured with both DAS-TJC44 and DAS-TJC53 with cor-
responding higher classification leads to less radiological damage in the HDA group of these 
scores. Differences are nonetheless very small. The percentages of patients with RRP were 
not influenced by the use of VAS-PGA or VAS-GH, neither in the alternative DAS nor in the 
original DAS28. 
A limitation to the current study is caused by rapid reduction in disease activity in this early 
severe RA population, leading to an infrequency of graded joint scores above 1, which ex-
plains the overlap between DAS0-1 and DAS. If in daily practice RAI scores of 3 are more 
prevalent, we expect a greater difference between the original DAS and alternative versions 
in higher activity levels. In modern practice were treatment is aimed at achieving remission 
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variants are valid at the group level and for the vast majority of patients, however for some 
individual patients differences between scores may be larger.  
In conclusion, we have shown that scoring the presence or absence of tenderness in individual 
joints to calculate a disease activity score performs as good as scoring a graded tenderness 
score in joints groups. In daily practice or clinical studies, using a DAS alternative may be 
much easier than the original DAS with RAI. The score based on assessment of tenderness in 
the same 44 joints assessed for swelling may be most practical.
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Assessment of global disease activity in RA patients monitored in 





















































To compare the patient’s (PtGDA) and physician’s (PhGDA) assessment of global disease 
activity and to identify factors that might influence these differences, as well as factors that 
may influence the patients and the physicians score separately. 
Methods
Anonymous data were used from 2118 Dutch patients included in the METEOR database. 
PtGDA and PhGDA were scored independently on a 100mm visual analogue scale (VAS) with 
0 and 100 as extremes. The agreement, Intraclass correlation coefficients (ICC), was calcu-
lated and a Bland Altman plot was created to visualize the differences between PtGDA and 
PhGDA. Linear Mixed Model analysis was used to model PtGDA and PhGDA. Logistic repeated 
measurements were used to model the difference in PtGDA and PhGDA (PtGDA>PhGDA vs. 
PtGDA≤PhGDA). Gender, age, swollen joint count, tender joint count, VAS pain, disease dura-
tion and ESR were considered as possible determinants in both models.
Results
Mean (SD) age was 57 (15) years and 67% of the patients were female. Agreement between 
PtGDA and PhGDA was moderate (ICC: 0.57). Patients scored on average 11 units higher 
(worse) than rheumatologists (95% limits of agreement: -25.2 to 47.6). Patient’s perception 
of pain (VAS) was positively associated with a PtGDA being higher than PhGDA. Similarly, 
ESR and swollen joint counts were positively associated with a PtGDA being lower or equal 
to the PhGDA.
Conclusion
Patients rate global disease activity consistently higher than their rheumatologists. Patients 
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INTRODuCTION
The importance and use of patient reported outcomes (PROs) in health care increased during 
the past decades. PROs are considered valuable in measuring status and change in health 
care 1. However, in addition to the PRO, similar information is also collected by the physi-
cian, e.g. assessment of level of disease activity. As patients and physicians may differ in their 
perception of health status, discordant observations may occur and may affect patient care. 
For example, patients are likely to report dissatisfaction with a treatment if their physician 
underestimates their perceived level of disease activity 2-4.
The 100mm visual analogue scale (VAS) is an instrument used to measure global disease 
activity (GDA) in rheumatoid arthritis (RA). It can be completed by the patient (PtGDA) (and 
is then considered then a PRO) as well as by the physician (PhGDA). Discordances between 
patients and rheumatologists rating their impression of GDA on a VAS have been reported; 
patients tend to score their GDA higher than their physician 5,6. It is not clear which factors 
determine the occurrence and magnitude of these discrepancies between patient’s and 
physicians’ perceptions.
The METEOR (Measurement of efficacy of Treatment in the Era of Rheumatology) database 
provides data on several patient- and physician-reported outcome measures in RA. Here we 
have compared PtGDA and PhGDA reported in individual patients, and identified which fac-
tors determined the discordance in PtGDA and PhGDA.
METHODS
Patients
Data collected in the ongoing prospective international METEOR database were used. ME-
TEOR is an acronym for Measurement of efficacy of Treatment in the Era of Rheumatology 
hat has been started in 2008. METEOR is used by rheumatologists to monitor patients with 
rheumatic diseases. Data are collected in a central database in a completely anonymous way. 
Both newly diagnosed patients and patients with more advanced disease are included in 
de database. Measures of disease activity and Health Assessment Questionnaire data are 
registered every visit. Currently, the tool is used worldwide and data is available from 100 
hospitals, which included more than 14.800 patients. More details on the METEOR database 
are described elsewhere 9 .
A sample of 2.118 patients was taken from the METEOR database covering the time span 
between 2008 and 2011. The number of visits (8.509 in total) varied with a range of 1 to 
17 visits per patient as did time intervals between visits. PtGDA and PhGDA were measured 
on a 100mm visual analysis scale (VAS) with 0 (best possible) and 100 (worst possible) as 











































20mm difference between PtGDA and PhGDA was used as a binary outcome variable (patient 
scores higher versus rheumatologist scores equal or higher). A difference in rating of 20mm 
between PtGDA and PhGDA score was chosen as cutoff value, since it was considered to be a 
relevant discordance in previous literature5.
Statistical analyses
Descriptive statistics were performed using the mean and standard deviation (SD) or median 
and interquartile ranges (IQR) as appropriate for continuous variables, and number and 
percentages for categorical variables.
A Bland and Altman plot was performed to visualize the differences between PtGDA and
PhGDA. This is based on the standard deviation of the differences in PtGDA and PhGDA 
calculated from variance components in a linear mixed model (LMM), and used to construct 
the 95% limits of agreement 7. The agreement between patient and physician was expressed 
as intraclass correlation coefficient (ICC) using variance components in a LMM with a random 
intercept for patients.
LMM was also used to model the PtGDA and PhGDA. Gender, age, swollen joint count, tender 
joint count, pain (VAS), disease duration (diagnosis until first visit) and erythrocyte sedimen-
tation rate (ESR) were considered as possible determinants for the model.
Non-linear mixed modeling (repeated measures logistic regression) was used to model the 
difference in PtGDA and PhGDA as binary outcome (patient’s score higher than physician’s 
score as “event”). Gender, age, swollen joint count, tender joint count, pain (VAS), disease 
duration and ESR were considered as possible determinants for the model.
Software programs SAS version 9.2 and SPSS version 17.0 were used for the analyses
and P-values smaller than 0.05 were considered statistically significant.
RESuLTS
Of the 2118 patients, 1338 (67%) were female. The mean (SD) age at entry was 57 15
years (table 1). 
Agreement between PtGDA and PhGDA was moderate (ICC: 0.57; p<0.01). Patients rated 
their GDA on average 11mm higher (worse) than rheumatologists at the first registered visit 
(95% limits of agreement: -25.2 to 47.6). A few scores showed large discrepancy between the 
PtGDA and PhGDA score, on average 75 mm (figure 1). Patients scored the GDA significantly 
higher when the number of tender joint count, and VAS pain increased (p<0.01). VASpain 
(p<0.01), number of swollen and tender joint count (p=0.04 and ESR (p<0.01) independently 
contributed to an increase in GDA score by the physician. Physician’s score decreased by 
increasing disease duration (p=0.03) and patient’s scores increased by decreasing swollen 
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Pain (VAS), ESR and the number of swollen joints all independently contributed to the dif-
ferences between patient’s GDA and physician’s GDA. A higher patient GDA score compared 
to the physicians score is positively correlated with pain (VAS). A higher or equal GDA score 
of the physician compared to the patient is positively correlated with ESR and swollen joint 
count. (Table 3)
Table 1: Baseline characteristics (Visit 1)
Variables Patients N total (N=2118)
Age, mean (SD) 57 (15) 1879
Female, N (%) 1338 (67) 2007
CRP, median (IQR) 5 (3-13) 167
ESR, median (IQR) 14 (6-29) 1489
DAS 28, mean (SD) 3.2 (1.4) 1408
HAQ, mean (SD) 0.9 (0.3) 575
Duration complaints until diagnosis (mo), median (IQR) 4 (1-12) 758
Duration complaints until first registered visit (yrs), median (IQR) 7 (2-15) 775
Duration diagnosis until first registered visit (yrs )median (IQR) 6 (1-13) 790
CCP positive, N (%) 212 (64) 334
RF positive, N (%) 726 (74) 987
Erosions present, N (%) 596 (65) 923
Swollen joint count 28, median (IQR) 1 (0-3) 1872
Tender joint count 28, median (IQR) 2 (0-4) 1872
VAS, median (IQR)
Global health physician 21 (10-41) 903
Global health patient 34 (14-55) 1615
Pain patient 39 (15-60) 1476
N: number;  SD: standard deviation; CRP: C-reactive protein; ESR: erythrocyte sedimentation rate; IQR: inter quartile range; DAS: disease activity 
score; HAQ: health assessment questionnaire;  Mo: months; yrs: years; CCP: anti cyclic citrullinated peptides  antibodies;  RF: rheumatoid factor; 










































7 Figure 1: Bland Altman’s plot: GDA patient versus GDA physician
GDA patient: global disease activity according to the patient; GDA physician: global disease activity according to the physician; PtGDA: global 
disease activity according to the patient; PhGDA: global disease activity according to the physician
Table 2: Linear mixed model predictors of GDA disease activity by patients and physicians
PtGDA PhGDA




































PtGDA: global disease activity according to the patient; PhGDA: global disease activity according to the physician; β: beta; CI: confidence 
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DISCuSSION
On average, patients tend to score GDA systematically higher than rheumatologist. The 
agreement between both is only moderate. Determinants of the differences in scores are pain 
(more pain means higher GDA by the patient), and swollen joint count as well as ESR (higher 
SJC/ESR means higher GDA by physician). PtGDA and PhGDA separately are partly associated 
with the same determinants: tender joint count and pain are both taken into consideration 
by the patients and physicians assessment of GDA. In addition, the objective measures, swol-
len joint count and ESR, are taken into consideration by the physician. Expectedly, physicians 
put more weight on the value of ESR and SJC, whilst patients put more weight on pain.
Patients and physicians take partly the same determinants in consideration when they assess 
global disease activity; they both consider tender joints and pain of the patient. However 
the patient does not take into consideration objective measures. In fact the swollen joint 
count even has a negative association with PtGDA which we cannot explain. The physician 
takes both objective (swollen joint count, acute phase reactants and disease duration) and 
subjective (patients pain and tender joint count) measures in consideration in assessing the 
GDA. The discrepancy in factors both patients and physicians take into consideration for their 
Table 3: Non-linear mixed model predictors of GDA difference between patients and physicians
PtGDA versus PhGDAa



















VAS pain patient 0.05
-0.06, 0.06
<0.01
PtGDA: global disease activity according to the patient; PhGDA: global disease activity according to the physician; β: beta; CI: confidence 
interval; yrs: years; ESR: erythrocyte sedimentation rate; SJC28: swollen joint count in 28 joints; TJC28: tender joint count in 28 joints; VAS: visual 











































GDA assessment might lead to the systematic difference in patients and physicians scores of 
almost 11 units (on a scale from zero to 100) and to the only moderate agreement between 
patients and physicians. Other studies also reported discordances between patients and 
physicians in rating the GDA. Barton et al. showed that patients’ GDA score was on average 
15 points higher than the physicians’ mean GDA score 8. Also, the QUEST-RA study showed a 
higher mean GDA of patients (approximately 11 points) than GDA of physicians 5. In concor-
dance with the latter study, we also found a difference of approximately 11 points. However, 
it is questionable if 11 points is a clinical relevant discrepancy between patient’ and physician’ 
GDA score since we defined 20 points to be a difference. On the other hand, the moderate 
agreement between patients and physicians might support that patients and physicians rate 
RA disease activity differently. This confirms the statement of an earlier study that patient and 
physicians differ in perception of disease activity 6.
A previous study, carried out in several European countries, also showed only a moderate 
agreement between GDA patient and GDA physician 5. Other studies, performed in the 
United States and in Europe showed low correlations and low agreement between physician 
and global health assessments [9, 10]. The discrepancies between the results of previous 
studies might suggest differences between countries in GDA of patient and physician due 
to cultural factors.
Our study shows that the difference in scoring might be explained by differences in the in-
terpretation of ESR, swollen joints and pain. Pain is more likely to be associated with an equal 
or higher score of the patient. This statement was confirmed by the large QUEST-RA study, 
which studied factors on discordance between GDA of the patient and that of the physi-
cian. Pain was one of the most important factors that caused discordances. Pain increased 
significantly when patient scored GDA higher compared to the physician. Furthermore, the 
QUEST-RA also used 20mm difference in GDA score as the cut off value of a true difference 
between patient and physician 5.
In our study, patients with a high ESR and swollen joint count are more likely to be scored 
higher by the physician. A previous study confirms this result. 8. Another study showed that, 
besides swollen joints, physician put more weight on ESR than patients 6.
As we can see from the results of our study, patients and physicians focus on different factors 
when assessing disease activity. Patients are more influenced by subjective feelings, such 
as pain, while physicians base their score more on objective measures, such as number of 
swollen joints and ‘blood levels’. This is supported by previous literature 11. Patients base 
their assessments on needs, priorities, experiences, expectations and attitude, which are all 
subjective domains. Physicians, on the other hand, rely on the patient’s physical health status, 
which is considered more objective in nature [12, 13] .
This study has some limitations. The first is missing values, as these might not be randomly 
missing. Patients that perform worse in their opinion may stay at home and miss an appoint-
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Another limitation is that the included patients were not always newly diagnosed RA patients. 
Some patients are already treated for years and patients expectations and perceptions can 
change as a result of improvement or worsening of their health 14. Therefore, long treatment 
duration might influence patient’s assessment of GDA.
In conclusion, patients and physicians both assess GDA using partly similar determinants. 
Differences in GDA scores may be explained by pain, ESR and swollen joint count. Patients 
put more weight on pain and physicians on ESR and swollen joint count. Also cultural dif-
ferences may have contributed to the moderate level of agreement between patients and 
physicians. We already see a difference in agreement between patient’s and physician’s score 
by comparing studies performed in several countries.
In clinical practice, it should be recommended to spend more time educating patients on 
how to rate the global disease activity. Patients need to be clearly informed on the difference 
between the disease activity and pain, as patients let pain influence their GDA score. A good 
understanding of the GDA score by the patient is important since a previous study showed 
that patients with a high PtGDA score, while having a normal ESR and low SJC and TJC, are 
not in remission 15.
Further research should be conducted to find out what the clinical impact is of these dis-
crepancies between patients and physicians since previous research might suggest that 
treatment strategy is only based on the rheumatologist’s opinion and not on the patient’s 
opinion or the DAS28 [16 ]. Also differences in PtGDA and PhGDA score per country should 
be studied and whether GDA assessment is influenced by cultural factors.
ACkNOwLEDGEMENTS
METEOR is a free-for-use online software program developed by the Merit Foundation and 
aims to improve treatment of RA by the measurement of patient outcomes and benchmark-












































 1. Otter, S.J., Lucas, K., Springett, K., et al., Identifying Patient-Reported Outcomes in Rheumatoid 
Arthritis: The Impact of Foot Symptoms on Self-Perceived Quality of Life. Musculoskeletal Care, 2012.
 2. Hewlett, S.A., Patients and clinicians have different perspectives on outcomes in arthritis. The Journal 
of Rheumatology, 2003. 30(4): p. 877-879.
 3. Suarez-Almazor, M.E., et al., Lack of congruence in the ratings of patients’ health status by patients 
and their physicians. Medical Decision Making, 2001. 21(2): p.113- 121.
 4. Wartman, S.A., Morlock, L.L., Malitz, F.E., Palm, E., Impact of divergent evaluations by physicians and 
patients of patients’ complaints. Public Health Reports, 1983. 98(2): p. 141.
 5. Khan, N.A., Spencer, H.J., Abda, E., et al., Determinants of discordance in patients’ and physicians’ 
rating of rheumatoid arthritis disease activity. Arthritis Care & Research, 2012. 64(2): p. 206-214.
 6. Nicolau, G., Yogui, M.M., Vallochi, T.L., Gianini, R.J., Laurindo, I.M.M., Novaes, G.S., Sources of dis-
crepancy in patient and physician global assessments of rheumatoid arthritis disease activity. The 
Journal of Rheumatology, 2004. 31(7): p. 1293-1296.
 7. Foti, C., Cisari, C., Carda, S., et al., A prospective observational study of the clinical efficacy and safety 
of intra-articular sodium hyaluronate in synovial joints with osteoarthritis. European journal of 
physical and rehabilitation medicine, 2011. 47(3): p. 407.
 8. Barton, J.L., Imboden, J., Graf, J., Glidden, D., Yelin, E.H., Schillinger, D., Patient-physician discor-
dance in assessments of global disease severity in rheumatoid arthritis. Arthritis Care & Research, 
2010. 62(6): p. 857-864.
 9. Kwoh, C.K., O’Connor, G.T., Regan-Smith, M.G., et al., Concordance between clinician and patient as-
sessment of physical and mental health status. The Journal of Rheumatology, 1992. 19(7): p. 1031.
 10. Ward, M., Clinical measures in rheumatoid arthritis: which are most useful in assessing patients? The 
Journal of Rheumatology, 1994. 21(1): p. 17.
 11. Neville, C., Clarke, A.E., Joseph, L., Belisle, P. Ferland, D., Fortin, P.R., Learning from discordance 
in patient and physician global assessments of systemic lupus erythematosus disease activity. The 
Journal of Rheumatology, 2000. 27(3): p.675.
 12. Liang, M., K. Cullen, and M. Larson, In search of a more perfect mousetrap (health status or quality of 
life instrument). The Journal of Rheumatology, 1982. 9(5): p. 775.
 13. Pincus, T., Summey, J.A., Soraci, S.A., Wallston, K.A., Hummon, N.P., Assessment of patient satisfac-
tion in activities of daily living using a modified Stanford Health Assessment Questionnaire. Arthritis 
& Rheumatism, 1983. 26(11): p. 1346-1353.
 14. Ward, M.M., Rheumatology care, patient expectations, and the limits of time. Arthritis Care & Re-
search, 2004. 51(3): p. 307-308.
 15. Vermeer, M., Kuper, H.H., Bijl, van der, A.E., et al., The provisional ACR/EULAR definition of remission 
in RA: a comment on the patient global assessment criterion. Rheumatology, 2012.
 16. Pyne, L., Bykerk., Boire., et al., Increasing Treatment in Early Rheumatoid Arthritis Is Not Determined 
by the Disease Activity Score But by Physician Global Assessment: Results from the CATCH Study. The 




Association with joint damage and physical functioning of 9 




D.M.F.M van der Heijde 
A.H. Gerards

















































Objective To compare nine disease activity indices and the new American College of Rheu-
matology (ACR)/European League against Rheumatism (EULAR) remission criteria in rheu-
matoid arthritis (RA) and to relate these to physical function and joint damage progression. 
Methods 5-year data from the BeSt study were used, a randomized clinical trial comparing 
four treatment strategies in 508 patients with recent onset RA. Every three months disease 
activity was assessed with nine indices (DAS, DAS-C-reactive protein (DAS-CRP), DAS28, 
DAS28-CRP, Simplified Disease Activity Index (SDAI), Clinical Disease Activity Index, and three 
DAS versions with adjusted tender joint scores) and were categorized into remission, low, 
moderate and high disease activity (LDA, MDA, HDA). In addition, the recent ACR/EULAR 
clinical trial and practice remission was assessed three-monthly, with 28 and 66/68 joint 
counts. For each  index, Generalized Estimating Equations analyses were performed to relate 
disease activity levels and the absence/presence of remission to three-monthly assessments 
of physical functioning and annual radiological progression.
Results From the composite indices, CDAI and SDAI were most stringent definitions of remis-
sion and classified more patients as in LDA. DAS28 and DAS28-CRP had the highest propor-
tions remission and MDA, and a smaller proportion LDA. ACR/EULAR remission percentages 
were comparable to CDAI/SDAI. The variant including CRP and 66/68 joint counts was the 
most stringent. 
For all indices, higher levels of disease activity were associated with decreased physical 
functioning and more radiological damage progression. Despite differences in classification 
between indices, no major differences in the relation to the two outcomes were observed. 
Conclusion The associations of nine composite indexes and ARC/EULAR remission criteria 
with functional status and joint damage progression showed high accordance, whereas the 
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INTRODuCTION 
Assessing disease activity and response to treatment is of vital importance in rheumatoid 
arthritis (RA), both in clinical trials and in daily practice. By early and effective suppression of 
inflammation, severe joint destruction and functional disability can be prevented.1;2 The use 
of a tight controlled treatment approach, including frequent disease activity measurements 
and treatment towards a preset goal, have further improved outcomes.3-6
In order to measure disease activity, several composite scores have been developed, such as 
the Disease Activity Score (DAS)7, the Disease Activity Score in 28 joints (DAS28)8, the Clinical 
Disease Activity index (CDAI)9, and the Simplified Disease Activity Index (SDAI)10 as a combi-
nation of variables might represent actual disease activity better than single measures.11 We 
recently validated three new variants of the original DAS with adjusted tender joint counts 
(TJC).12 
All composite scores on continuous scales can be subdivided into categories (remission, 
low disease activity (LDA), moderate disease activity (MDA) and high disease activity (HDA)), 
which are nowadays also being used as tools to guide treatment decisions for individual 
patients. Beside these index based criteria, an international taskforce from the American Col-
lege of Rheumatology (ACR) and the European League against Rheumatism (EULAR) recently 
developed new remission criteria for clinical practice and clinical trials.13 
In previous studies but the number of indices compared, patient numbers or follow-up dura-
tion were limited and few studies related disease activity levels to functional ability or radio-
logical damage progression in time. Little is known about the performance of the new ACR/
EULAR remission criteria in comparison with existing index based remission definitions.14 To 
be able to compare results of registries or clinical trials reliably using different composite 
scores, a more extended comparison is needed. 
Therefore, the aims of this study were: 1. to compare classification of disease activity accord-
ing to nine composite scores into remission, LDA, MDA and HDA; 2. to compare remission 
percentages of composite scores and new ACR/EULAR remission criteria; and 3. to relate 
these levels of disease activity to physical functioning and progression of joint damage. 
METHODS
Patients
Five-year follow-up data of the BeSt study were used, in which 508 patients with recent-
onset rheumatoid arthritis with a disease duration ≤2 years were randomized into 4 dynamic 
treatment strategies: 1. sequential monotherapy; 2. step-up combination therapy; 3. initial 
combination with prednisone; 4. initial combination with infliximab. Details have been 











































disease activity.7;16 If DAS was >2.4 the next step of the protocol was taken. If DAS was ≤2.4 
for ≥6 months the medication was tapered to monotherapy in maintenance dose. From the 
third year, the last disease-modifying anti rheumatic drug (DMARD) could be tapered and 
discontinued if DAS was <1.6 for ≥6 months in patients on monotherapy in maintenance 
dose. The last DMARD was restarted if DAS was ≥1.6. The study was approved by the Medical 
Ethics Committees, and all patients gave written informed consent. 
Clinical assessments
Every three months the following variables were collected: 66 swollen joint count (SJC), 
68 tender joint count (TJC), erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), 
patient’s assessment of global health (VAS-GH) on a visual analogue scale (0-100mm) and 
physician’s global assessment of disease activity (VAS-PGA). 
At each time point, disease activity was calculated according to the following composite 
indices (see supplementary table S1; published online only): the original DAS with ESR or CRP 
(DAS; DAS-CRP), DAS28 with ESR or CRP (DAS28; DAS28-CRP), SDAI, CDAI, and 3 variants of 
the original DAS with adjustments in the TJC of the score.12 In the first adjustment (DAS0-1), 
the same joints and joint groups are used as in the Ritchie Articular Index, but scoring only 
absence (0) or presence (1) of tenderness instead of grading tenderness from 0 to 3. In the 
second adjusted version (DAS-TJC53), grading as well as assessment of joint groups were 
omitted; all 53 joints of the RAI were counted separately for absence or presence of tender-
ness. In the last version, only 44 joints (equal to the joints assessed for swelling) were assessed 
for absence or presence of tenderness (DAS-TJC44).  Furthermore, the presence or absence 
of ACR/EULAR remission was assessed using the following components: SJC≤1, TJC≤1, VAS 
global health ≤1cm and CRP ≤1g/dL. Four variants were used (see supplementary table S1; 
published online only): a clinical trial definition including CRP and a clinical practice definition 
excluding CRP, each with a 28/28 swollen/tender count and both with a 66/68 swollen/tender 
joint count.  
At each time point, patients were classified as being in remission (yes/no) according to 9 
composite indices and ACR/EULAR remission-criteria or in low (LDA), moderate (MDA) or high 
disease activity (HDA) according to the composite indices based on previously published 
cut-off points.16-20(see appendix supplementary table S1; published online only) For the three 
simplifications of the original DAS cut-offs of the original DAS were used.
Outcome assessments
Every three months functional capacity was assessed using the Health Assessment 
Questionnaire(HAQ).21 Joint damage was assessed on annual radiographs from baseline until 
year 5 per patient in random order using the Sharp/vdHeijde method22, by two independent 
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Statistical analysis
SPSS version 17.0 was used for all analyses. To assess the relationship between disease activity 
category according to nine disease activity indices, ACR/EULAR remission criteria and HAQ, 
four Generalized Estimating Equations (GEE) analyses were performed per index: first with 
HAQ per patient as continuous outcome and second with HAQ per patient as dichotomous 
outcome (for 3 cut-off points: HAQ>1.0, HAQ>0.5, HAQ>0). 
The disease activity level was added as explanatory variable, categorized as remission, LDA, 
MDA and HDA, or as remission yes/no. All analyses were corrected for baseline HAQ, time, 
age, gender and treatment group with additional correction for time*time in the continuous 
HAQ analysis to approach linearity. For each disease activity level (remission, LDA, MDA, HDA 
or remission yes/no) and per composite score, the mean HAQ scores (continuous outcome) 
and probabilities of a HAQ above the cut-off (dichotomous outcome) were estimated within 
the GEE model. For this purpose the Estimated Marginal Means subcommand was used, 
which fills in the regression equation by fixing continuous values of covariates at their means 
and estimates HAQ values for each level of a categorical variable. This option was used to 
avoid differences in distribution of confounders between different disease activity levels and 
composite scores. 
To assess the relationship between level of disease activity according to the different com-
posite indices, ACR/EULAR remission and the progression of joint damage, four GEE analyses 
were performed for each composite index: first with absolute annual SHS progression per 
year as continuous outcome and then with annual SHS progression as dichotomous out-
come (cut-off points: ≥1, ≥3, ≥5 SHS units progression per year). Since radiographs were 
taken annually and disease activity measured every three months, for the analysis including 
composite scores only, the mean disease activity per year was calculated by the following 
formula: (½*DAS1+DAS2+DAS3+DAS4+½*DAS5)/4 and categorized into remission, LDA, 
MDA and HDA. This categorical mean disease activity level per year or remission yes/no was 
added as explanatory variable. Remission per year was defined as ≥3 out of 4 visits remission. 
Only patients with complete data were used; for single missing values we used a last observa-
tion carried forward method before calculating mean disease activity per year. 
The SHS analyses were corrected for total SHS at the beginning of each year, time, presence of 
cyclic-citrullinated peptides antibodies (anti-CCP), treatment group, age and gender. Mean 
progression scores and probabilities for progression were estimated for each index and each 
disease activity level using estimated marginal means.   
The GEE method with M-dependence covariance structure was used to correct for within 













































At baseline (n=508), patients had active disease with a mean (SD) DAS of 4.4 (0.9) and a mean 
(SD) HAQ of 1.4 (0.9). Mean (SD)/median (IQR) SHS at baseline was 7.1 (10.2) / 3.0 (0.5 – 9.5). 
Spider diagrams
Spider diagrams (figures 1a and 1b) illustrate the classification into disease activity categories 
according to the different composite indices. Irrespective of the composite score used, more 
patients were classified in higher disease activity categories in year 1 than in year 5, reflect-
ing treatment efficacy. From the composite indices, CDAI and SDAI had the most stringent 
definitions of remission and thus classified a relative high proportion of patients in LDA. The 
proportions of patients in MDA and HDA were comparable between CDAI, SDAI and DAS 

































































































































Figure 1: Spider diagrams showing the cumulative percentage of patients in remission, low, moderate and high disease activity according to 
the different composite indices at t=1 year  (panel A, n=415) and t=5 year (panel B, n=317). Bar charts show the percentage (number) of 
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and a relatively small proportion of patients in LDA. Of adjusted DAS versions, DAS0-1 was 
very comparable with the original DAS. The absolute DAS-TJC53 and, to a lesser extend, DAS-
TJC44 was slightly higher than the original DAS, resulting in higher percentages of patients 
in HDA. Figures 1c and 1d show the remission percentages of the composite indices and 
ACR/EULAR remission criteria. The most stringent definition is the clinical trial definition with 
66/68 joints. Clinical trial remission-criteria showed lower remission percentages than clinical 
practice remission-criteria, as did the criteria including a full 68/66 joint count compared with 
the criteria based on a 28 joint count. Numerical remission percentages per definition are 
presented online (see supplementary table S2 and S3; published online only). 
Relation with functional ability
In general, predicted HAQ values among disease activity levels based on the composite in-
dices showed high agreement (table 1). As expected, HAQ values were lower when the level 
of disease activity was lower. Although CDAI and SDAI classified fewer patients in remission, 
CDAI and SDAI remission was not associated with lower HAQ scores than in other indices 
(table 1). DAS28 variants, compared to other indices, classified the highest proportion of 
patients in remission and MDA and fewer patients in LDA, but HAQ levels in remission, LDA 
Table 1: Mean predicted HAQ score for patients in remission, LDA, MDA and HDA.
Remission LDA MDA HDA


















































































Covariates and factors appearing in the model are fixed at the following values: baseline HAQ 1.4; visit 10.6; age 53.9; treatment group 1; female 
gender. LDA: low disease activity; MDA: moderate disease activity; HDA: high disease activity; CI: confidence interval; DAS: disease activity score; 
CRP: C-reactive protein; DAS28: disease activity score in 28 joints; SDAI: simplified disease activity index; CDAI: clinical disease activity index; DAS 











































and MDA were comparable to other indices. Patients in HDA according to DAS-TJC53 and 
DAS-TJC44 had lower HAQ scores than patients in HDA according to other indices.
Similar results were seen with regard to the probability of a HAQ score >0.5 as outcome 
(table2). Overall 34-91% of patients were limited in functioning depending on their disease 
activity level. HDA corresponds with a higher change of functional limitations. In general 
there was little difference between percentages of HAQ scores >0.5 for all composite scores, 
Table 2: Estimated probability (95% CI) for HAQ scores>0.5 in patients in remission, LDA, MDA and HDA.
Remission LDA MDA HDA
Probability (95% CI) Probability (95% CI) Probability (95% CI) Probability (95% CI)
DAS 0.34 (0.27-0.40) 0.49 (0.42-0.57) 0.69 (0.63-0.75) 0.90 (0.86-0.93)
DAS CRP 0.34 (0.27-0.41) 0.52 (0.44-0.59) 0.73 (0.67-0.79) 0.90 (0.85-0.94)
DAS28 0.36 (0.29-0.43) 0.48 (0.40-0.55) 0.63 (0.56-0.70) 0.87 (0.83-0.92)
DAS28 CRP 0.39 (0.32-0.46) 0.51 (0.44-0.58) 0.68 (0.62-0.75) 0.90 (0.86-0.94)
SDAI 0.31 (0.25-0.38) 0.47 (0.40-0.55) 0.70 (0.63-0.76) 0.86 (0.81-0.91)
CDAI 0.31 (0.25-0.38) 0.47 (0.39-0.54) 0.70 (0.64-0.76) 0.85 (0.80-0.89)
DAS 0-1 0.34 (0.27-0.41) 0.50 (0.43-0.58) 0.70 (0.64-0.76) 0.91 (0.88-0.95)
DAS TJC53 0.34 (0.28-0.41) 0.49 (0.42-0.56) 0.65 (0.59-0.72) 0.85 (0.80-0.89)
DAS TJC44 0.35 (0.28-0.41) 0.49 (0.41-0.56) 0.66 (0.59-0.72) 0.85 (0.81-0.90)
Covariates and factors appearing in the model are fixed at the following values: previous HAQ 1.4; visit 10.6; age 53.9 treatment group 1; female 
gender. LDA: low disease activity; MDA: moderate disease activity; HDA: high disease activity; CI: confidence interval; DAS: disease activity score; 
CRP: C-reactive protein; DAS28: disease activity score in 28 joints; SDAI: simplified disease activity index; CDAI: clinical disease activity index; DAS 
0-1, disease activity score with RAI 0-1; TJC53: tender joint count 53 joints; TJC44: tender joint count 44 joints
Table 3 Mean predicted delta SHS for patients in remission, LDA, MDA and HDA.
Remission LDA MDA HDA
Mean (95%CI) Mean (95%CI) Mean (95%) Mean (95%)
DAS 3.49 (-0.06-7.04) 5.50 (2.35-8.66) 7.34 (4.09-10.60) 11.70 (7.39-16.01)
DAS CRP 4.08 (0.95-7.21) 5.44 (2.34-8.55) 6.69 (3.58-9.81) 11.72 (7.09-16.35)
DAS28 3.57 (0.12-7.02) 4.61 (1.43-7.79) 6.88(3.77-9.98) 10.83 (6.83-14.83)
DAS28 CRP 3.54 (-0.03-7.10) 5.54 (2.34-8.74) 8.05 (4.80-11.30) 13.18 (8.51-17.84)
SDAI 4.01 (0.76-7.26) 4.67 (1.37-7.97) 7.39 (4.16-10.61) 11.48 (7.25-15.71)
CDAI 3.85 (0.64-7.06) 4.66 (1.41-7.91) 7.40 (4.18-10.61) 10.95 (6.89-15.00)
DAS 0-1 3.41 (-0.05-6.87) 5.45 (2.33-8.57) 7.21 (4.01-10.42) 12.66 (8.21-17.12)
DAS TJC53 3.54 (0.17-6.90) 4.78 (1.45-8.11) 6.89 (3.69-10.08) 9.92 (6.02-13.82)
DAS TJC44 3.64 (0.28-7.00) 4.92 (1.60-8.24) 7.16 (3.96-10.36) 10.24 (6.25-14.23)
Covariates and factors appearing in the model are fixed at the following values: previous SHS 10.3, year 2.8, age 53.8, treatment group 1, 
anti-CCP positive patients; female gender. LDA: low disease activity; MDA: moderate disease activity; HDA: high disease activity; CI: confidence 
interval; DAS: disease activity score; CRP: C-reactive protein; DAS28: disease activity score in 28 joints; SDAI: simplified disease activity index; 
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but the same subtle differences were found as were seen previously. In the analysis including 
ACR/EULAR remission definitions the same pattern was found (table 5). Predicted HAQ scores 
and probabilities for a HAQ score >0.5 were comparable for all definitions, with SDAI, CDAI 
and ACR/EULAR remission-criteria at the lower end of the range. Very little difference was 
found within the group of ACR/EULAR remission definitions. Supplementary data for other 
cut-off values are shown in the appendix (supplementary table S4; published online only).
Relation to the progression of joint damage
Table 3 shows predicted values of SHS progression for patients in different disease activity 
levels according to the 9 indices. All indices showed similar joint damage progression in dif-
ferent disease activity levels, and all composite indices showed a dose response, with a higher 
level of disease activity yielding more joint damage progression. Although CDAI and SDAI 
classifed fewer patients as being in remission, CDAI and SDAI remission were not associated 
with less damage progression. In the HDA category, patients with DAS-TJC53 and DAS-TJC44 
had somewhat less SHS progression than patients in HDA according to other indices (table3). 
Predicted probabilities for SHS progression ≥3 units for patients in remission, LDA, MDA 
and HDA categories according to the 9 indices are shown in Table 4. The proportions of 
SHS progression between different composite indices were very similar. The percentage of 
CCP-positive female patients in remission showing joint damage progression varied between 
9-12% for progression ≥3 units (table 4). The chance for progression ≥3 units in CCP- patients 
in remission was lower (3-4% for SHS progression ≥3, data not shown). Patients in SDAI and 
CDAI remission had comparable chances for progression ≥3 units compared to other indices 
(9% versus 9-12%). The probability for progression ≥3 units in LDA was slightly lower with 
Table 4: Estimated probability in % (95% CI) for SHS progression ≥3 units in patients in remission, LDA, MDA and HDA.
Remission LDA MDA HDA
Probability (95% CI) Probability (95% CI) Probability (95% CI) Probability (95% CI)
DAS 0.10 (0.06 – 0.15) 0.18 (0.12 – 0.25) 0.31 (0.21 – 0.40) 0.59 (0.44 – 0.74)
DAS CRP 0.12 (0.07 – 0.18) 0.19 (0.13 – 0.26) 0.33 (0.23 – 0.43) 0.61 (0.46 – 0.76)
DAS28 0.09 (0.05 – 0.14) 0.14 (0.08 – 0.20) 0.27 (0.19 – 0.35) 0.55 (0.40 – 0.69)
DAS28 CRP 0.10 (0.06 – 0.15) 0.18 (0.12 – 0.24) 0.34 (0.24 – 0.43) 0.66 (0.49 – 0.82)
SDAI 0.09 (0.03 – 0.14) 0.15 (0.10 – 0.20) 0.32 (0.23 –0.41) 0.54 (0.40 – 0.68)
CDAI 0.09 (0.04 – 0.15) 0.15 (0.10 – 0.21) 0.34 (0.25 – 0.44) 0.50 (0.37 – 0.63)
DAS 0-1 0.10 (0.05 – 0.15) 0.19 (0.12 – 0.25) 0.31 (0.22 – 0.40) 0.66 (0.51 – 0.81)
DAS TJC53 0.10 (0.05 – 0.14) 0.17 (0.11 – 0.23) 0.29 (0.20 – 0.38) 0.46 (0.34 – 0.58)
DAS TJC44 0.09 (0.05 – 0.14) 0.18 (0.12 – 0.24) 0.31 (0.22 – 0.40) 0.47 (0.35 – 0.60)
Covariates appearing in the model are fixed at the following values: previous SHS 10.3; year 2.8; treatment group 1; anti-CCP positive; female 
gender. LDA: low disease activity; MDA: moderate disease activity; HDA: high disease activity; CI: confidence interval; DAS: disease activity score; 
CRP: C-reactive protein; DAS28: disease activity score in 28 joints; SDAI: simplified disease activity index; CDAI: clinical disease activity index; DAS 
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SDAI, CDAI and DAS28 than with other indices. Patients classified in the HDA according to 
DAS-TJC53 and DAS-TJC44 had a lower chance to progress ≥3 units than patients in HDA ac-
cording to other indices. The four versions of ACR/EULAR remission-criteria were comparably 
related to joint damage progression (table5). The probability of annual SHS progression ≥3.0 
for patients in remission was 9-12%, compared with 24-28% for patients not in remission. 
Probabilities for progression as well as absolute SHS progression values were comparable for 
all definitions. 
Comparable patterns were seen for annual SHS progression ≥1 and ≥5 units (supplementary 
table S5; published online only).  
DISCuSSION
We compared classification into remission, LDA, MDA and HDA or remission yes/no categories 
with nine composite disease activity scores and ACR/EULAR remission-criteria and assessed 
the relationship with functional ability and radiological damage progression. Although 
proportions of patients classified varied between some of the score cut offs and definitions, 
the associations of all composite scores and remission definitions  with HAQ and SHS show 
overall high accordance. All showed a good dose-response relationship of disease activity 
with HAQ and SHS progression.   
This analysis expands on earlier studies comparing composite indices. We compared com-
posite scores including 28 joint counts, and also the original DAS and several adjustments. 
Previous studies showed that DAS28 classifies more patients in remission23-26, while SDAI and 
CDAI are strict in classifying remission23;27, as reflected by lower remission percentages, which 
is in line with our results. In general, the studies that link composite scores to functional 
ability and radiological damage progression show that DAS28, SDAI and CDAI correlate com-
parably with HAQ and/or Larsen scores. They demonstrate that levels of disease activity of 
these indices discriminate between levels of functional state and radiological damage.9;10;17;28 
We showed that all nine composite indices show a comparable relationship with radiological 
joint damage or physical functioning. Omitting grading in tender joint counts and/or omit-
ting scoring tender joints in joint groups did not change this relationship. The same is true if 
acute phase reactants are left out (CDAI and clinical trial ACR/EULAR remission-criteria).
Which index should be preferred will depend on the reason for using the index and on per-
sonal preferences. In clinical practice composite scores without an acute phase reactant or a 
limited joint count can be used, whereas in a clinical trial setting a more elaborate composite 
score can be valuable. If treatment is aimed at remission, a stricter remission criterion carries 
a higher risk for overtreatment. However, a less strict definition may lead to residual disease 
activity and thereby undertreatment. SDAI, CDAI and ACR/EULAR remission-criteria classi-











































associated with lower HAQ scores and did not lead to clinically significant less joint damage 
progression. DAS28 and DAS28 CRP classified the highest proportion of patients in clinical 
remission without compromising on HAQ and joint damage progression. However, within 
these indexes patient’s feet are not examined which may not be appreciated. If LDA should 
be the target, DAS28 variants may be less useful, because DAS28 and DAS28 CRP classified 
fewer patients in LDA and remission together than other indices, without leading to better 
HAQ and progression percentages.  
Our results emphasize what was seen earlier: clinical remission does not necessarily coincide 
with radiological remission.29-31 The predicted probability for joint damage progression 
(≥3 unit) was 9-12% in anti-CCP positive patients. This suggests that there is (sub)clinical 
inflammation in patients with clinical remission, even with stricter definitions. An additional 
explanation might be that there is a delay between inflammation measured with clinical 
parameters and progression of joint damage visible on conventional X-rays. Part of the joint 
damage progression seen in patients in clinical remission might reflect disease activity that 
was present before onset of clinical remission.32 Our results emphasize that a comprehensive 
definition of disease remission needs to include a radiological outcome.  
Previous studies have showed that, early in the disease course, active inflammation (reflected 
in composite indices) is the main determinant of functional limitations, while in more es-
tablished disease,  joint damage becomes more important.1;33;34We analyzed the association 
between disease activity levels and HAQ in patients with limited joint damage during a 5 
year follow up period. In more advanced disease the dose response between disease activity 
levels and HAQ is probably less pronounced and/or HAQ values inpatients in remission might 
be higher.
There is a large body of evidence supporting the benefit of targeted treatment. Less is known 
on what the target should be.5;35 RCTs directly comparing LDA and remission as targets are 
lacking. In the BeSt study treatment was aimed at LDA. There is little difference between the 
mean HAQ in LDA (~0.60) and in remission (~0.50). However, progression rates in patients in 
LDA are considerably higher than those in patients in remission, suggesting that treatment 
should aim at remission. It is unknown what the gain would be on clinical and radiological 
outcomes while risking higher turnover in treatment options. 
When outcomes are dichotomized only part of the data is being used, in contrast to using 
data on a continuous scale. Joint damage progression (and to a lesser extend HAQ), does 
not follow a Gaussian distribution. Although the GEE method is relatively robust against 
violations of the normal distribution, it is impossible to disentangle the complete effect of 
the distribution on continuous outcomes and predicted means. This may explain part of 
the high predicted annual progression rate, which can also be explained by unfavorable 
characteristics like anti-CCP positivity and treatment group. With dichotomous outcomes, 
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The strengths of our study are that we compared the most widely used composite indices 
for rheumatoid arthritis and recently published ACR/EULAR remission-criteria with different 
joint counts, and related classification of these indices to HAQ and Sharp-van der Heijde 
progression in a large group of patients. Also, all indices/criteria were repeatedly measured 
over time, increasing the number of observations, and were incorporated in the GEE analyses. 
One limitation might be that ‘old’ ACR remission-criteria were not included in the analyses, as 
not all components of these criteria were gathered three-monthly. 
In conclusion, although there are differences in classification between the nine different 
disease activity composite indices and the ACR/EULAR remission definitions for RA, the as-
sociation with functional status and joint damage progression are highly comparable. The 
choice of composite index is dependent on its intended use.
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Is achieving remission associated with better health related 
quality of life than maintaining low disease activity in rheumatoid 
arthritis patients? 
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Objective To assess if achieving remission is associated with a better health related quality of 
life (HRQoL) than maintaining low disease activity (LDA). 
Methods Data were used of 508 patients with recent onset rheumatoid arthritis (RA) par-
ticipating in the BeSt study, whose treatment was steered at LDA (DAS≤2.4), to investigate 
the relationship between DAS and HRQoL. Two summary scales of the Short Form-36 were 
used: the Physical and Mental Component Scale (PCS, MCS). Three linear mixed models were 
specified with PCS/MCS as dependent variable and with disease activity category, change in 
DAS score or change in disease activity category as independent variables. Remission was 
defined as DAS<1.6, or, separately, according to the ACR/EULAR remission criteria.  
Results Patients in remission (DAS<1.6) compared to LDA had a significantly better PCS and 
MCS, with a difference of 4.0 and 1.0 points respectively (p<0.001). An increase of 1 point in 
DAS was associated with a decrease of 4.6 (95% CI 4.4;4.8) in PCS and a decrease of 1.6 (95% 
CI 1.3;1.9) in MCS. Achieving DAS-remission resulted in a 3.8 point gain in PCS compared to 
maintaining LDA, but no difference in MCS. Similar results were found for remission accord-
ing to the ACR/EULAR criteria. 
Conclusion Improvement of disease activity is associated with improvement of HRQoL, with 
also a clinically relevant improvement in PCS score for patients achieving remission when 
compared to maintaining LDA. Patients who move from LDA to remission gain 4 points in 
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INTRODuCTION 
Advances in treatment for RA patients have led to improved clinical and structural outcomes. 
Following recent recommendations, treatment should be started early and requires adjusting 
the medication until a target of remission or at least low disease activity (LDA) is achieved.1;2 
Achieving such a target is associated with better functional ability and less radiological dam-
age.3 
It remains unclear if it would be better to treat to the target of remission than of LDA as 
comparative studies are lacking. Also, the influence on Health Related Quality of Life (HRQoL), 
of achieving these different levels of disease activity is uncertain. As HRQoL reflects a more 
broad perspective of the influence of disease on daily life than most outcome measures, it 
may give more guidance on which disease activity level should be preferred. 
Therefore we investigated in a low disease activity targeted cohort including early RA pa-
tients whether 1) remission or achieving remission was associated with a better HRQoL than 
LDA or maintaining LDA and whether 2) a change in disease activity was associated with a 
relevant change in HRQoL.  
METHODS 
Patients
Five-year follow-up data from the BeSt trial were used, where 508 patients with recent onset 
active RA were dynamically treated according to a step-wise treatment protocol aiming at 
a disease activity score (DAS) ≤2.4. Patients were randomized to four different treatment 
strategies: 1. sequential monotherapy; 2. step-up combination therapy; 3. initial combination 
therapy with prednisolone and 4. initial combination therapy with infliximab. Clinical assess-
ment of disease activity was performed every three months, and included a joint count for 
tenderness and swelling, erythrocyte sedimentation rate (ESR) and patient’s assessment of 
global disease activity. This study was approved by the ethical committees of participating 
centers and all patients provided informed consent. More details about the BeSt study have 
been described elsewhere.4 
Outcome assessment
HRQoL was assessed with the Short Form 36 version 2 (SF-36),5 which covers eight domains 
of health status: physical functioning, role-physical, bodily pain, general health, vitality, social 
functioning, role-emotional, and mental health. The SF-36 score ranges from 0 (worst) to 100 
(best) and norm based scoring is available to compare different populations. Two summary 
measures, representing the physical component of HRQoL (physical component scale; PCS) 











































scales cover all HRQoL domains but more weight is given to physical functioning, role-
physical, bodily pain and general health in the PCS, whereas more weight is given to vitality, 
social functioning, role-emotional and mental health in the MCS. The SF-36 was filled out 
every 3 months in the first two years of treatment and yearly thereafter. A clinically important 
improvement from baseline for RA patients has previously been established as a minimum of 
2.5 to 5 points improvement for the two summery measures.6 
Statistical methods
Statistical analyses were performed with the software program SPSS version 20.0 (SPSS, Chi-
cago, Illinois). Linear mixed models (LMM) were used to investigate the association between 
disease activity (levels) and HRQoL over time, while correcting for within patient correlation. 
For all analyses the unstructured covariance matrix was used, which does not assume a 
specific covariance structure and estimates every variance and correlation.
Two continuous outcomes, both of which normally distributed, were used for all analyses: 
the PCS and the MCS.  Three models with these outcomes and the following independent 
variables were used: 1) disease activity category, 2) delta DAS (absolute), previous DAS and 
previous PCS or MCS score and 3) change in disease activity category (remission to LDA and 
vice versa) and previous PCS or MCS score. 
For the first and third model, patients were categorized according to their disease activ-
ity category: high disease activity, low disease activity (based on the DAS), or remission.7 
Remission was defined as DAS<1.6,8 or, in a separate analysis, according to the ACR/EULAR 
remission criteria.9 Patients were first divided into ACR/EULAR remission yes/no, and patients 
not in ACR/EULAR remission were then classified into low or high disease activity depending 
on their DAS. The ACR/EULAR remission criteria were not designed to compare against DAS 
categories, but as there is no alternative classification method that allows for comparison 
of ACR/EULAR remission against other levels of disease activity we used this approach. In 
model 3, all possible changes were included in the model. We first used staying in low disease 
activity as reference category and then staying in remission and will only report on changing 
from low disease activity to remission and vice versa. Time was added as categorical covari-
ate in all models in order to estimate the effect for each time point separately. The baseline 
visit was excluded because none of the patients were in remission at this visit. The following 
potential baseline confounders were considered: age, gender, HAQ, DAS, erosions (yes/no), 
anti-citrullinated protein antibodies, duration of complaints at inclusion, smoking, body 
mass index (BMI), alcohol intake and treatment group. None of the potential confounders 
importantly altered β-estimates or p-values when added to the model as separate variable, 
so these were not included in the final models. Values for mean HRQoL at each time point per 









































 Quality of life and DAS
9
RESuLTS
In total 508 patients with a mean (SD) DAS at baseline of 4.4 (0.9) were included. Mean PCS 
(SD) was 38.8 (7.9) and mean MCS at baseline was (47.0 (11.4). At year 5, DAS was reduced to a 
mean (SD) level of 1.7 (0.8) while PCS and MCS had improved to a mean (SD) level of 44.8 (9.8) 
and 52.4 (8.6) respectively. Over 5 years (excluding the baseline evaluation), DAS-remission 
was recorded in 34% of the evaluations, while ACR/EULAR remission was recorded in 15%.
(table 1) 
Absolute disease activity scores in relation to QoL scores
Remission (DAS<1.6) was associated with a clinically relevant higher PCS than higher levels 
of disease activity, with a dose response relationship. The difference in PCS when in remission 
with PCS when in LDA (ß) was 4.0, and the difference with HDA 8.8, all p<0.001.(table 2, figure 
1) Likewise, DAS categories with lower DAS were associated with higher MCS, although differ-
ences were smaller: LDA ß=1.0, HDA ß=3.1. Repeating the analyses with remission according 
to the ACR/EULAR remission criteria gave similar results.(table 2)





Remission 1667 (34%) 662 (15%)
Low disease activity 1704 (35%) 2384 (53%)
High disease activity 1570 (32%) 1453 (32%)
DAS disease activity score, n number, ACR American College of Rheumatology, EULAR European League Against Rheumatism ; *For 442 
visits, patients could not be classified because of missing values for C-reactive protein; Low disease activity: DAS ≤2.4, but not remission, High 
disease activity: DAS>2.4 
Table 2: Difference in absolute physical component scale score and mental component scale score for patients in low and high disease activity 










(defined according to ACR/
EULAR criteria)
LDA 4.0 (3.5;4.4) 4.1 (3.5;4.8) 1.0 (0.5;1.5) 0.9 (0.2;1.6)
HDA 8.8 (8.3;9.4) 9.7 (9.0;10.5) 3.1 (2.5;3.7) 3.1 (2.3;3.9)
PCS physical component scale score Short form 36 (SF36), MCS mental component scale score SF36, ref reference, DAS disease activity 
score, LDA low disease activity (DAS ≤2.4, but not remission), HDA high disease activity (DAS>2.4) ; Data are presented as ß estimates (95% 











































The univariable analysis showed that DAS category, gender, time, treatment group, alcohol 
intake, BMI and baseline DAS were also associated with outcome PCS, and DAS category, 
time, gender, baseline erosiveness (yes/no), baseline smoking status and baseline DAS were 
univariable predictors for MCS. Of the possible confounding variables none had a significant 
effect on the ß-estimates per disease activity category when added separately to the model, 
neither on the outcome PCS nor on MCS. 
Changes in disease activity scores in relation to changes in HRQoL scores 
Absolute changes in DAS scores were significantly associated with changes in both PCS and 
MCS. Patients showed an increase of 4.6 (95% CI 4.4;4.8) points in PCS when decreasing 1 
point in DAS, independent of their previous DAS score and previous PCS (p<0.001). Similar 
results are seen for the MCS, however this difference is smaller: 1.6 (95% CI 1.3;1.9) points 
(p<0.001) improvement in MCS per 1 point decrease in DAS. The interaction term between 
previous DAS and DAS change was not significant, implying that the relationship between 
change in DAS and change in PSC/MCS is independent of the preceding DAS level. 
Changes in DAS category in relation to change in PCS and MCS
For patients who had LDA, achieving remission was associated with a significant improvement 
in PCS of 3.8 points, when compared to patients who stayed in LDA, but no improvement in 
MCS.(table 3) Patients who had been in remission but flared to LDA showed a 4.0 point dete-
rioration in PCS when compared to patients who stayed in remission, and no change in MCS.
Table 3: Change in component score (physical component scale score and mental component scale score) when achieving remission from low 
disease activity, and loosing remission to low disease activity, with remission defined as *DAS<1.6 and **according to the ACR/EULAR remission 
criteria
PCS MCS
Staying in low disease 
activity
ref ref ref ref 
Achieving remission 
from low disease 
activity
3.8 (3.0;4.5)* 4.0 (3.1;4.9)** 0.5 (-0.3;1.3)* 1.0 (-0.01;2.0)**
Staying in remission ref ref ref ref
Loosing remission to 
low disease activity
-4.0 (-4.8;-3.2)* -4.0 (-5.1;-2.9)** -1.2 (-2.1;-0.3)* -0.7 (-1.9;0.5)**
PCS physical component scale score Short form 36 (SF36), MCS mental component scale score SF36, ref reference, DAS disease activity 
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DISCuSSION
In this disease activity targeted treated cohort, lower disease activity was associated with 
better health related quality of life (HRQoL), both in the physical and mental component 
scale, although differences in the latter were smaller. This association was independent of the 
previous disease activity level and related to the final level of disease activity. A change in 
disease activity resulted in a change in HRQoL. We found that a clinically significant improve-
ment of quality of life (in the physical component scale) was achieved when patients who 
were in a state of LDA went on to achieve remission. 
To date, remission is recommended to be the optimal treatment target in RA patients,2 but 
aiming for remission could increase the costs of treatment and the risk of side effects. In 
patients who have already achieved LDA, it is questionable if a further suppression of disease 
activity to a level of remission (whether based on a composite score threshold such as <1.6 in 
the disease activity score or based on the boolean ACR/EULAR remission criteria), also results 
in a further improvement in quality of life. This we have shown was indeed the case (and 
reversely, there was a deterioration in HRQoL if disease activity deteriorates from remission 
to LDA) in this LDA targeted cohort.
Previous studies have shown a cross-sectional correlation between active disease and 
impaired quality of life measured with generic HRQoL instruments,10;11 and a dose-response 
effect of the different disease activity categories.12;13 In longitudinal analyses over 2 years 
and over 10 years, it has already been suggested that an improvement in disease activity is 
associated with better HRQoL.14;15 This association over a long time span may be influenced 
by other factors such as damage progression. As disease activity may fluctuate over time, 
we focused in our longitudinal analysis on shorter time intervals, and within these shorter 
time interval we found that improving in DAS and more specifically achieving remission is 
associated with improved HRQoL. 
There are several limitations to our study. A DAS<1.6 may not denote true remission,3 and the 
distinction with LDA (DAS ≤2.4) is relatively arbitrary. We repeated the analysis using the ACR/
EULAR remission criteria, but here we were limited by the absence of associated ACR/EULAR 
low disease activity criteria. Instead, we again compared with ‘not in ACR/EULAR remission’ 
with established DAS categories for increased disease activity. Although according to the 
ACR/EULAR criteria, less patients were in remission than when using DAS remission, this did 
not result in a difference in the association between disease activity and HRQoL. 
Second, although the association between disease activity category and HRQoL was indepen-
dent of a number of patient characteristics, there might still have been residual confounding, 
for example caused by co-morbidity. Therefore, we cannot conclude that the achievement of 
remission causes patients to have better health related quality of life. There could be unmea-











































comparing a treatment strategy aiming at LDA with a strategy aimed at remission using the 
same therapies would help to answer this question.  
Although the change in MCS associated with achieving remission from LDA was statistically 
significant, it was not clinically significant. However, the mental component was also less 
impaired from the outset. The finding that disease activity shows a stronger relation with 
the physical than the mental component scale is in line with previous analyses from this 
study, where improvement of disease activity was associated with a smaller improvement 
of the MCS than the PCS,16 and data from other cohorts.17;18 This may be caused by the fact 
that in particular the mental component of HRQoL could be affected by other variables such 
as pain experience, psychological comorbidity, mental status, coping strategies and social 
networks. Also, MCS may depend more on stable patient traits such as optimism than on 
disease characteristics, and therefore show less variation.19-22
In conclusion, we have shown that a decrease in disease activity in patients with RA is associ-
ated with better HRQoL and that achieving remission after being in LDA is associated with 
achieving clinically significant improvement of HRQoL. This may suggest that remission is the 
preferred target of treatment and have implications for future (research on) goal setting in 
the treatment of RA.
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Objective Tight control in rheumatoid arthritis (RA) necessitates frequent disease monitor-
ing; patients might participate by self-assessment of their functional status. Therefore, we 
assessed the feasibility and acceptability of autonomous online registry of physical function-
ing.
Methods In two tertiary-care centers (in the Netherlands and France), consecutive RA 
patients were approached to perform autonomous registry of the Health Assessment Ques-
tionnaire (HAQ) in an electronic medical record. Feasibility and acceptability of autonomous 
HAQ registry was assessed through: (1) the percentage of acceptance; (2) the time needed to 
register the HAQ (the Netherlands); (3) patients’ satisfaction with autonomous registry, and 
(4) willingness for future home-based HAQ completion, either self-declared (the Netherlands) 
or actual file access from home within 6 months (France). 
Results In all, 214 patients were approached; 163 agreed to participate; 137 (64% of 214) 
had complete data which were analyzed. Median age was 56 years (range 20-78), 80% were 
female, median disease duration was 9 years. The median time needed to fill in the HAQ in the 
waiting room was 5.8 minutes; patient satisfaction was high (mean score 4.1 out of 5), self-
declared willingness of autonomous registry at home was 73%. In the six-month follow-up 
period, 46% patients accessed their medical file from home at least once. 
Conclusion Many RA patients reported willingness to self-monitor their disease online, but 
fewer than half of the patients actually did. To enhance patient autonomous monitoring, 
progress is needed in terms of internet access, continuous patient support, and importantly, 
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INTRODuCTION
In patients with rheumatoid arthritis (RA), regular assessment of disease activity is recom-
mended to evaluate the efficacy of treatment and steer treatment adjustments. 1 Although 
evidence suggests that a targeted treatment approach (‘tight control’) is superior to routine 
care2,3, its implementation in current daily practice is hampered and successful implementa-
tion strategies are lacking.4 Frequent disease monitoring necessary to perform tight control 
strategies may pose practical difficulties (i.e. lack of physician availability). One possible 
solution could be providing patients with access to electronic medical records (EMR) and 
obtaining autonomously registered data such as symptoms and functional ability. 
Electronic registration in online files by patients has several advantages: intermediates han-
dling data and processing are unnecessary, completeness of data can be improved and data 
are immediately available for all participating parties.5 Online disease monitoring by patients 
could stimulate physicians to integrate frequent disease monitoring and targeted treatment 
adjustments into daily routine using such data.6,7 
Many scores and questionnaires are available that could be object of autonomous electronic 
registration. The Health Assessment Questionnaire8 is one of the most validated question-
naires in RA and is as informative as joint counts, radiographic or laboratory data for assess-
ment of baseline status and change during interventions. 9The HAQ is also predictive of 
long-term outcomes such as mortality and future physical disability.10 
Before demonstrating that autonomous disease monitoring by patients is useful in terms of 
treatment decisions or outcomes, a first necessary step is assessment of the feasibility and ac-
ceptability of such autonomous assessment. In the present study, we assessed the feasibility 




A cross-sectional (the Netherlands) and longitudinal study design (France) was used to assess 
the feasibility of autonomous data registry, using a patient-accessible EMR enabling online 
data registry. The setting comprised of two tertiary-care university hospitals, LUMC hospital 
in Leiden, the Netherlands and Cochin hospital in Paris, France. 
A study nurse or trained student was available to include RA patients visiting the out patient 











































stand local language and willingness to fill in the EMR and evaluation form. The number of 
patients refusing to participate was recorded with reasons where possible, to assess both 
feasibility and acceptability. These study results were collected during routine evaluation of 
patient care and therefore ethical approval for this study was not required. 
Data collection
As part of daily practice, an electronic patient file registering demographic data was cre-
ated using the METEOR tool.11 This free-of-charge tool was designed by rheumatologists for 
online registration of patient- and physician-derived outcomes, including composite scores 
for disease activity, patient’s global assessment of disease activity or pain, and the HAQ8. 
Patients were provided with online access codes to gain access to their EMR in METEOR. All 
received a verbal instruction from study nurse or student about the system before accessing 
and registering their HAQ. Patients could access their file either at home, or in the waiting 
room before visiting the rheumatologist.
Outcome assessment
The outcome criteria were all related to feasibility and acceptability but varied between the 
two centers.
In the Netherlands (n=78), the assessment was performed in the waiting room before the 
visit to the rheumatologist with the help of a student (NAdG) if needed. Registered outcomes 
were: (a) the time needed for patients to fill in the HAQ and need for assistance, (b) patients’ 
satisfaction with autonomous registry (assessed on a 0-5 Likert-scale, higher scores indicate 
higher satisfaction), and (c) self-declared willingness for future online HAQ registration either 
home-based or in the waiting room (yes/no). 
In France (n=59) the outcome assessment was performed six months after the initial visit. 
At that time, each patient was contacted by the research nurse (ClB) and (d) self-declared 
autonomous access to the medical file from home within six months and (e) satisfaction with 
the online registry system (assessed on a 0-5 Likert scale) were collected as outcome criteria. 
Statistical analyses
Analyses were descriptive for demographic characteristics and feasibility of online registry. 
To search for factors explaining willingness to perform online home-based data registry, 
univariate logistic regression analyses using the SPSS program version 17.0 or Statistical 
Analysis System (SAS) version 9.4, were performed. Demographic variables (age, sex, disease 
duration) and educational level were analyzed to explain willingness to participate in future 
online home-based HAQ registration (the Netherlands) or self-declared autonomous access 













































Of 214 eligible RA patients, 163 (76%) agreed to participate. Frequently mentioned reasons 
for refusal were inexperience with computer and/or internet use, and lack of time. Only few 
patients stated they did not want to perform autonomous disease assessments at all. In total, 
137 patients (78 from the Netherlands in the cross sectional study, 59 from France in the 
follow-up study) completed the whole evaluation: 26 did not, either because they did not 
complete the evaluation (N=14, the Netherlands) or because they did not fill in the 6-month 
assessment (N=12, France) (see  supplementary figure S1; published online only). 
Patients had a median age of 56 (interquartile range, IQR 46-65) years and a long disease 
duration with a median of 8.6 (IQR 6.0-13.8) years. Most were female (80%)  and 51% had 
received higher education (Table 1). 
Feasibility and acceptability of online registry in the waiting room (the 
Netherlands, n=78)
Patients needed a median (IQR) of 5.8 (4.0-8.0) minutes to access METEOR and fill in the 
complete HAQ (outcome a). In total 58 patients (74%) needed at least some assistance dur-
ing the process, although patients perceived registration as easy (mean 4.6 out of 5; SD 1.0; 
range 1-5). Patients were very satisfied (outcome b) (mean 4.1 out of 5; SD 1.1; range 1-5) with 
autonomous registration of the HAQ in the waiting room (Table 2). 
The vast majority of patients reported willingness to fill in the HAQ online on a future oc-
casion, more frequently in the waiting room (96%) than at home (73%) (outcome c). Eighty-
three percent said they would come to the hospital earlier, with the largest percentage (72%) 
agreeing maximum of 20 minutes. 
Table 1 Baseline characteristics of patients accepting to perform autonomous online registration of HAQ in two tertiary-care hospitals. 
All France Netherlands
Number of patients 137 59 78
Age, median (IQR), years  56 (46-65) 55 (43-61) 59 (47-67)
Female gender, n (%) 109 (80%) 48 (81%) 61 (78%)
Duration of RA, median (IQR), years 8.6 (6.0-13.8) 8.1 (6.5-13.7) 9.5 (5.8-15.0)
Educational level, n (%)
     Lower 15 (11%) 5 (9%) 10 (13%)
     Medium 51 (38%) 18 (31%) 33 (43%)
     Higher 69 (51%) 36 (61%) 33 (43%)











































Willingness to use home-based autonomous registry in the LUMC was associated with 
younger age (Odds ratio (OR) 0.8 95% CI 0.7-0.9) and higher educational level (OR 4.0 per level 
increase 95% CI 1.7-9.3) and not associated with gender, RA duration or patient satisfaction. 
Feasibility and acceptability of home-based online registry in 6 months follow-up 
period (France, n=59)
In the six months follow-up period in the French study, 27 (46%) patients reported having 
accessed their online file from home at least once (outcome d). The median score for patient 
satisfaction was 3.0 (out of 5; range 1.0-5.0), and only 19% of patients reported high satisfac-
tion with autonomous online registration of data in METEOR (outcome e; Table 2). 
File access during 6 months follow-up was associated with higher satisfaction with online 
registry (OR 2.8, 95% CI 1.6-4.9) and longer disease duration (OR 3.4, 95% CI 1.1-10.1) and not 
associated with age, gender or educational level. 
When the patients were asked informally by the study nurse why they did not access their file, 
they reported access to internet, but also perceived usefulness of the data collection, e.g. not 
seeing the physician using their data was not encouraging. 
DISCuSSION
These data show that although many RA patients were willing to use an online EMR, either 
home-based or at the outpatient clinic, less than half of those who did get access used the 
EMR in the next 6 months. These results are disappointing, since many studies show that self 
management can lead to sustainable health benefits.12,13,14 







1. Did you appreciate filling in the HAQ on the computer in this way? (not 
at all-very much) 
In the waiting room - Netherlands 6.5% 23.4% 70.1%
From home- France 47.5% 33.9% 18.6%
2. Netherlands only
What was your opinion about filling in the HAQ in the computer program? (very 
difficult-very easy)
6.4% 3.9% 89.7%
Would you be capable to fill in the questionnaire with the program independently 
the next time? 
(definitely not-definitely yes)
10.3% 11.5% 78.2%
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Self-assessment is increasingly introduced in the rheumatologic field and can be combined 
with electronic registration to use advantages of both. Previous studies have shown that 
(online) computer systems are a good option for regularly capturing clinical data15,16,17 and 
patient’s attitudes towards these EMRs appeared positive.18 Involvement and knowledge may 
then empower patients by establishing a decision-making process on equal level between 
rheumatologist and patients and start up the dialogue about implementation of tight control 
strategies.19 This might also help to motivate patients to comply with proposed therapeutic 
interventions. As monthly monitoring has been shown to be superior to a less frequent moni-
toring schedule2, self-assessment can assist in preserving resources for face-to-face contacts. 
This study shows the gap between theory and practice. Although in theory, autonomous data 
registry in EMRs is highly desirable, in practice in the present study willingness was limited.   
This study highlights some of the limitations which impede autonomous data registration 
and should be taken into account when developing EMRs or implementation strategies.20 
A first limitation is related to online access. To optimize patient involvement and online moni-
toring of disease-related data such as the HAQ, internet access and computer facilities for 
home access are the first necessities. The most common reason not to participate was lack of 
computer/internet experience and/or facilities. Access to internet is available for 69% of the 
French population and for 87% of the Dutch population, compared to 68% in the European 
Union and 77% in the United States (internet world stats). On the other hand, registry in the 
out patient clinic itself does overcome problems in facilities and has the advantage of im-
mediate availability and more awareness, creating enhanced collaboration between patient 
and health care provider.  
A second limitation relates to EMR software, which needs to be easy to use. Having been 
instructed and assisted during their first use of METEOR, most patients were confident that 
they could fill in the HAQ autonomously in subsequent visits. Data security may be of concern 
to patients, especially in online systems, but very few patients actually indicated this as a 
reason not to participate. METEOR is password protected and patientidentifying informa-
tion is encrypted and complies with data protection legislation. A third important limitation 
which may hamper autonomous registry relates to patients, and physicians. Patients have 
to feel that autonomous HAQ registration is beneficial to them and need to get feedback on 
their efforts. This concept is related to shared decision-making and will need adaptation from 
both patient and physician. Also, if patients fill in the HAQ autonomously this might allow 
more time during the outpatient visit to discuss other issues with the rheumatologist.
A fourth limitation is the choice of which data are registered autonomously. In current clinical 
practice, it appears the HAQ is not widely used21, even though it has been demonstrated to 
be a useful score9, and monitoring physical ability is advised by current guidelines.1 Patients 











































from their rheumatologists on their status. This will create a feeling of personal benefit for 
patients.20 Each of these aspects should be addressed, when implementing patient autono-
mous data registry. 
There are several limitations to this study. First, although issued from out patient clinics 
without selection, patients may not be representative of all patients in a rheumatologic 
clinic. Only approximately three-quarters of all patients participated, and comparative de-
mographic data for patients refusing participation are unavailable. Selection bias is possible, 
since patients unlikely to use the online HAQ tool probably declined to participate. The high 
educational level in this sample could indicate that these patients are more eager to take part 
in disease assessment. 
Furthermore, self-reported willingness may have been positively influenced because of so-
cially desirable behavior. Although reported willingness in advance was high, self-reported 
home-based autonomous assessment in METEOR during six months of follow-up was sub-
stantially lower. It may also indicate that patients prefer registration on site rather than at 
home, which might explain the discordance in satisfaction between the two centers. A final 
limitation may be that extensive support by health care providers was available in this study, 
but may not be in other centers. However, these limitations only strengthen the conclusions 
of our study, since we can consider that the conditions in the present study were favorable 
for patients to perform autonomous registry. 
In conclusion, the present study indicates that a majority of patients are willing to self-assess 
their disease status by registering a HAQ in an online medical file, but fewer than half of 
the patients actually did so from home within 6 months. This is a potentially feasible way to 
involve patients and to obtain regular disease assessments in the era of tight control, but 
patients need to experience more personal benefit. If this is achieved, online HAQ registra-
tion could lead to improved disease monitoring, quicker treatment decisions and ultimately 
better outcomes.
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In the treatment of rheumatoid and undifferentiated arthritis major advances have been 
made in the last decades, due to improved earlier treatment as well as reliable estimation 
of disease activity by means of composite scores and intensified monitoring strategies 
(tight control), specifically aimed at pre-defined goals in outcome (treat to target).1-3 Recent 
guidelines underscore the importance of goal setting and targeted treatment, which can be 
applied in practice by setting remission as preferred target and adjusting the medication 
until this target is achieved.4-6 To complement composite scores measuring disease activity, 
radiological evaluation of damage to joints, and questionnaires such as the Health Assess-
ment Questionnaire (HAQ) for functional ability and the Short Form 36 (SF-36) for quality of 
life are frequently introduced to assess the efficacy of therapeutic interventions.4;5;7 
However, as outcomes of disease are improving with earlier treatment, questions regarding 
the usefulness of these traditional outcome measures arise. This thesis focuses on the follow-
ing questions: What should be monitored in patients with undifferentiated or rheumatoid 
arthritis? Which imaging modalities should be used and which characteristics or abnormali-
ties should be looked out for? How can the treating physician evaluate disease activity and 
what is the role of the patient in the monitoring process? What level of disease activity has 
to be set as a treatment goal? And last but not least: how can measurement strategies be 
implemented in daily clinical practice?   
IMAGING IN uNDIFFERENTIATED ARTHRITIS
The value of measuring structural damage and the optimal method of assessment in rheuma-
toid arthritis (RA) patients have become matters of debate, as in our current era with targeted 
treatment strategies the amount of  joint damage as seen on conventional radiographs has 
become very little. It has been shown that a one point increase in the Sharp-van der Heijde 
score (SHS) (which includes joint space narrowing (JSN) and joint erosions on radiographs of 
both hands and feet), corresponds with a 0.01 point deterioration in the HAQ score 8, where 
a change in HAQ of around 0.20 is clinically relevant. As in recent disease activity steered 
studies we have observed that in most patients during a 1-2 year  follow-up period median 
levels of SHS progression scores remain below five points, 1-3;9 radiological outcome will affect 
functional ability only after years. Still, some patients do show rapid radiological damage pro-
gression, even after early aggressive treatment and a DAS steered regime.8;9 If these patients 
could be identified before damage progression occurs, possibly using sensitive imaging 
techniques at presentation, effective treatment could be administered to prevent irreversible 
damage. It has also been suggested that more sensitive tools than conventional radiographs 











































risk of deterioration to chronic and damaging disease. More sensitive imaging options may 
be magnetic resonance imaging (MRI) and ultrasound (US) investigation.
In Chapters 2 and 3 we have assessed the diagnostic and prognostic value of three imaging 
techniques in undifferentiated peripheral arthritis: conventional radiographs, MRI and US. 
Our literature review concerning conventional radiographs (Chapter 2) revealed that the 
presence of erosions is predictive of a future diagnosis of RA or a poor prognosis of UA. Stud-
ies concerning solely UA populations were scarce, as most studies also included patients with 
arthritis who fulfilled the 1987 classification criteria for RA, reflecting a chronic disease state. 
Furthermore, since the presence of erosions on conventional radiographs is one of the seven 
classification criteria (where four are required to classify as RA), the performance of our test is 
overestimated. On the other hand, no widely accepted validated alternative for establishing 
a diagnosis of RA was present. No studies were available that showed other radiographic 
features than erosions to be predictive of a diagnosis of RA or poor prognosis in UA. Also, no 
evidence was found on the preferred frequency of radiographic assessment. The preferred 
areas to radiograph were the hands, but if the feet were also radiographed, this provided 
additional value. 
Few studies were found on the value of MRI and US in UA. Most studies were performed in 
a population including both UA and RA (Chapter 3). MRI features that have shown of value 
in UA patients for predicting a diagnosis of RA, are bone edema, MRI synovitis and erosion 
patterns in the hands. For US, only in studies with both UA and RA patients, we found that 
ultrasound power Doppler signals and gray scale ultrasonography may be of value in predict-
ing disease flare or persistence of arthritis. For neither imaging modality data was available 
on preferred frequency of follow-up imaging.  
More recent literature (published after our review) on MRI and US has shown that including 
presence of MRI bone edema in a model aiming at prediction of progression to classifiable 
RA in UA patients has added value 10, but more extensive validation is necessary.11 A recent 
initiative formulated recommendations regarding the use of imaging in RA patients based 
on the combination of systematic literature reviews and expert opinion and advised con-
ventional radiographs of hands and feet as initial imaging technique for the assessment of 
joint damage. However, MRI and/or US may be used for prediction of a future diagnosis of 
RA in UA patients and patients with diagnostic uncertainty, or as assessment of (subclinical) 
inflammation in patients who are in clinical remission. It has also been suggested that these 
enhanced techniques may be of value in disease activity monitoring, predicting therapy 
response and establishing prognosis.12 There are however, no long term follow-up studies 
yet that can match early abnormalities on MRI and/or US with later relevant and irreversible 
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The results of the systematic literature reviews on imaging were integrated with the results 
of the other reviews on the remaining clinical questions and combined with clinical expertise 
of an international panel of rheumatologists in order to formulate recommendations on how 
to investigate and follow-up UA patients. (Chapter 4) 
Features and sites of joint damage on radiographs in relation to physical 
functioning
The relationship between joint damage and physical functioning has been extensively de-
scribed in the literature.13-15 Recently, it has been suggested that JSN may impose a larger 
effect on physical decline than joint erosions 16, although some questions regarding this 
relationship remain.17 Moreover, unknown to date was whether damage in specific joints, 
which are included in our current scoring method, is more prominently related to functional 
impairments. In Chapter 5 we have shown that separate JSN and erosion scores in our cohort 
of patients with recent onset RA treated in a tight controlled setting, were not related to 
functional disability measured by the HAQ. However, when considering joint groups (e.g. 
feet, wrists, metacarpophalangeal joints and proximal interphalangeal joints), we found that 
joint damage in the wrist, and more specifically erosive damage, was independently preditive 
of a worse HAQ score. 
This implies that damage especially in the wrist has a major impact on patient’s physical func-
tioning. This finding also raises the question whether site-specific treatment (for example 
corticosteroid injections) may be able to locally prevent joint damage and thus improve daily 
physical functioning. Additional research is needed to further assess the association of dam-
age in specific joint areas on MRI and US with  functional decline.   
Disease activity in Rheumatoid Arthritis
One of the composite scores most often used to measure disease activity, the disease activity 
score (DAS), combines clinical and laboratory results as indicators of disease activity in one 
continuous score to yield a more complete estimate of active disease.18;19 The original DAS has 
been adjusted several times, diminishing the number of counted joints or the time needed 
for calculation.20-22 Although widely used in clinical trials, the DAS is not systematically used 
in clinical practice world-wide.23 Implementation may be stimulated by simpler and faster 
ways of DAS measurement or calculation. In Chapter 6 we have assessed three variations 
of the DAS in which the tender joint count component is differently registered, but keeping 
both hands and feet included. These variations have the advantage of easier scoring and 
calculation, without the exclusion of the feet (as seen for example in the DAS28), which are 
frequently involved in RA.19 Instead of the graded Ritchie Articular Index (RAI) 24, we used a 











































joints (DAS TJC53) and a tender joint count in 44 separate joints (DAS TJC44) to calculate the 
DAS. 
Overall, we have demonstrated that these three versions of the DAS show a high correlation 
with the original DAS and classify the different disease activity levels similarly (convergent 
validity). A similar degree of radiological progression across categories of all DAS versions 
was observed, demonstrating construct validity, and with all DAS versions differences in 
disease activity between the treatment arms in our study could be found after three months 
follow-up (discriminate validity). However, scores with the adjusted versions DAS-TJC53 and 
DAS-TJC44 were higher, leading to shifts in classification mostly from the low and moderate 
disease activity category into the higher categories, but not importantly affecting the clas-
sification into the remission category. As the overall validity of the DAS versions appeared 
comparable, which DAS variation is preferred may therefore depend on more practical argu-
ments. Since the RAI remains difficult to calculate, physicians and other health care providers 
may want to choose a composite score with a reduced non-graded joint count including the 
feet, such as the DAS TJC44.
We also compared the use of two patient derived visual analogue scales (VAS) within the 
DAS: the VAS for patient’s global assessment of disease activity (VAS-PGA) and the VAS for 
general health (VAS-GH) (Chapter 6). Both are used in daily practice, although the DAS vali-
dation was based on the latter.18 We found that within the composite score DAS these can be 
used interchangeably, without importantly affecting the score of the DAS. Yet, differences 
between VAS-PGA and VAS-GH are considerable, and their correlation with each other is low. 
Possibly, the concepts that these two scores cover differ in the minds of patients scoring the 
questions, which may also be related to the phrasing of the questions. While global disease 
activity may be perceived as primarily as reflecting arthritis activity, general health may be 
experienced as a broader concept,maybe influenced by co-morbidity as well. Within the DAS 
limited weight is given to these components and therefore the use of both VAS scores in 
practice is possible. Yet, as these VAS scores may be used as individual scores as well, atten-
tion should be given to the observed difference. Moreover, when VAS-PGA and VAS-GH are 
used solitary this decreases face validity as compared to using a composite measure with the 
inclusion of a laboratory measure or a physician derived judgement.25   
In Chapter 7 we compared a VAS score for assessment of global disease activity derived from 
patients (PtGDA) with the same VAS score derived from physicians (PhGDA), based on data 
from the METEOR database.26 We found that patients consistently score their disease activity 
higher than physicians, on average 11 points (on a scale of 100), confirming results of previ-
ous studies.27-29 The higher rating of patients compared to physicians was associated with 
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to higher ESR and/or higher swollen joint counts. A possible explanation is that patients in 
their judgment attribute more influence on their perceived discomfort, whereas physicians 
tend to be driven by more objective variables. This would align with the observation that 
patients and physicians differ in their disease perspectives on active disease.30 As a patient 
VAS is part of the new ACR/EULAR remission criteria31;32, patients with a high VAS and no 
other signs of active disease may be classified as not in remission, consequently triggering 
treatment adjustments (when targeting at remission), that aim at reducing inflammation that 
is not present.32 However, this also indicates that for some patients remission according to 
the physician based on joint counts and laboratory measures, is not perceived as complete 
disease control. 
Using various definitions, drug free remission as ultimate treatment goal, can be achieved 
in 9-25% of all RA patients, as demonstrated in several recent clinical trials.33 However, the 
optimal way to define remission (either drug free or not) is still a matter of debate. Several 
composite measures, such as DAS, DAS28, SDAI and CDAI have specific cutoff values to define 
remission.34-36 In Chapter 8 we investigated the relationship of nine composite indices plus 
the newest ACR/EULAR remission criteria31;32 with physical functioning and radiological dam-
age to gain further insight into their differences in definition of remission. We have shown 
that SDAI, CDAI and ACR/EULAR definitions are more stringent in defining remission than the 
other composite measures, as fewer patients were able to reach that state. However, these 
more stringent definitions were not associated with clinically relevant better HAQ scores or 
lower SHS scores. To define remission more stringently seems therefore clinically not very rel-
evant with regard to joint damage progression and physical functioning. Whether (steering 
towards) stricter remission definitions lead to better outcomes on the long term, or higher 
quality of life, better symptom control and less flares remains to be determined. 
In addition, some definitions have been shown to allow more residual disease activity than 
others37-39 and defining remission using less strict definitions could thus give a false sense 
of security, as (subclinical) disease activity can remain. That radiological progression is not 
necessarily haltered during clinical remission is demonstrated in our study by the prediction 
of radiological damage progression for some of the patients in remission. Future research 
should give direction on how to identify the patients with continued damage progression 
despite appearing in clinical remission, so that we will be able to treat them appropriately 
thereby preventing both over and under treatment. We believe that all remission definitions 
that were evaluated showed good construct validity and that the choice of the preferred 











































Quality of life and disease activity
Health Related Quality of Life (HRQoL) is among one of the most broad outcome measures 
reflecting a wide range of variables determining general well-being in the presence of dis-
ease.40 Different measures for HRQoL exist, both general and disease specific instruments.41 
In the BeSt study, HRQoL was measured three-monthly (in the first two years of the study) 
using the Short Form 3642, a generic measure consisting of the following eight factors: 
physical functioning, role-physical, bodily pain, general health, vitality, social functioning, 
role-emotional, and mental health. We investigated the relationship of two summary scale 
measures, the Physical Component Scale (PCS) and the Mental Component Scale (MCS) (both 
using all factors, yet with different weights) with the DAS. (Chapter 9)
We found that a lower DAS was related with a clinically significantly higher and thus better 
HRQoL for both the PCS and MCS, although in the MCS the difference was less than the previ-
ously established clinically important level of improvement (e.g. >2.5 points).43 A decrease in 
DAS was related to an improvement in HRQoL and more specifically, a lowering of disease 
activity to the level of remission was associated with a clinically relevant better PCS, indepen-
dent of the previous level of DAS. This relationship was not found for the MCS, which may be 
explained by the MCS depending on other factors such as pain experience, comorbidity and 
coping strategies as oppose to the PCS.44-46 
The PCS results may suggest that a goal as strict as remission is to be preferred over one of 
low disease activity, since this would result in better quality of life for patients. As our analysis 
was based on a LDA steered cohort, future research should focus on the comparison of steer-
ing treatment at remission and LDA and compare the achieved level of HRQoL between these 
groups for definite conclusions on the preferred treatment goal.   
Disease monitoring in daily practice
Patients have demonstrated a positive attitude towards electronic health records and such 
records could perfectly be used for regular monitoring of disease, either by the patient him-
self or by health care providers.47-49 In Chapter 10 we have assessed the feasibility of online 
HAQ registry by patients, either from their homes or at the outpatient clinic. We learned 
that, although at the outpatient clinic the majority of patients indicated to find registry easy 
and valuable, in a follow-up setting for registry at home only a minority indeed declared to 
have registered the HAQ. This questions the feasibility of uncontrolled registry at home. An 
explanation may be that patients have given socially desirable answers, not matching their 
actual actions. Another possibility is that initially patients may have had the intention to fill in 
the questionnaire, but in the end refrain from using the system, as they do not perceive direct 
benefits from registration. Without feedback on their efforts and knowledge about benefits 
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GENERAL CONCLuSIONS AND FuTuRE PERSPECTIVES
This thesis focused on disease monitoring in both RA and UA patients with respect to value 
of imaging, the assessment of disease activity, the preferred treatment target and the imple-
mentation in daily practice. 
Which imaging modalities should be used in patients with arthritis and which 
characteristics should be looked out for? 
Structural damage assessment in patients with rheumatoid or undifferentiated arthritis can 
be performed with conventional radiographs, MRI or US. Conventional radiographs of hands, 
wrists and feet are valuable in early undifferentiated disease to predict future diagnosis and 
prognosis, but for MRI and US little evidence was available on their value. However, recent 
studies have implied that these techniques may be able to establish active disease in UA 
patients.50;51 As more treatment advances are made and radiological damage may further 
diminish, these techniques might in time replace the traditional radiographs, especially to 
establish subclinical disease activity (e.g. in patients in remission) and possibly continued 
joint damage progression.12  
It needs to be further investigated how abnormalities on MRI and/or US relate to limitations 
in physical functioning and especially HRQoL, which directly represents the patient’s well-
being. Also, it is not sure to date if these abnormalities, for example in patients in clinical 
remission, are treatable, and what the magnitude of the possibly improved outcomes would 
be. 
Radiographs may still be used to evaluate structural abnormalities related to previous periods 
of active disease.52 In RA patients extra attention may be given to radiographic damage in the 
wrists, given the high impact of localized damage in this area on physical functioning. Future 
research should establish if local intra-articular therapy can prevent or halt local damage 
progression and stabilize or improve functional ability. If localized damage on alternative 
techniques such as MRI or US also highly impacts on physical functioning remains to be 
determined. 
How can the treating physician evaluate disease activity and what is the role of 
the patient in the monitoring process? 
When treating patients with arthritis, specifically rheumatoid arthritis but possibly other 
forms of chronic arthritis as well such as undifferentiated arthritis, disease activity assess-
ment with a composite score including the feet should be regularly performed to steer 
treatment decisions. Inclusion of the feet is essential, as RA frequently affects the feet and 











































ity.37 These measurements can be performed by physician using several composite scores, of 
which some are more practical than others, but all relate to physical functioning and struc-
tural damage similarly. Another option is the assessment of active disease by patients. Yet, 
we have seen that physicians and patients do not score active disease similarly and factors 
which are predicting their score differ. Within composite scores, the inclusion of “objective” 
measures such as laboratory measures and signs on physical examination filters out these 
differences between patients and physicians, although the question remains if disease ac-
tivity measured based on laboratory results and physician derived judgment captures the 
complete construct of active disease. Factors such as pain relief, fatigue or coping strategies 
should also be carefully monitored and addressed in order to accomplish primarily a more in 
depth understanding and secondly an improvement of the actively experienced disease by 
these patients.3334  
What level of disease activity should be the goal of our treatment?
The preferred treatment target still remains a matter of debate. According to treat to target 
recommendations, the primary goal of treating the patient with rheumatoid arthritis is “to 
maximise long-term health-related quality of life through control of symptoms, prevention 
of structural damage, normalisation of function and social participation” while “abrogation of 
inflammation is the most important way to achieve this goal.”4 We have seen that achieving 
a goal as strict as remission leads to improved outcomes in terms of radiological damage, 
physical functioning, and most importantly HRQoL. Yet, the differences with a low disease 
activity state are small and not always clinically relevant. On the other hand, as continued 
structural damage progression is possible even in patients in clinical remission53;54, we believe 
that the lowest possible disease activity state should be reached. Remission can be defined 
with a composite score such as the DAS, which does include the feet, in contrast to the new 
ACR/EULAR remission criteria. Another advantage over the Boolean version of the ACR/
EULAR remission criteria is that composite measures do not solely allow single variables to 
determine whether a patient is in remission or not, which can be problematic such as with 
the patient derived VAS score. Future research should directly compare treatment strategies 
steering at remission and LDA and focus on HRQoL as an outcome.  
How can measurement strategies be implemented in current daily practice?
Although many of our resources are used for research on new treatment (strategies) of RA 
patients and on the development of such strategies, relatively little attention is given to their 
implementation in practice. Research regarding successful implementation is scarce and few 
implementation strategies have been shown valuable.23;55 Yet, there is an increased pressure 
for registry of disease status, also from insurance companies requiring objective arguments 
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cific diseases including RA are now steering and forcing certain changes in the organisation 
of our health care.4;6
Patient engagement in this changing healthcare system is becoming more and more impor-
tant. Patients need to be part of it and be educated about their role in this process. They need 
to be aware of the importance of regular disease assessment for their disease outcome and 
how they can participate in this assessment. ICT solutions, such as electronic patient files, 
may support their involvement in this disease monitoring process. Furthermore, patients 
need to receive feedback from their health care providers on their efforts in monitoring, their 
outcomes and the consequences of these results for the management of their disease, pos-
sibly including treatment alterations.
In conclusion, to improve management and outcomes of patients with undifferentiated and 
rheumatoid arthritis, physicians should regularly assess disease activity using composite 
measures and strive for remission by appropriate treatment adjustments according to the 
treat to target paradigm. Patients have to be actively engaged in the management of their 
disease by regularly assessing their daily physical functioning and HRQoL. Treatment can be 
aimed at the lowest possible state of disease activity, without symptoms, physical limita-
tions and with a good HRQoL. Additional future research should principally aim at directly 
comparing treatment strategies with different treatment goals with the inclusion of newer 
imaging techniques to identify subtle signs of disease activity and/or damage, and secondly 
at their implementation. Successful implementation of the best strategies and measuring 
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In de behandeling van ongedifferentieerde (UA) en reumatoïde artritis (RA) is in de afgelopen 
decennia veel vooruitgang geboekt. Met name de mogelijkheid tot vroege behandeling met 
DMARDS (“disease modifying anti rheumatic drugs”) gecombineerd met een betrouwbare 
schatting van de ziekteactiviteit door middel van samengestelde scores (de zogenaamde 
‘composite scores’) en intensievere controle strategieën (“tight control”), specifiek gericht op 
pre- gedefinieerde doelen in uitkomsten (“targetted treatment”) hebben bijgedragen aan 
een enorme verbetering in prognose van RA patiënten. Recente richtlijnen onderstrepen 
ook het belang van het stellen van een behandeldoel met frequente evaluaties, hetgeen 
in de praktijk uitgevoerd kan worden door frequente metingen van ziekteactiviteit en zo 
nodig therapieaanpassingen tot het behandeldoel is bereikt. Naast het meten van de 
ziekteactiviteit kan  radiologische schade aan gewrichten middels Röntgen- foto’s in kaart 
worden gebracht en kunnen vragenlijsten worden afgenomen zoals de Health Assessment 
Questionnaire (HAQ) voor het inschatten van dagelijks functioneren en de Short Form 36 
(SF-36) om de kwaliteit van leven te meten. Al deze maten kunnen worden meegenomen bij 
het beoordelen van de effectiviteit van therapeutische interventies.
Met de op dit moment betere resultaten van behandeling is het de vraag of deze traditionele 
meetinstrumenten op dit moment nog wel voldoen. Dit proefschrift richt zich daarom op 
de volgende vragen: Wat moet worden gecontroleerd bij patiënten met UA of RA? Welke 
beeldvormende technieken kunnen worden gebruikt en welke kenmerken op deze beeld-
vormende technieken moeten worden geëvalueerd? Hoe kan de behandelend arts ziekteac-
tiviteit evalueren  en wat is de rol van de patiënt hierin? Welk niveau van ziekteactiviteit kan 
als streefdoel van de behandeling worden ingesteld? En last but not least: hoe kunnen onze 
meetstrategieën in de dagelijkse klinische praktijk worden geïmplementeerd? 
Beeldvormende technieken in ongedifferentieerde artritis
De waarde van het meten van structurele gewrichtsschade in RA patiënten en de optimale 
evaluatiemethode van deze schade staat ter discussie. Met de huidige  behandelingsstrat-
egieën is de hoeveelheid gewrichtsschade op Röntgenfoto’s drastisch afgenomen tot 
op het niveau dat pas na jaren actieve ziekte de mate van progressie van Röntgenschade 
daadwerkelijk het functioneren zal beïnvloeden. Echter, bij een klein deel van de patiënten 
is er wél sprake van snelle radiologische schade progressie, zelfs met vroege ziekteactiviteit 
gestuurde en intensieve behandeling. Als deze patiënten zouden kunnen worden geïdenti-
ficeerd voordat deze schade optreedt, eventueel met behulp van gevoeligere beeldvormende 
technieken, kan een effectieve behandeling op tijd worden toegediend om onomkeerbare 
schade te voorkomen. Er is gesuggereerd dat gevoeligere technieken dan de conventionele 
röntgenfoto (zoals echografie en magnetic resonance imaging (MRI)) daarvoor in aanmerk-











































is van een ongedifferentieerde artritis die UA patiënten te identificeren met kans op een 
progressief en persisterend ziekte beloop. 
In de hoofdstukken 2 en 3 hebben we door middel van literatuur onderzoek de diagnost-
ische en prognostische waarde van drie beeldvormende technieken geëvalueerd in ongedif-
ferentieerde artritis: MRI, echografie en conventionele Röntgenfoto’s. Het blijkt dat erosies 
op Röntgenfoto’s van UA patiënten voorspellend zijn voor een toekomstige diagnose van RA, 
en tevens voorspellend voor een slechter beloop van de ziekte. Het aantal verrichte studies 
specifiek in deze UA populatie was beperkt, de meeste studies waren verricht in een groep 
patiënten waarvan een deel vroege RA patiënten was, die al aan de 1987 RA classificatie 
criteria voldeden. Aangezien de aanwezigheid van erosies op conventionele röntgenfoto ook 
onderdeel is van deze classificatie criteria, wordt op die manier de waarde van deze ‘test’ 
overschat. Echter, er bestaat geen algemeen aanvaarde andere gevalideerde definitie van RA. 
Er werden geen studies gevonden over de waarde van andere karakteristieken die zichtbaar 
kunnen zijn op Röntgenfoto’s. Data over gewenste follow-up frequentie van het nemen van 
Röntgenfoto’s werd niet gevonden. Om afwijkingen in kaart te brengen is het nuttig de 
handen te fotograferen, maar de evaluatie van ook de voeten gaf additionele informatie. 
Er werden maar weinig studies gevonden over de waarde van MRI en echografie in UA 
patiënten. De meeste studies werden uitgevoerd in een gemengde populatie van zowel UA en 
RA patiënten.(hoofdstuk 3). Beenmergoedeem, synovitis en het erosiepatroon op MRI heb-
ben prognostische waarde in UA patiënten om een toekomstige RA diagnose te voorspellen. 
Doppler signalen en ‘gray scale synovitis’ zichtbaar met echografie, kunnen van waarde zijn 
bij het voorspellen van opvlamming van de ziekte of het persisteren van de artritis. Ook voor 
echografie was niet duidelijk geen wat de gewenste follow-up frequentie zou moeten zijn. 
Recentere literatuur (gepubliceerd na onze review) laat zien dat het meenemen van de 
aanwezigheid van beenmergoedeem op MRI, binnen een model om een toekomstige RA 
diagnose te voorspellen in UA patiënten, toegevoegde waarde heeft 10, maar dit dient verder 
te worden gevalideerd. De geformuleerde aanbevelingen van een recent initiatief aanbev-
elingen met betrekking tot het gebruik van beeldvorming bij RA patiënten adviseren  als 
eerste conventionele röntgenfoto’s van handen en voeten te maken voor  de beoordeling 
van gewrichtsschade. Echter, MRI en/of echografie kan worden gebruikt voor het voorspellen 
van een toekomstige diagnose van RA in UA patiënten en bij patiënten met onduidelijkheid 
over de diagnose of bij de evaluatie van (subklinische) inflammatie bij klinische remissie. Er is 
ook gesuggereerd dat deze verbeterde technieken van waarde kunnen zijn bij het monitoren 
van de ziekteactiviteit, het voorspellen van de reactie op therapie en het voorspellen van de 











































afwijkingen op MRI en en/of echografie goed correleren met latere gewrichtsschade op 
conventionele röntgenfoto’s.
De resultaten van deze twee systematische literatuur onderzoeken werden geïntegreerd met 
de resultaten van de andere literatuur studies betreffende UA patiënten en gecombineerd 
met de klinische expertise van een internationaal panel van reumatologen om aanbevelin-
gen te formuleren over hoe UA patiënten te onderzoeken en te vervolgen. De resultaten 
daarvan leest u in hoofdstuk 4.
De relatie van het soort gewrichtsschade en de locatie daarvan met dagelijks 
functioneren
De relatie tussen gewrichtsbeschadiging en fysiek functioneren is uitvoerig beschreven in 
de literatuur. Recentelijk is gesuggereerd dat gewrichtsspleet- versmalling een groter effect 
op het dagelijks functioneren heeft dan erosies 16, hoewel enkele aspecten hiervan nog 
onopgehelderd blijven. Tot op heden was onbekend of schade op specifieke gewrichtsloca-
ties prominenter gerelateerd zijn aan de functionele beperkingen. In hoofdstuk 5 hebben 
we aangetoond dat afzonderlijke JSN en erosie scores an sich niet gerelateerd waren aan 
verminderd dagelijks functioneren. Echter, bij het analyseren van schade per gewrichtsgroep 
(voeten, polsen, metacarpofalangeale gewrichten en proximale interfalangeale gewrichten), 
vonden we dat de schade (erosies en gewrichtsspleetversmalling) in de pols, en dan met 
name de erosieve schade, onafhankelijk predictief waren voor een slechtere HAQ score. Dit 
houdt in dat de schade met name in de pols een grote invloed heeft op het fysieke func-
tioneren van de patiënt. Deze bevinding werpt ook de vraag op of behandeling per locatie 
(bijvoorbeeld door middel van injecties met corticosteroïden) in staat zijn om lokaal gewrich-
tsschade te voorkomen en daarmee het dagelijks functioneren te waarborgen. Aanvullend 
onderzoek is nodig om schade in specifieke gewrichten of in gewrichtsgroepen op andere 
beeldvormende technieken zoals MRI en echografie te relateren aan functioneren. 
Ziekteactiviteit in reumatoïde artritis
De meest gebruikte composite score om ziekte te meten is de DAS (disease activity score) 
welke klinische en laboratoriumresultaten als indicatoren van ziekteactiviteit combineert 
om zo een volledigere inschatting van actieve ziekte te maken. De oorspronkelijke DAS is 
meerdere malen aangepast, onder andere door het verminderen van het aantal gescoorde 
gewrichten en door de berekening van de totale score te vergemakkelijken. Hoewel de DAS 
veel wordt gebruikt in klinische studies, wordt de DAS niet systematisch toegepast in de 
klinische praktijk. Om de implementatie van DAS metingen in de praktijk te stimuleren, kan 
wellicht een versimpeling van de DAS meting of de berekening daarvan een goede bijdrage 
leveren. In hoofdstuk 6 hebben we drie varianten van de DAS geëvalueerd, waarin de pi-











































de voeten werden gescoord. Juist omdat de voeten vaak betrokken zijn bij RA. 19 In plaats 
van de gegradeerde ‘Ritchie articular index’ (RAI), gebruikten we een ja/nee pijn score in 
dezelfde gewrichten/gewrichtssgroepen. (DAS 0-1), een ja/nee pijnscore in 53 afzonderlijke 
gewrichten (DAS TJC53) en een ja/nee pijnscore in 44 afzonderlijke gewrichten (DAS TJC44) 
en vergeleken deze varianten met de originele DAS.
De varianten vertonen een hoge correlatie met de originele DAS en classificeren van de 
verschillende levels van ziekteactiviteit ongeveer gelijk (convergente validiteit). Er werd 
een vergelijkbare mate van radiologische progressie in alle categorieën van alle DAS versies 
waargenomen, waaruit blijkt construct validiteit, en met alle DAS versies konden verschillen 
in activiteit van de ziekte tussen de behandelingsgroepen in ons onderzoek na drie maanden 
follow-up worden aangetoond (discriminante validiteit). Echter, de scores gescoord met de 
DAS-TJC53 en DAS-TJC44 waren hoger, waardoor verschuivingen optraden in de ziekteactiv-
iteit categorieën, en wel met name bij patiënten in lage ziekteactiviteit (volgens de originele 
DAS) die vervolgens werden ingedeeld als gemiddelde ziekteactiviteit. Dit gold niet voor 
de patiënten in remissie. Gezien het feit dat alle versies vergelijkbare resultaten lieten zien, 
kan de keuze van composite score gemaakt worden op basis van praktische argumenten. 
Aangezien de gradeerde RAI lastig blijft te scoren en te berekenen , zouden zorgverleners 
een composite score kunnen kiezen die dit heeft vereenvoudigd,  zoals bijvoorbeeld de DAS 
TJC44, waarbij toch de voeten zijn geïncludeerd. 
We vergeleken visuele analoge schalen (VAS) die beide worden gebruikt als onderdeel van 
de DAS: enerzijds de VAS voor de algemene indruk van de patiënt betreffende ziekteactivit-
eit (VAS-PGA) en anderzijds de VAS voor de algemene gezondheid (VAS-GH) (hoofdstuk 6). 
Beide worden gebruikt in de dagelijkse praktijk, hoewel de DAS gevalideerd is op basis van de 
laatste. We vonden dat binnen DAS deze scores door elkaar kunnen worden gebruikt, zonder 
dat dit een belangrijke invloed heeft op de uiteindelijke score van de DAS. Toch verschillen 
VAS-PGA en VAS-GH apart aanzienlijk van elkaar en de correlatie tussen beide is laag. De 
interpretatie door patiënten van de achterliggende concepten die deze twee scores meten, 
lijkt te verschillen. Dit zou onder andere te maken kunnen hebben met de formulering van 
de vragen. Terwijl globale ziekteactiviteit gezien kan worden als een gevolg van artritis activ-
iteit, kan de algemene gezondheid ervaren worden als een ruimer begrip, wellicht beïnvloed 
door factoren als co-morbiditeit. Aangezien binnen de DAS het toegekende gewicht voor 
de VAS beperkt is, is gebruik van beide VAS scores in de praktijk goed mogelijk. Echter, om 
deze VAS scores afzonderlijk te kunnen gebruiken moet er aandacht gegeven worden aan de 
verschillen aangezien hierdoor de indruksvaliditeit kan verlagen omdat geen lab waardes of 











































In hoofdstuk 7 vergeleken we de VAS-score voor de beoordeling van de globale ziekteactiv-
iteit beoordeeld door patiënten (PtGDA) met dezelfde VAS score voor ziekteactiviteit beoor-
deeld door artsen (PhGDA). Hiervoor werden gegevens gebruikt uit de  METEOR database. 
We vonden dat de patiënten consequent hoger scoren dan artsen, gemiddeld 11 punten 
(op een schaal van 100), iets wat eerder gezien werd in andere studies. Een hogere score van 
patiënten in vergelijking met artsen was geassocieerd met een hogere pijnperceptie door 
patiënten, terwijl indien artsen hoger scoorden, dit was gerelateerd aan hogere bezinking en 
een hoger aantal gezwollen gewrichten. Een mogelijke verklaring is dat patiënten zich in hun 
oordeel meer laten beïnvloeden door hun gevoel van ongemak, en dat artsen meer worden 
gedreven door objectievere variabelen. Dit klopt met de waarneming dat patiënten en artsen 
verschillen in hun perspectief van actieve ziekte. Aangezien de patiënt VAS onderdeel is van 
de nieuwe ‘boolean’ ACR / EULAR remissiecriteria, kunnen patiënten met slechts een hoge 
VAS en geen andere tekenen van actieve ziekte, geclassificeerd worden als niet in remissie. 
Dit kan leiden tot therapie aanpassingen (indien behandeling gericht is op remissie), wellicht 
voor behandeling van inflammatie die niet daadwerkelijk aanwezig is. Lastig is dus dat door 
sommige patiënten remissie die gedefinieerd wordt volgens de arts op basis van gewrichts-
scores en laboratorium maten, niet gezien wordt als volledige controle van de ziekte.
Medicatie vrije remissie als ultiem behandeldoel, gedefinieerd volgens diverse uitkomst-
maten, kan in 9-25% van alle RA patiënten worden bereikt. Echter, de optimale manier om 
remissie te definiëren (met of zonder medicamenteuze therapie) is nog steeds onderwerp 
van discussie. Verschillende composite scores, zoals DAS, DAS28, SDAI en CDAI hebben met 
behulp van specifieke cutoff waarden remissie gedefinieerd. In hoofdstuk 8 onderzochten 
we de relatie tussen negen composite scores plus de nieuwste ACR / EULAR remissie criteria 
met fysiek functioneren en radiologische gewrichtsschade om meer inzicht te krijgen in de 
verschillen in remissie definities. We hebben aangetoond dat SDAI, CDAI en ACR / EULAR 
definities strenger zijn bij het definiëren van remissie dan de andere composite scores, zodat 
minder patiënten in staat waren om die toestand te bereiken. Nochtans waren deze strengere 
definities niet geassocieerd met klinisch relevante betere HAQ scores of lagere SHS scores. 
Het strenger definiëren van remissie lijkt daarom klinisch niet erg relevant (met betrekking 
tot gewrichtsschade en fysiek functioneren). Of (sturen op) remissie volgens strengere defini-
ties leidt tot betere resultaten op de lange termijn, of een hogere kwaliteit van leven, een 
betere symptoomcontrole en minder ziekte opvlammingen, moet nog worden bepaald.
Een aantal definities laat meer residuele ziekteactiviteit toe dan andere en het definiëren 
van remissie met minder strikte definities zou dus een onterecht  gevoel van veiligheid 
geven want het is mogelijk dat er toch (subklinische) ziekteactiviteit aanwezig blijft. Dat 
radiologische progressie tijdens klinische remissie niet noodzakelijkerwijs afwezig is, wordt 











































bij enkele patiënten in remissie. Toekomstig onderzoek moet richting geven aan hoe de 
patiënten te identificeren zijn die schade progressie hebben ondanks klinische remissie, 
zodat we hen adequaat kunnen behandelen en zowel over- als onderbehandeling kunnen 
voorkomen.  Wij zijn van mening dat alle remissie definities die werden geëvalueerd goede 
construct validiteit toonden en dat de keuze van de gewenste meetinstrumenten kan wor-
den gebaseerd op andere factoren, zoals bijvoorbeeld praktische factoren.
De relatie tussen kwaliteit van leven en ziekteactiviteit
Gezondheid gerelateerde kwaliteit van leven (Health Related Quality of Life; HRQoL) be-
hoort tot een van de meest brede uitkomstmaten, omdat het een groot aantal variabelen 
meeneemt om het algemeen welzijn in aanwezigheid van de ziekte te bepalen. Er bestaan 
verschillende meetinstrumenten voor het in kaart brengen van HRQoL, zowel algemene als 
ziekte specifieke instrumenten. In de BeSt studie, werd HRQoL gemeten om de drie maan-
den (in de eerste twee jaar van de studie) met behulp van de Short Form 36, een generiek 
instrument dat bestaat uit de volgende acht factoren: fysiek functioneren, rolbeperkingen 
door fysieke gezondheidsproblemen, pijn, algemene gezondheidsbeleving, vitaliteit, sociaal 
functioneren, rolbeperkingen door emotionele problemen, en geestelijke gezondheid. Deze 
factoren kunnen gesommeerd worden in een lichamelijke en een psychische schaal: de 
Physical Component Scale (PCS) en de Mental Component Scale (MCS) (beide maten gebrui-
ken alle factoren, echter met verschillende gewichten). Wij onderzochten in hoofdstuk 9 de 
relatie van de PCS en MCS met de DAS. 
 
We vonden dat een lagere DAS geassocieerd was met een klinisch significant hogere en dus 
betere kwaliteit van leven, voor zowel de PCS en MCS. Echter, voor de MCS was het verschil 
minder dan de eerder vastgestelde klinisch belangrijke verbetering van >2,5 punten. Een 
afname in DAS hing samen met  een verbetering van de kwaliteit van leven en met name 
een verlaging van ziekteactiviteit tot op het niveau van remissie, was geassocieerd met een 
klinisch relevante betere PCS, onafhankelijk van het voorgaande niveau van DAS. Deze relatie 
werd niet gevonden voor de MCS, wat kan worden verklaard doordat de MCS afhankelijker 
is van andere factoren, zoals pijn, co-morbiditeit en coping-strategieën, in tegenstelling tot 
de PCS. 
De PCS resultaten lijken te suggereren dat remissie als doel te prefereren is boven lage 
ziekteactiviteit, omdat dit zou leiden tot een betere kwaliteit van leven voor patiënten. Onze 
analyse was gebaseerd op een lage ziekteactiviteit gestuurd cohort, dus zal toekomstig 
onderzoek zich moeten richten op de vergelijking van het niveau van kwaliteit van leven in 
een remissie versus lage ziekte activiteit gestuurd cohort om definitief conclusies te trekken 












































Ziekte monitoring in de dagelijkse klinische praktijk
Patiënten vertonen een positieve houding ten aanzien van het gebruik van elektronische 
patiënten dossiers, welke perfect zouden kunnen worden ingezet voor het monitoren van 
ziekte. Dit kan gedaan worden door de patiënt zelf dan wel door de zorgverlener. In hoofd-
stuk 10 hebben we de haalbaarheid van het online registeren van de HAQ door patiënten 
beoordeeld zowel thuis als op de polikliniek. We hebben geleerd dat hoewel op de polikli-
niek de meerderheid van de patiënten aangeeft het registeren gemakkelijk te vinden en 
waardevol, vervolgens in een follow-up studie thuisregistratie slechts door een minderheid 
verricht wordt. Dit werpt vragen op over de haalbaarheid van thuisregistratie. Een verklar-
ing hiervoor kan zijn dat patiënten sociaal wenselijke antwoorden hebben gegeven, niet in 
overeenstemming met hun daadwerkelijke gedrag. Een andere mogelijkheid is dat patiënten 
in eerste instantie de bedoeling hebben gehad de vragenlijst in te vullen, maar uiteindelijk 
daarvan hebben af gezien omdat ze geen directe voordelen van registratie zagen. Het is 
belangrijk om feedback te geven aan patiënten over hun registratie en de voordelen van 
deze inspanningen en het regelmatig monitoren te bespreken, omdat anders initiatieven ter 
bevordering van regelmatige ziekte monitoring gedoemd zijn te mislukken. 
Algemene conclusies en toekomstperspectieven
Dit proefschrift richt zich op het monitoren van ziekte in zowel RA als UA patiënten en kijkt 
daarbij naar de waarde van de beeldvorming, het beoordelen van ziekteactiviteit, het vast te 
stellen behandeldoel en de implementatie van monitoring in de dagelijkse praktijk.
Welke beeldvormende technieken dienen te worden gebruikt bij patiënten met 
artritis en welke kenmerken daarvan zullen in ogenschouw genomen moeten 
worden?
Het in kaart brengen van structurele schade bij patiënten met RA of UA kan gedaan wor-
den met conventionele röntgenfoto’s, MRI of echografie. Conventionele röntgenfoto’s van 
handen, polsen en voeten zijn waardevol in het begin van ongedifferentieerde ziekte om 
de toekomstige diagnose en prognose te voorspellen, maar voor de aanvullende waarde 
van MRI en echografie werd weinig bewijs gevonden. Echter, recente studies hebben gesug-
gereerd dat deze technieken in staat zijn om actieve ziekte aan te tonen in UA patiënten. 
Naarmate de behandeling van RA en ongedifferentieerde artritis zich verder ontwikkelt, en 
mogelijk de radiologische schade nog verder afneemt, zouden deze technieken conventio-
nele Röntgenfoto’s kunnen vervangen bijvoorbeeld om subklinische ziekteactiviteit vast te 
stellen bij patiënten in klinische remissie met progressieve gewrichtsschade.
Het moet nader worden onderzocht hoe de afwijkingen op de MRI-en en/of echografie relat-
eren aan beperkingen in fysiek functioneren en met name ook aan gezondheid gerelateerde 











































meten. Ook is het op dit moment niet zeker of deze afwijkingen, bijvoorbeeld bij patiënten 
in klinische remissie, te behandelen zijn en wat de winst met betrekking tot bijvoorbeeld 
HRQoL of lichamelijk functioneren zou zijn bij behandeling. 
Röntgenfoto’s kunnen worden gebruikt om structurele afwijkingen te objectiveren na voor-
gaande perioden van actieve ziekte. Bij RA patiënten zou extra aandacht gegeven kunnen 
worden aan de schade ter plaatse van de pols, gezien de hoge impact van schade in dit 
gebied op het fysieke functioneren. Toekomstig onderzoek moet vaststellen of lokale intra-
articulaire therapie deze plaatselijke schade kan voorkomen of progressie kan remmen en 
of dit ook tot de gewenste verbetering dagelijks functioneren leidt. Of gewrichtsschade op 
specifieke locaties gemeten met MRI of echo ook relateert aan fysiek functioneren is niet 
bekend. 
Hoe kan de behandelend arts ziekteactiviteit meten en wat is de rol van de patiënt 
bij het regelmatig meten van ziekteactiviteit? 
Bij de behandeling van patiënten met artritis, met name RA, maar mogelijk ook andere vor-
men van chronische artritis en UA, moet het meten van de ziekteactiviteit met een composite 
score, met inbegrip van de voeten, regelmatig worden uitgevoerd om behandeling goed te 
kunnen sturen. Het mee scoren van de voeten is daarbij essentieel, omdat bij RA de voeten 
vaak meedoen en dit dus invloed heeft op de ziekteactiviteit. Deze metingen kunnen door 
de arts worden uitgevoerd met diverse composite scores, waarvan sommige praktischer zijn 
dan andere, die echter alle op een vergelijkbare manier relateren aan fysiek functioneren en 
structurele schade. Een andere optie het meten van ziekteactiviteit door patiënten. Echter, 
we hebben gezien dat artsen en patiënten verschillen in hun mening over actieve ziekte 
en de factoren die hun scores voorspellen verschillen. In de composite scores zitten naast 
de VAS “objectievere” maten van ziekteactiviteit, zoals de bezinking of gewrichtsscores, wat 
de verschillen tussen patiënten en artsen compenseert. Aan de andere kant is het de vraag 
of met deze objectievere factoren wel de daadwerkelijke ziekteactiviteit in kaart gebracht 
wordt en of dit niet meer lastiger te meten factoren bevat. Factoren zoals pijn, vermoeidheid 
en coping-strategieën moeten ook in ogenschouw genomen worden om een beter begrip, 
en anderzijds een verbetering van de ervaren actieve ziekte bij deze patiënten te bewerkstel-
ligen. 
Welk niveau van de ziekteactiviteit moet het doel van onze behandeling zijn?
Het na te streven doel van behandeling blijft nog steeds onderdeel van discussie. Volgens 
recent geformuleerde aanbevelingen moet het primaire doel van de behandeling van de 
patiënt met reumatoïde artritis zijn: “het waarborgen van de gezondheid gerelateerde kwalit-
eit van leven op de lange termijn, door middel van symptoom controle, het voorkomen van 
structurele schade, het normaliseren van functioneren en de maatschappelijke participatie 











































doel te bereiken.” We hebben gezien dat het bereiken van een doel zo streng als remissie 
leidt tot betere resultaten met betrekking tot radiologische schade, fysiek functioneren, en 
vooral HRQoL. Toch zijn de verschillen met het streven naar een lage ziekteactiviteit klein en 
niet altijd klinisch relevant. Aan de andere kant weten we dat de voortschrijdende structurele 
schadeprogressie zelfs bij patiënten in klinische remissie mogelijk is. Dit is een argument 
vóór het streven naar de laagst mogelijke ziekteactiviteit. Remissie kan worden gedefinieerd 
met een composite score zoals de DAS, die wel de voeten meeneemt, in tegenstelling tot 
de nieuwe ACR / EULAR remissie criteria. Een ander voordeel over de ‘boolean’ versie van de 
ACR / EULAR remissiecriteria is dat het resultaat van de DAS berekening een continu getal is, 
in tegenstelling tot de recente ja/nee remissie criteria waarbij een factor het totale oordeel 
zelfstandig kan bepalen wat tot problemen kan leiden zoals bij de VAS gescoord door de 
patiënt. In de toekomst zal onderzoek zich moeten richten op het direct vergelijken van 
behandelingsstrategieën sturend op verschillende behandeldoelen en daarbij focussen op 
kwaliteit van leven als uitkomst.
Hoe kan regulaire ziekte monitoring in de huidige dagelijkse praktijk worden 
geïmplementeerd?
Hoewel veel van onze beschikbare middelen gebruikt worden voor onderzoek naar nieuwe 
behandelingen of behandelstrategieën voor artritis patiënten, wordt relatief weinig aandacht 
besteed aan de implementatie van regulaire ziekte monitoring. Er zijn weinig implementatie 
studies beschikbaar en de studies die er zijn, hebben teleurstellende resultaten. Toch is de 
druk om regelmatig ziekteactiviteit te registreren hoog, mede opgelegd door verzekerings-
maatschappijen die objectieve argumenten eisen om dure behandelingen al dan niet te ver-
goeden. Deze kwaliteitsindicatoren die worden vastgesteld voor diverse ziekten dwingen nu 
bepaalde veranderingen af in de organisatie van onze gezondheidszorg voor RA patiënten.
Het betrekken van patiënten bij de behandeling wordt in de huidige gezondheidszorg steeds 
belangrijker. Patiënten moeten deel uitmaken van het behandelproces en onderwezen 
worden over hun rol in dit proces. RA patiënten moeten zich bewust zijn van het belang 
van regelmatige ziekte monitoring voor hun uiteindelijke ziekte uitkomst. Het is van belang 
dat zij weten hoe zij kunnen deelnemen aan deze evaluaties. ICT-oplossingen, zoals elek-
tronische patiëntendossiers, kunnen de betrokkenheid van patiënten bij ziekte monitoring 
ondersteunen. Daarnaast moeten patiënten feedback krijgen van hun zorgverleners op 
hun ziektemonitoring, hun behandelresultaten en de gevolgen van deze resultaten voor 
eventueel noodzakelijke behandelaanpassingen. 
Tot slot, om het monitoren en de uitkomsten van patiënten met UA en RA te verbeteren, 
moeten artsen regelmatig ziekteactiviteit beoordelen met composite scores en streven naar 











































bij het monitoren van hun ziekte door het regelmatig zelf beoordelen van hun dagelijks 
functioneren en van hun kwaliteit van leven. Behandeling kan worden gestuurd op het 
laagst mogelijke niveau van ziekteactiviteit, waarbij patiënten klachtenvrij zijn, geen fysieke 
beperkingen hebben met daarbij een goede kwaliteit van leven. Toekomstig onderzoek zal 
gericht moeten zijn op directe vergelijking van behandeling- en monitor strategieën met 
verschillende behandeldoelen, gebruik makend van nieuwere beeldvormende technieken 
om subtiele tekenen van de ziekteactiviteit en/of schade te identificeren, en ten tweede het 
gebruik daarvan. Succesvolle implementatie van de beste monitoring en behandelstrat-
egieën in de dagelijkse klinische praktijk kunnen dan uiteindelijk leiden tot betere zorg en 
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Je mag natuurlijk hopen dat ook maar iets van jouw proefschrift zoveel gelezen wordt als 
het dankwoord. (Voor de waaghalzen onder jullie verwijs ik graag naar de stellingen, of zelfs 
de Nederlandse samenvatting.) Op deze plek wil ik graag iedereen bedanken die aan de 
totstandkoming van dit proefschrift heeft bijgedragen. 
Tom, werken op jouw afdeling reumatologie voelde aan als een warm bad! De uitgebreide 
mogelijkheden en kennis op de afdeling hebben me gebracht waar ik nu ben in mijn carrière. 
Desirée, mijn eerste project was het 3E  initiative en wat een goede, internationale en vooral 
leuke start was dat. Bedankt voor de fijne samenwerking, jouw kritische blik en method-
ologisch inzicht. Lieve Renée, van kledingadviezen en visuele aantrekkelijkheid tot schrijf en 
presentatie tips, het totaal pakket wat nodig was als onderzoeker heb jij mij bijgebracht. Ik 
heb bijzonder veel van je geleerd! 
Dear fellows, mentors and other colleagues from the 3E initiative, I have so much enjoyed 
working together in this great stimulating project. Isabel and Pedro, both of you have shown 
me that with effort all is possible in this field. It is really special to me that we are still keeping 
in touch, both personally and work related. 
Het METEOR Nederland team (Jan-Peter, Emilia) met als organiserend talent Annemarie 
Korevaar bedankt voor de fijne samenwerking. Het datamanagement (Jose, Cederic) en het 
secretariaat (Joyce, Hanny, Nancy) plus alle research nurses: zonder jullie ondersteuning zou 
de afdeling niet zo goed kunnen draaien. Hughine, dank voor al je warmte en wijze woorden 
op belangrijke momenten. 
Wat was C1-45 een fijne kamer, zoveel collega’s (Badelog, Mohammed, Diane, Annemiek, 
Lotte, Emalie, Willemien, Jessica, Kirsten, Rani, Els) op een paar vierkante meters zorgde voor 
een hechte band en heel veel mooie tijden. Dank daarvoor! De tegenhanger C1-46 (Manouk, 
Annemarie, Diederik, Rachel, Michael, Nina, Angga, Wing-Yee, Rosaline, Rute en alle AIOS) 
zorgde voor een waardige, deels ook klinische, aanvulling. Bedankt voor de leuke discussies 
en fijne samenwerking. 
Naomi, ik vond het heel bijzonder om (als generale repetitie) jouw paranimf te mogen zijn, 
en wat deed je het goed! Door al jouw gasten werd ik zoveel moed ingesproken dat ik vervol-
gens ook mijn boekje verder afrondde. Melek, hoe is het mogelijk dat er iemand bestaat die 
altijd zo vrolijk en positief door het leven gaat? Ik denk met veel plezier terug aan onze reizen 










































Karen, van jou heb ik op werk gebied bijzonder veel geleerd (en leer ik nog steeds!). Als 
fantastische voorgangster bij het 3E project heb ik altijd veel bewondering voor jou gehad. 
Daarnaast ben je ook een fantastische vriendin! Jouw hulp bij het dankwoord, de stellingen 
of kiezen van een locatie bleek onontbeerlijk. Hoe fijn is het dat jij naast me staat op deze 
mooie dag, en wie anders kon het zijn! 
Ons enige echte BeSt duo: Linda, buurvrouw, en Marianne, wat heb ik met jullie veel gelachen. 
Gelukkig leerden jullie beiden me de oplossing voor alle problemen! Dank voor al het harde 
werken qua data verzameling waar ik prettig gebruik van mocht maken.  
Queridas amigas e amigos brasileiros, Natasha, Duda e Daniel, muito obrigada para curtir a 
vida comigo durante um tempão no meu amado Rio. Vocês fizeram com que eu esquecesse 
do meu estresse, deixando a escrivaninha não usada, durante tantos momentos tão especiais! 
Ana-Carozinha, eu espero nós dividamos muito mais experiências de dermatologia no futuro. 
Lieve lieve vrienden, uit Goes (Yvonne, Majonne), Rotterdam (Christine, Annemarie, Jeske, 
Irma, Chantal, Annelot, Sandra) en soms wat verder weg (Renée, Albert, Marlies): dank voor 
jullie vriendschap en de heerlijke, noodzakelijke afleiding gedurende mijn promotie tijd! Ik 
kijk er naar uit de komende tijd samen weer veel te genieten. 
Lieve fijne collega’s van het UMC Utrecht. Bedankt voor jullie hartelijke ontvangst op deze 
bijzondere afdeling met de zeer gewaardeerde en beroemde veilige leeromgeving. Ik voel 
me erg thuis. Dank voor de steun, het meeleven en de tijd die jullie me hebben gegeven om 
dit proefschrift te kunnen afronden. Berit, wat leuk dat we met onze achtergrond nu écht 
collega’s zijn!
Lieselotte, mijn kleine wel-gebalanceerde zus! Hoewel we (wat?) anders zijn van karakter, 
voelt het altijd als thuiskomen we elkaar weer zien. Met jou lach ik toch echt het hardst! Ik 
heb bewondering voor jouw nauwgezetheid als arts, fijn dat jij vandaag ook de vragen kunt 
beantwoorden ;-) Sjors en Hup, mijn Rotterdamse huisgenoten en thuisfront, bij jullie voel ik 
me altijd goed! Lieve pap en mam, zonder jullie stond ik hier natuurlijk nu niet. Dank voor al 











































Rosanne Koevoets werd geboren in Goes op 13 oktober 1981. Na het afronden van het 
Voorbereidend Wetenschappelijk Onderwijs, is zij medische biologie gaan studeren aan de 
Universiteit van Amsterdam. In 2000 is zij overgestapt naar de studie geneeskunde aan de 
Erasmus Universiteit te Rotterdam en in 2007 behaalde zij aldaar haar artsendiploma. Zij is 
daarna werkzaam geweest als arts-assistent op de afdeling cardiologie in het Lange Land 
ziekenhuis en op de acute opname afdeling van de psychiatrie bij de BAVO te Rotterdam. In 
2008 startte zij met haar promotie promotietraject in het Leids Universitair Medisch Centrum, 
waarbij zij betrokken is geweest bij het 3e initiatief, METEOR en de BeSt studie. Momenteel 
is zij werkzaam in het Universitair Medisch Centrum Utrecht als dermatoloog in opleiding. 
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